<allTrials totalCount="301" xmlns="http://www.67bricks.com/isrctn"><fullTrial>
  <trial lastUpdated="2007-12-21T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-12-21T00:00:00.000Z">23612807</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Multicentre randomised placebo-controlled trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease</title>
      <scientificTitle/>
      <acronym>CANOX trial</acronym>
      <studyHypothesis>Long-term oxygen therapy (LTOT) is the only component of the management of chronic obstructive pulmonary disease (COPD) that improves survival in patients with severe daytime hypoxemia. In Canada, LTOT is usually provided by a stationary oxygen concentrator and is recommended to be used for at least 15 - 18 hours a day. Several studies have demonstrated a deterioration in arterial blood gas pressures and oxygen saturation during sleep in patients with COPD. Sleep-related oxygen desaturation often occurs in patients not qualifying for LTOT. The suggestion has been made that the natural progression of COPD to its end stages of chronic pulmonary hypertension, severe hypoxemia, right heart failure, and death is dependent upon the severity of desaturation occurring during sleep. This is an attractive hypothesis and is supported by the fact that hypoxemic episodes during sleep are accompanied by substantial increases in pulmonary arterial pressure and often by important cardiac arrhythmias. Supplemental nocturnal oxygen alleviates both the acute increases in pulmonary arterial pressure and the cardiac arrhythmias.  

It has been suggested that, over the long run, nocturnal oxygen therapy (N-O2) may halt the progression of long-standing cor pulmonale and prolong survival. Probably due to the fact that the recommendations of scientific societies regarding the indications for and use of N-O2 in COPD not qualifying for conventional LTOT are presently imprecise, a number of patients are currently treated with N-O2 although the beneficial effects of this therapy have not been confirmed.

Hypothesis:
In patients with Chronic Obstructive Pulmonary Disease (COPD) not qualifying for Long Term Oxygen Therapy (LTOT) but who present significant nocturnal arterial oxygen desaturation, nocturnal oxygen therapy provided for a period of 3 years is effective in decreasing mortality or delaying the requirement for LTOT, and is cost-effective and favourably compares to other medical interventions</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcomes of this trial are mortality from all cause or requirement for LTOT (composite outcome).</primaryOutcome>
      <secondaryOutcome>1. Quality of life and utility measures
2. Costs from a societal perspective 
3. Compliance with oxygen therapy</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Pending as of 20/10/2006.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN23612807</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>MOP-36329</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A 3-year, multicentre, placebo-controlled, randomised trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2013-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="883624d6-4d6d-4c28-9130-caa5da73b5cf">
	  <name>Centre de Pneumologie</name>
	  <address/>
	  <city>Québec</city>
	  <state/>
	  <country>Canada</country>
	  <zip>G1V 4G5</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with a diagnosis of COPD supported by an history of past or current smoking and obstructive disease with forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) less than 60%
2. Presence of mild-to-moderate daytime hypoxemia with a daytime partial pressure of oxygen in arterial blood (paO2) in the range of 56 - 69 mmHg
3. Patients fulfilling our definition of nocturnal oxygen desaturation: greater than or equal to 30% of the recording time with transcutaneous arterial oxygen saturation less than 90% on two consecutive recordings</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>600</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>600</totalTarget>
      <exclusion>1. Patients fulfilling the usual criteria for continuous oxygen therapy (CONT-O2) at study entry: 
1.1. PaO2 less than or equal to 55 mmHg, or
1.2. PaO2 less than or equal to 59 mmHg with clinical evidence of at least one of the following: 
1.2.1. Pulmonary hypertension
1.2.2. Right ventricular hypertrophy
1.2.3. Cor pulmonale
1.2.4. Haematocrit greater than or equal to 55%
2. Patients with sleep apnea (defined by an apnoea/hypopnoea index of greater than or equal to 15 events/hour
3. Patients currently on nocturnal oxygen therapy (N-O2)
4. Patients with known left heart or congenital heart diseases, interstitial lung diseases, bronchiectasis as the main cause of their obstructive disease, lung carcinoma or other severe diseases that could influence survival (hepatic cirrhosis and chronic renal failure)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2008-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2013-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic obstructive pulmonary disease (COPD)</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Chronic obstructive pulmonary disease (COPD)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Nocturnal oxygen therapy group: N-O2 will be delivered overnight to allow the oxygen saturation to be greater than 90%
2. Placebo: the patients allocated in the control group will receive room air delivered by sham concentrator</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Nocturnal oxygen therapy</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15743-0</funderId>
      <contactId>Contact53681_15743</contactId>
      <sponsorId>Sponsor52235</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53681_15743">
    <title>Dr</title>
    <forename>Yves</forename>
    <surname>Lacasse</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Centre de Pneumologie
Hôpital Laval
2725 chemin Ste-Foy</address>
      <city>Québec</city>
      <country>Canada</country>
      <zip>G1V 4G5</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 418 656 4747</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">yves.lacasse@med.ulaval.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52235">
    <organisation>Laval University (Canada)</organisation>
    <website>http://www.ulaval.ca/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Cité Universitaire
C.P. 2208</address>
      <city>Québec</city>
      <country>Canada</country>
      <zip>G1K 7P4</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">yves.lacasse@med.ulaval.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.23856.3a</gridId>
    <rorId>https://ror.org/04sjchr03</rorId>
  </sponsor>
  <funder id="Funder15743-0">
    <name>Canadian Institutes of Health Research (CIHR) (Canada) - http://www.cihr-irsc.gc.ca (ref: MOP-36329)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-18T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2007-12-18T00:00:00.000Z">34931928</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effects of homocysteine-lowering vitamin supplementation on migraine disability</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Does vitamin therapy including folic acid reduce homocysteine and migraine disability, and is the effect dependent on MTHFR genotype?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Migraine disability, as measured using the Migraine Disability Assessment (MIDAS) score at baseline and 6 months.</primaryOutcome>
      <secondaryOutcome>1. Migraine frequency. Duration of follow-up: 6 months
2. Migraine pain: MIDAS pain score 1-10 (10 = most severe) at baseline and 6 months</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the Griffith University Ethics Committee on 11 November 2005 (ref: 3425)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN34931928</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-11-30T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-11-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Australia</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="11a24be8-9a86-4feb-b250-fa2667ed342a">
	  <name>Griffith University</name>
	  <address/>
	  <city>Gold Coast</city>
	  <state/>
	  <country>Australia</country>
	  <zip>9726</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Current diagnosis of regular migraine with aura attacks
2. &gt;18 and &lt;70 years old</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Co-morbid vascular or neuropsychiatric disease
2. Pregnant
3. Currently taking B vitamins</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-11-30T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-11-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Migraine with aura</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Migraine with aura</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Daily B vitamin (B6, B9, B12) therapy vs placebo for 6 months</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17311-0</funderId>
      <contactId>Contact55272_17311</contactId>
      <sponsorId>Sponsor53840</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55272_17311">
    <title>Prof</title>
    <forename>Lyn</forename>
    <surname>Griffiths</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Griffith University
Gold Coast campus</address>
      <city>Gold Coast</city>
      <country>Australia</country>
      <zip>9726</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">L.Griffiths@griffith.edu.au</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53840">
    <organisation>Griffith University (Australia)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>c/o Prof Lyn Griffiths
Gold Coast campus
Griffith University Qld 4222</address>
      <city>Gold Coast</city>
      <country>Australia</country>
      <zip>9726</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">L.Griffiths@griffith.edu.au</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.1022.1</gridId>
    <rorId>https://ror.org/02sc3r913</rorId>
  </sponsor>
  <funder id="Funder17311-0">
    <name>Brain Foundation of Australia</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-18T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2007-12-18T00:00:00.000Z">35143689</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Candesartan in renal artery stenosis (CARLAS)</title>
      <scientificTitle/>
      <acronym>CARLAS</acronym>
      <studyHypothesis>Despite beneficial effects on blood pressure with endovascular treatment, the prognosis remains ominous in patients with renal artery stenosis because of increased cardiovascular mortality. In patients with atherosclerotic renal artery stenosis, the mortality is increased six-fold compared to an age-matched population. It is reasonable to speculate that the high cardiovascular mortality in patients with renal artery stenosis could partly be explained by increased inflammatory activity caused by activation of the renin-angiotensin system. We believe that Percutaneous Transluminal Renal Angioplasty (PTRA) followed by angiotensin receptor blockade may improve this disease state. 

The angiotensin receptor blocker candesartan given to patients with renovascular hypertension post-PTRA, will improve long-term renal function  (3 years) and decrease the risk of restenosis.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Renal function measured by EDTA-clearance and frequency of restenosis 3 years after PTRA.</primaryOutcome>
      <secondaryOutcome>Cardiovascular events 3 years after PTRA.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Ethical Committees of the Universities of Göteborg and Lund on the 14th of April 2003.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN35143689</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>S 131-03</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A two-center randomized controlled open study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-04-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d7bae0d5-a852-4018-85f3-2d76806b2d80">
	  <name>Department of Nephrology</name>
	  <address/>
	  <city>Göteborg</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>413 45</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Blood pressure above 140 mmHg/90 mmHg
2. Confirmation of renal artery stenosis by either duplex ultrasonography, CT-angiography or MR-angiography</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>200</totalTarget>
      <exclusion>1. Renal size &lt;7.5 cm at the stenotic side 
2. Age &gt;80 years 
3. Pregnancy or nursing mother 
4. Terminal renal failure (Glomerular Filtration Rate [GFR] &lt;15 ml/min) 
5. Treatment with Angiotensin-Converting Enzyme (ACE) inhibitors or angiotensin receptor blockers 
6. Renovascular hypertension of other etiology than atherosclerosis or Flow-Mediated Dilation (FMD) 
7. Chronic glomerular disease with urinary albumin excretion (in mg/24h) (tU-alb) &gt;1g/day 
8. Diabetic nephropathy with tU-alb &gt;0.3 g/day 
9. Contraindication for renal angiography/PTRA (eg. serious contrast allergy)
10. Other forms of secondary hypertension 
11. Serious malignant disease 
12. Treatment with immune-modulating medications eg. cyclosporin and oral steroids</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-04-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Renal artery stenosis</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Renal artery stenosis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This study is carried out at two centers in Sweden (Göteborg and Malmö). 

Four weeks after renal angioplasty, all subjects will be randomized to anti-hypertensive treatment with either candesartan (oral) (intervention group) or conventional anti-hypertensive treatment (control group). The choice of drug used for the treatment of each participant in the control group will depend on his/her condition. The choices are betablockers, calcium antagonists, diuretics and alphablockers. 

The maximum daily doses: 200 mg for metoprolol (betablocker), 20 mg for felodipine (calcium antagonist), as much as needed for furosemide (diuretic), 8 mg for doxazosin (alphablocker). Candesartan was titrated up to a dose of 16 mg once daily.

Duration of intervention: three years</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Candesartan</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17182-0</funderId>
      <funderId>Funder17182-1</funderId>
      <funderId>Funder17182-2</funderId>
      <funderId>Funder17182-3</funderId>
      <funderId>Funder17182-4</funderId>
      <funderId>Funder17182-5</funderId>
      <funderId>Funder17182-6</funderId>
      <funderId>Funder17182-7</funderId>
      <funderId>Funder17182-8</funderId>
      <contactId>Contact55143_17182</contactId>
      <sponsorId>Sponsor53708</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55143_17182">
    <title>Prof</title>
    <forename>Hans</forename>
    <surname>Herlitz</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Nephrology
Sahlgrenska University Hospital</address>
      <city>Göteborg</city>
      <country>Sweden</country>
      <zip>413 45</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 31 3428477</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">hans.herlitz@medic.gu.se</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53708">
    <organisation>AstraZeneca (Sweden)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Argongatan 2D</address>
      <city>Mölndal</city>
      <country>Sweden</country>
      <zip>431 86</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 31 7788500</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mikael.forsby@astrazeneca.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.418151.8</gridId>
    <rorId>https://ror.org/04wwrrg31</rorId>
  </sponsor>
  <funder id="Funder17182-0">
    <name>The Ernhold Lundström Foundation (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17182-1">
    <name>Research Funds at Malm General (University) Hospital (Malm Allmnna Sjukhus - MAS) (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17182-2">
    <name>The Albert Påhlsson Foundation (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17182-3">
    <name>The Hulda Ahlmroth Foundation (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17182-4">
    <name>The Göteborg Medical Society (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17182-5">
    <name>The Swedish Medical Society</name>
    <fundRef/>
  </funder>
  <funder id="Funder17182-6">
    <name>The Swedish Association for Kidney Patients</name>
    <fundRef/>
  </funder>
  <funder id="Funder17182-7">
    <name>AstraZeneca, Mölndal (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder17182-8">
    <name>The Swedish state under the LUA/ALF agreement</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-18T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-12-18T00:00:00.000Z">08808171</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effectiveness of the follow-up of depressed patients by  nurses</title>
      <scientificTitle/>
      <acronym>MADEIRA</acronym>
      <studyHypothesis>1. The average depressive symptoms at the end of six months of follow-up among the group of depression patients treated by the primary care nurse and the group treated by the family doctor do not exceed the difference of 2.5 on the BDI scale, which is considered a difference not clinically relevant. 
2. There will be no significant difference in change in the quality of life between the two groups. 
3. Level of satisfaction will be similar in both groups, or greater among patients followed by nurses than the participants who are treated by the doctors
4. Adherence to treatment will be similar in both groups, or higher in patients followed by the nurses</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Differences between groups in the average of decrease in depression symptoms, measured by BDI at 6 months
2. Increase in quality of life, measured by the 12-item Short Form health survey (SF-12) at 6 months
3. Increase in satisfaction with the professional, measured by the satisfaction questionnaire of Baker at 6 months</primaryOutcome>
      <secondaryOutcome>1. Percentage of acceptance of the intervention (comparison of the two groups): patient satisfaction and losses that occur at different times of follow-up
2. Average of differences between the two groups with respect to:
2.1. Frequency and duration of visits
2.2. Referrals
2.3. Drug treatment
3. Comparison of adherence to treatment between the two groups</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Research Ethics Committee of the Jordi Gol i Gurina Primary Care Research Institute (IDIAP), Barcelona, on 4 July 2006 (ref: P06/39)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN08808171</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>PI061281</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>GP practice</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2008-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Spain</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b3dc29f4-7c76-4de9-9699-4a82e7579c5d">
	  <name>Lope de Vega 138</name>
	  <address/>
	  <city>Barcelona</city>
	  <state/>
	  <country>Spain</country>
	  <zip>08005</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients between 25 and 70 years of age
2. Rating of 20 or more points in the Beck Depression Inventory Scale (BDI) 
3. Whose family practitioner thinks they suffer from depression and they need to initiate anti-depressant treatment</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>460</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>460</totalTarget>
      <exclusion>1. Pregnancy or breastfeeding
2. Background of severe psychiatric disorders: psychosis, paranoia, severe personality disorders, delusional thoughts
3. Existence of suicidal ideation or attempts
4. Two or more episodes of major depression, or one or more episodes that might require hospitalization
5. Patients who have received antidepressant medication in the past year
6. Patients with mental health problems who have been referred to psychiatric specialists for these reasons 
7. Substance abuse and/or drugs 
8. Treatment for Parkinson's disease or epilepsy
9. Temporal residents (plan to move in the next six months) 
10. Unable to communicate in Spanish or Catalan languages</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2008-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Major depression</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Major depression</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Half of the participants will be allocated to the intervention group and another half into the control group. This trial involves 23 doctors and 23 nurses from 12 primary care teams in Barcelona.

Intervention group: Implementation of a depression management protocol, based on evidence-based clinical guidelines, by the primary care nurse. This protocol includes pharmacological treatment with fluoxetine or another Selective Serotonin Re-uptake Inhibitor (SSRI), and the participants will have at least 6 appointments with the nurses during the 6 months of follow-up. At each visit, each patient will be informed about the disease and pharmacological treatment. In addition, the nurse will ask the patient about changes in mood and try to enhance compliance. Nurses will also provide emotional support. If the patient does not improve, he will be referred to his doctor. 

Control group: Six-month follow-up by family doctors. Family doctors will provides usual care management. They can prescribe fluoxetine or another SSRI. Participants will have at least 6 appointments with their doctor during the 6 months of follow-up.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17301-0</funderId>
      <contactId>Contact55262_17301</contactId>
      <sponsorId>Sponsor53830</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55262_17301">
    <title>Dr</title>
    <forename>María Isabel</forename>
    <surname>Fernández San Martín</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Lope de Vega 138</address>
      <city>Barcelona</city>
      <country>Spain</country>
      <zip>08005</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53830">
    <organisation>Jordi Gol i Gurina Primary Care Research Institute (IDIAP Jordi Gol i Gurina) (Spain)</organisation>
    <website>http://www.idiapjgol.org/</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Gran Via de les Corts Catalanes
587 àtic</address>
      <city>Barcelona</city>
      <country>Spain</country>
      <zip>08007</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.452479.9</gridId>
    <rorId>https://ror.org/0370bpp07</rorId>
  </sponsor>
  <funder id="Funder17301-0">
    <name>Carlos III Health Institute of the Spanish Ministry of Health and Consumption (Fondo de Investigación Sanitaria, Instituto de Salud Carlos III, Ministerio de Sanidad y Consumo), Health Research Fund   (Spain)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-21T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-12-14T00:00:00.000Z">46535923</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Comprehensive care of infants: development and evaluation of an intervention strategy to enhance the promotion of health and quality of life of infants 2007 - 2010</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Does a public health intervention aimed at promoting improved feeding practices delivered at home and facility levels increase the duration of exclusive breastfeeding in the first 6 months of life and reduce the prevalence of obesity among infants 6 - 12 months?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Prevalence of exclusive breastfeeding among infants up to 6 months of age
2. Prevalence of "recommended infant feeding practices" (continued breastfeeding and three complementary feeds/day) at 6 - 11 months
3. Prevalence of Body Mass Index (BMI)/age equal of greater than 2SD at 6 - 11 months</primaryOutcome>
      <secondaryOutcome>1. Diarrhoea and pneumonia in the 2 weeks before interview
2. Hospitalisations in the past year (and their cause)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from:
1. World Health Organization (WHO) Ethics Review Committee on the 21st November 2007 (ref: NCH07006)
2. Comite de Etica de la Investigacion (Cuba) on the 20th November 2007</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN46535923</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>NCH 07006</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>This is a cluster-randomised controlled trial of a public health intervention</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-10-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Cuba</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="081e3cb5-9509-44bc-b8c1-e475ee7fe854">
	  <name>World Health Organization</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH-1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Participants are all infants living in the community area served by health centres included in the study.</inclusion>
      <ageRange>Child</ageRange>
      <gender>Both</gender>
      <targetEnrolment>12800</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>12800</totalTarget>
      <exclusion>The only exclusion criteria identified is the patient's refusal to participate.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Infant feeding practices</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Infant feeding</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention group:
Promotion of improved feeding at the health facility and community levels using multiple channels:
1. Face-to-face
2. Community based media
3. Community groups

Control group:
Receives usual care.

Some of the details of the intervention, such as the frequency or duration of contact or exposure to the channels will only be fully defined at the end of the formative research phase. Interventions at the health facility level may include in-service training of the physicians and nurses in the health centres to improve their communication and counselling skills. Training of health workers and community counselors in this course will, we believe, be an important component of the intervention. The intervention may also include changes in management procedures to make them more compatible with family needs and expectations. Access to off-hour advice, privacy of consultations, triage and waiting time and characteristics of the waiting room are some of the examples of areas that may be considered for improvement. 

Interventions at the community level will make maximal use of appropriate existing channels either to be the primary sources of dissemination of messages or to re-enforce them. In addition to face-to-face communications individually or in group, the team will also consider the use of local mass media (e.g. local radio, pamphlets, banners, and posters), work and social clubs. The intervention will probably include the provision of information and the development with families of problem-solving approaches/strategies to deal with significant constraints. Face-to-face counselling will be one of the key components. Additional components may be included to remove existing barriers or promote actions that will support an increase in prevalence of a desired behaviour (for example, making breastfeeding counsellors available in the community for greater ease of access to counselling and support when mothers face a feeding difficulty).

Eighteen months after the introduction of the intervention, when we expect that the intervention will have been fully functional in all intervention clusters for at least 12 months, the post-intervention survey will be conducted to measure the impact on infants up to 12 months old. The length of exposure to the intervention will depend on the age of the infant and the period he/she has been residing in the community. Control clusters will continue to be provided the usual type of health care.

Contact details for Principal Investigator:
Dr Ibargollen Negrin Longina
Ministerio de Salud Publica
MCH Division
Calle 23 entre M y N. Vedado
Havana
Cuba 
Tel: +53 (0)7 833 2336</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17359-0</funderId>
      <contactId>Contact55320_17359</contactId>
      <sponsorId>Sponsor53889</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55320_17359">
    <title>Dr</title>
    <forename>Jose Carlos</forename>
    <surname>Martines</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>World Health Organization
20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 2634</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">martinesj@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53889">
    <organisation>The Department of Child and Adolescent Health (CAH)/World Health Organization (WHO) (Switzerland) </organisation>
    <website>http://www.who.int/child-adolescent-health</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Avenue Appia 20</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 2634</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mertinesj@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder17359-0">
    <name>World Health Organization (WHO) (Switzerland) (ref: NCH 07006)</name>
    <fundRef>http://dx.doi.org/10.13039/100004423</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-07T00:00:00.000Z" version="18">
    <isrctn dateAssigned="2007-12-07T00:00:00.000Z">79227925</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Vitamin and mineral supplementation in reducing morbidity in Human Immunodeficiency Virus (HIV)-infected children in developing countries: an efficacy study</title>
      <scientificTitle/>
      <acronym>Mnuts/supps/HIV/children</acronym>
      <studyHypothesis>Micronutrient deficiencies contribute to immune dysfunction and can lead to increased infectious morbidity in Human Immunodeficiency Virus (HIV)-1-infected children. We hypothesised that micronutrient supplementation could reduce infectious morbidity in HIV-1-infected children.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Relative frequency of adverse or serious infective episodes, or death.</primaryOutcome>
      <secondaryOutcome>1. Viral load and CD4 count changes
2. Biochemical variables such as micronutrient levels measures
3. Relative frequency of minor infective episodes</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Research Ethics Committee (REC) of the University of Cape Town on 03/12/2001 (ref: RECRES 118/2001).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN79227925</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective, double-blind randomised, placebo-controlled clinical trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-04-23T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-11-26T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>South Africa</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e26de706-133f-4f14-bb36-1f67fae659a5">
	  <name>Ambulatory Paediatrics</name>
	  <address/>
	  <city>Cape Town</city>
	  <state/>
	  <country>South Africa</country>
	  <zip>7700</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Clinically stable (not acutely ill)
2. Vertically transmitted HIV-1 infected children
3. Attending the Infectious Diseases Clinic at Red Cross Children's Hospital
4. Aged six months to six years</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="6.0"/>
      <upperAgeLimit unit="Years" value="6.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>495</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>495</totalTarget>
      <exclusion>1. HIV-infected children aged less than six months
2. Children with an intercurrent infection or axillary temperature of more than 38°C
3. Children with any invasive opportunistic infection including tuberculosis
4. Children with bronchiectasis
5. Children who had received high dose vitamin A, trace elements or zinc supplements within the preceding eight weeks
6. Children recently hospitalised within the preceding six weeks</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-04-23T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-11-26T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Micronutrient supplementation of HIV-1-infected children</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Human Immunodeficiency Virus (HIV)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients are randomised into one of the three arms:
Group A - placebo
Group B - trace element supplement
Group C - high dose zinc supplement (3 mg/kg elemental zinc)

Trial drugs are given orally daily over six months and children are seen monthly for 12 weeks from start to end of the study.</description>
	<interventionType>Supplement</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Vitamin and mineral supplementation</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15831-0</funderId>
      <contactId>Contact53771_15831</contactId>
      <sponsorId>Sponsor52324</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53771_15831">
    <title>Dr</title>
    <forename>Heloise</forename>
    <surname>Buys</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Ambulatory Paediatrics
School of Child and Adolescent Health
Red Cross Children's Hospital
Klipfontein Road
Rondebosch</address>
      <city>Cape Town</city>
      <country>South Africa</country>
      <zip>7700</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52324">
    <organisation>Secure-The-Future Bristol-Myers Squibb (South Africa)</organisation>
    <website>http://www.bms.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Bristol-Myers Squibb 
HIV Research Institute
47 van Buuren Road
Bedfordview</address>
      <city>Gauteng</city>
      <country>South Africa</country>
      <zip>2008</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+27 (0)11 4566459</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">richardwanlass@bms.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder15831-0">
    <name>Secure-the-Future Bristol-Myers Squibb (South Africa) (ref: RES094/02)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-06T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-12-06T00:00:00.000Z">22412590</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Pilot study for the treatment of heart failure with Pycnogenol</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Pycnogenol, standardized French maritime pine bark extract, has shown beneficial effects on various cardiovascular health parameters such as blood pressure and cholesterol levels in both preclinical as well as clinical trials. The aim of this study is to investigate the effect of 200 mg daily of Pycnogenol on objective and subjective symptoms in patients with heart failure New York Heart Association (NYHA) status II.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Patients undergo tests for maximal workload and pressure-heart product at 0, 4, 8, and 12 weeks after enrollment. 

Maximal workload: As determined by a symptom-limited bicycle exercise test in the seated position. 
Pressure-heart rate product: Immediately after 2 min work at 50 W, systolic blood pressure and heart rate are recorded. Pressure-heart rate product is calculated by units of systolic blood pressure (mmHg) x heart rate per minute divided by 100.</primaryOutcome>
      <secondaryOutcome>Patients will report scores for dyspnea and fatigue for the foregoing 4 weeks upon enrollment (baseline) and repeat evaluation at 4, 8, and 12 weeks after enrollment. Symptom scores will be evaluated by asking patients about the severity of the following symptoms: 
1. Early fatigability
2. Dyspnea
3. General capability
4. Lassitude
5. Feeling depressed
6. Anxiety
 
Scores range from 0 = not present, 1 = occasionally mild, 2 = frequently mild, 3 = moderate, 4 = severe.
Blood analysis: Routine clinical chemistry in addition to the assays of BNP (NT-proBNP), C-Reactive Protein and troponin T.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Ethics Committee at Okuizumo Hospital in Shimane prefecture, Japan, on 24 May 2007</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN22412590</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>HF2007AM</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>12 week randomised, double-blind placebo-controlled matched pairs study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-08-10T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-07-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Japan</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="45ceb3d9-4390-4acf-a1d9-cc5ea1d96bf1">
	  <name>Kyoto University Graduate School of Medicine</name>
	  <address/>
	  <city>Kyoto</city>
	  <state/>
	  <country>Japan</country>
	  <zip>606 8507</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients over 40 years of age with chronic congestive heart failure (NYHA class II), known for at least 6 months which were previously untreated or treated with a diuretic and/or a low dose of an ACE inhibitor. Patients must have an exercise capacity of at least 75 watts as assessed by seated bicycle ergometry.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>1. NYHA status I, III or IV
2. Treatment with digitalis within the previous 6 months
3. Exercise capacity of &gt;75 W for 2 min at the test during run-in
4. Unstable angina or myocardial infarction within the last 6 months
5. Atrial fibrillation or ventricular arrhythmia greater than or equal to Lown III
6. Cardiac valvular disease or hypertrophic cardiomyopathy
7. Significant hypertension or hypotension (&lt; 60 mmHg or greater than or equal to 105 mmHg diastolic or &lt; 90 mmgH or &gt; 175 mmHg systolic)
8. Electrolyte disturbances, hyperuricemia, hypovolemia
9. Impaired renal function (creatinine &gt;1.8 mg/dL) or hepatic function
10. Obstructive airways disease 
11. Insulin-dependent diabetes
12. Malignant or other serious disease
13. Hypersensitivity to study drug
14. Pregnancy, unreliable contraception, breast-feeding mothers
15. Participation in another clinical trial within the last 6 weeks</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-08-10T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-07-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Heart failure</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Heart failure</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>200 mg Pycnogenol (standardized extract of French maritime pine bark) or placebo for 12 weeks. Patients receiving diuretics before enrollment should continue usage and not change dose/intake intervals. Drug intake will be controlled and any unwanted effect reported at each visit.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Pycnogenol</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16783-0</funderId>
      <contactId>Contact54741_16783</contactId>
      <sponsorId>Sponsor53297</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54741_16783">
    <title>Dr</title>
    <forename>Akira</forename>
    <surname>Matsumori</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Kyoto University Graduate School of Medicine
Department of Cardiovascular Medicine
54 Kawahara-cho Shogoin
Sakyo-ku</address>
      <city>Kyoto</city>
      <country>Japan</country>
      <zip>606 8507</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53297">
    <organisation>Kyoto University (Japan)</organisation>
    <website>http://www.kyoto-u.ac.jp/index-e.html</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>c/o Dr Akira Matsumori
Kyoto University Graduate School of Medicine
Department of Cardiovascular Medicine
54 Kawahara-cho Shogoin
Sakyo-ku
</address>
      <city>Kyoto</city>
      <country>Japan</country>
      <zip>6068507</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.258799.8</gridId>
    <rorId>https://ror.org/02kpeqv85</rorId>
  </sponsor>
  <funder id="Funder16783-0">
    <name>Kyoto University, Cardiomyopathy and Myocarditis Research Fund (Japan)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-28T00:00:00.000Z" version="18">
    <isrctn dateAssigned="2007-11-27T00:00:00.000Z">11132850</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy of oral intra-dialysis supplement  in haemodialysis patients with malnutrition</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Nutritional support in the form of oral supplement during the sessions of haemodilaysis improves the nutritional status of the patients, increases the oral food intake, improves the functional situation and quality of life and reduces the morbidity and mortality.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following data will be collected at the beginning of the study (basal), and at three and six months (final):
1. Serum albumin, measured by blood analysis
2. Prealbumin, measured by blood analysis</primaryOutcome>
      <secondaryOutcome>Collected at the beginning of the study (basal), collected at the beginning of the study (basal), and at three and six months (final):
1. Prevalence of malnutrition
2. Anthropometric nutritional parameters
3. Analytical nutritional parameters
4. Body composition (collected at the beginning of the study [basal] and at the sixth month [final] only)
5. Quality of life
6. Functional scale
7. Appetite
8. Oral food intake. Later on this information will be passed through a special program in order to calculate the total caloric intake and food composition (protein, carbohydrates and fat including saturated, mono- and poly-unsaturated fat)
9. Hospital admissions (collected as and when these events happen)
10. Mortality (collected as and when these events happen)
11. Morbidity and mortality rate (collected as and when these events happen)

Measurements taken to assess these outcomes will include:
1. Anthropometric measures: dry body weight, Body Mass Index (BMI), Brachial Muscle Circumference (BMC), triceps skin fold
2. Blood tests: Complete Blood Count (CBC), urea prior and post dialysis, creatinine, electrolytes, lipid profile, serum iron, ferritin, vitamin B12, folic acid, Parathyroid Hormone (PTH), calcium, phosphate, vitamin D3, transferrin, albumin, prealbumin, bicarbonate (HCO3) prior and post dialysis, insulin, fasting blood sugar, Homeostasis Model Assessment (HOMA) index, C-Reactive Protein (CRP)
3. Body composition: electrical Bioimpedance Analysis (BIA) monofrequency
4. Nutritional assessment: SGA and MIS
5. Questionnaires: charlson index, karnofsky scales (evaluated by interviewing each patient and by checking his medical history report at the beginning of the study, third month and sixth month), 36-item Short Form health survey (SF-36) and 8-item Council on Nutrition Appetite Questionnaire (CNAQ)
6. Dietary recall (48 hours): day of dialysis and day off will be collected from patients interview</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Ethical Committee of Clinical Investigation of the Hospital Clinico San Carlos on the 24th January 2007 (ref: 1.2/07). Signed by secretary of the committee Dr. M. Garcia Arenillas.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN11132850</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>06/178</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled single-blinded trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-11-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-05-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Spain</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4a1294e2-0024-483c-b430-5b14eb4b4e31">
	  <name>Avenida Marques de Corbera 6, 6d</name>
	  <address/>
	  <city>Madrid</city>
	  <state/>
	  <country>Spain</country>
	  <zip>28017</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients over 18 years old 
2. Maintained haemodialysis (at least 6 months on dialysis)
3. Malnutrition criteria (Subjective Global Assessment [SGA] grade B or C or Malnutrition Inflammation Score [MIS] score greater than 8) and at least  two altered analytical parameters (albumin less than 3.7 g/dl, prealbumin less than 30 g/l, total cholesterol less than 200 mg/dL with C-Reactive Protein [CRP] within normal range)</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>80</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>80</totalTarget>
      <exclusion>1. Lack of  signed consent 
2. Difficulty in understanding Spanish language
3. Patients diagnosed of cancer except skin cancer
4. Patients went through surgical operation in the last three months 
5. Patients with Dementia or Alzheimer disease</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-11-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-05-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Malnutrition</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Malnutrition</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Specific oral supplement formula for patients on haemodialysis (Nepro) plus dietetic consultation for the case group, versus only dietetic consultation for the control group. 
The formula is Nepro, a product of Abbott laboratory. Dosage is 236 ml in each session of haemodialysis, providing 472 kcal and 7 g of protein per 100 ml. 

Duration of intervention: 6 months</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder17255-0</funderId>
      <contactId>Contact55216_17255</contactId>
      <sponsorId>Sponsor53782</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55216_17255">
    <title>Dr</title>
    <forename>Waeel Ibrahim</forename>
    <surname>Alkrekshi</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Avenida Marques de Corbera 6, 6d</address>
      <city>Madrid</city>
      <country>Spain</country>
      <zip>28017</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+34 91 62 78 88 95 0</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">krekshi@hotmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53782">
    <organisation>Foundation of Metabolic Studies (Fundacion de estudios metabolicos) (Spain) </organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Hospital Clinico san Carlos 
C/ Martin Lagos S/N</address>
      <city>Madrid</city>
      <country>Spain</country>
      <zip>28040</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+34 91 33 03 64 3</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">krekshi@hotmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder17255-0">
    <name>Foundation of Metabolic Studies (Fundacion de estudios metabolicos) (Spain) - in cooperation with the Hospital Clinco San Carlos (Spain), Department of Endocrinology and Nutrition</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-22T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2007-11-22T00:00:00.000Z">38444899</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy of a Cognitive Behavioural group Therapy (CBT) for compulsive buying disorder</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Disorder specific group Cognitive Behavioural Therapy (CBT) can improve the compulsive buying behaviour.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Compulsive Buying Scale (CBS)
2. Yale-Brown Obsessive Compulsive Scale - Shopping Version (Y-BOCS-SV)
3. German Compulsive Buying Scale (G-CBS)

All participants were assessed at baseline. Participants assigned to CBT were assessed at the end of treatment and at the end of a 6-months follow-up period. Individuals assigned to the WLC were reassessed 12 weeks after the baseline assessment. All assessments were conducted by research staff members who remained blind to the treatment assignment throughout the study. Participants completed all self-report questionnaires during the assessment visits.</primaryOutcome>
      <secondaryOutcome>1. Symptom Check-List-90-R (SCL-90-R)
2. Barratt Impulsiveness Scale (BIS-11)
3. Saving Inventory - Revised (SI-R)

All participants were assessed at baseline. Participants assigned to CBT were assessed at the end of treatment and at the end of a 6-months follow-up period. Individuals assigned to the WLC were reassessed 12 weeks after the baseline assessment. All assessments were conducted by research staff members who remained blind to the treatment assignment throughout the study. Participants completed all self-report questionnaires during the assessment visits.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Institutional Ethics Committee of the University Hospital of Erlangen (Germany) on the 27th August 2003 (ref: 3008).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN38444899</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, controlled, efficacy study comparing CBT with waiting list control.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-05-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4f9e568b-66e2-4c36-97f4-4c77e2eb42ee">
	  <name>Department of Psychosomatic Medicine and Psychotherapy</name>
	  <address/>
	  <city>Erlangen</city>
	  <state/>
	  <country>Germany</country>
	  <zip>D-91054</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Current compulsive buying problems according to the criteria of McElroy et. al. (1994)
2. Aged 18 and over</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Active suicidal ideation
2. Current mania</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-05-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Compulsive buying disorder</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Adult personality disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This trial is a randomised controlled trial comparing a treatment group with a waiting list control group (2 arms). Because of logistical difficulties a simultaneous conduction of groups was not feasible in this monocentric study. Patients were assigned to groups upon enrolment, which were subsequently randomised to one of two conditions. Thirty-one participants were assigned to one of five CBT groups, and 29 individuals to one of five Waiting List Control (WLC) groups. Participants were blind to the randomisation. 

Intervention:
12-weekly outpatient disorder specific group CBT-sessions specifically aiming at interrupting and controlling the problematic buying behaviour, establishing healthy purchasing patterns, restructuring maladaptive thoughts and negative feelings associated with shopping and buying, and developing healthy coping skills. 

Control:
Waiting list control. 

Treatment lasted 12 weeks with one 90-minutes session per week. Groups were conducted with 5 - 8 participants. Follow-up was for 6 months after finishing the treatment for all participants.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17868641 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="2ce6bf78-f597-49da-913e-394ef7dc99f1" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-11-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17868641"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16920-0</funderId>
      <funderId>Funder16920-1</funderId>
      <contactId>Contact54881_16920</contactId>
      <sponsorId>Sponsor53444</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54881_16920">
    <title>Dr</title>
    <forename>Astrid</forename>
    <surname>Mueller</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Psychosomatic Medicine and Psychotherapy
University Hospital of Erlangen
Schwabachanlage 6</address>
      <city>Erlangen</city>
      <country>Germany</country>
      <zip>D-91054</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)9131 85 34890</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">astrid.mueller@uk-erlangen.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53444">
    <organisation>University Hospital of Erlangen (Germany)</organisation>
    <website>http://www.elan.uk-erlangen.de/e404/index_ger.html</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Erlanger Leistungsbezogene Anschubfinanzierung und Nachwuchsforderung (ELAN) fund 
Universitatsstrasse 40</address>
      <city>Erlangen</city>
      <country>Germany</country>
      <zip>D-91054</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)9131 85 23708</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">annette.pfeiffer@zuv.uni-erlangen.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.411668.c</gridId>
    <rorId>https://ror.org/0030f2a11</rorId>
  </sponsor>
  <funder id="Funder16920-0">
    <name>University Hospital of Erlangen (Germany) - Erlanger Leistungsbezogene Anschubfinanzierung und Nachwuchsforderung (ELAN) fund</name>
    <fundRef/>
  </funder>
  <funder id="Funder16920-1">
    <name>Bavarian Savings Bank Foundation (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-15T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2007-11-15T00:00:00.000Z">40223079</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy and safety of artesunate and sulfadoxine-pyrimethamine for the treatment of uncomplicated Plasmodium falciparum malaria and chloroquine for the treatment of vivax malaria in Nangarhar, Takhar and Faryab provinces, Afghanistan</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Monitor efficacy and safety of artesunate and sulfadoxine-pyrimethamine for the treatment of uncomplicated Plasmodium falciparum malaria and chloroquine for the treatment of vivax malaria.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. To measure the clinical and parasitological efficacy of artesunate and sulfadoxine-pyrimethamine among patients aged above six months suffering from uncomplicated falciparum malaria and chloroquine for vivax malaria, by determining the proportion of patients with:
1.1. Early Treatment Failure (ETF)
1.2. Late Clinical Failure (LTF)
1.3. Late Parasitological Failure (LPF)
1.4. Adequate Clinical and Parasitological Response (ACPR) 
As indicators of efficacy
2. To differentiate recrudescences from new infections by the Polymerase Chain Reaction (PCR) analysis
3. To evaluate the incidence of adverse events</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from:
1. Ministry of Public Health Afghanistan on the 15th September 2007
2. World Health Organization (WHO) Ethics Review Committee (ERC) on the 13th November 2007 (ref: RPC 243)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN40223079</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RPC243</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>One arm non-comparative study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-11-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-02-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Afghanistan</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9b1172ad-0422-4c61-b991-7967ad7d478f">
	  <name>World Health Organization</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH-1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age above 6 months
2. Mono-infection with P. falciparum or P. vivax
3. Parasitaemia, 1000 - 100,000 asexual forms per µl for falciparum malaria and above 250 asexual forms per µl for vivax malaria
4. Axillary temperature of 37.5°C or oral/rectal temperature of 38°C
5. Ability to swallow oral medication
6. Ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule
7. Informed consent from the patient or from a parent or guardian in case of children</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="6.0"/>
      <gender>Both</gender>
      <targetEnrolment>300</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>300</totalTarget>
      <exclusion>1. Presence of general danger signs among children less than 5 years old or other signs of severe and complicated falciparum malaria according to current WHO definitions (see Annex 1)
2. Mixed or mono-infection with another Plasmodium species
3. Presence of severe malnutrition (defined as a child whose weight-for-height is below -3 standard deviation or less than 70% of the median of the National Center for Health Statistics [NCHS]/WHO normalised reference values, or who has symmetrical oedema involving at least the feet or who has a Mid Upper Arm Circumference [MUAC] less than 110 mm)
4. Presence of febrile conditions due to diseases other than malaria (measles, acute lower tract respiratory infection, severe diarrhoea with dehydration, etc.), or other known underlying chronic or severe diseases (e.g. cardiac, renal, hepatic diseases, Human Immunodeficiency Virus [HIV]/Acquired Immune Deficiency Syndrome [AIDS])
5. History of hypersensitivity reactions to any of the drug(s) being tested or used as alternative treatment
6. Positive pregnancy test or lactating (if adults included)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-11-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-02-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Malaria</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Malaria</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Artesunate (12 mg/kg) and sulfadoxine (25 mg/kg single dose) - pyrimethamine (1.25 mg/kg single dose) over 3 days for falciparum malaria
2. Chloroquine 25 mg/kg over 3 days for vivax malaria

Contact details for Principal Investigator: 
Dr Ghulam Rahim Awab 
District/Phase - 4
Jalalabad City 
Nangarhar 
Afghanistan
Tel: +93 (0)70 004 4853
Email: awabgr@yahoo.com</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Artesunate, sulfadoxine-pyrimethamine, chloroquine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17277-0</funderId>
      <contactId>Contact55238_17277</contactId>
      <sponsorId>Sponsor53806</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55238_17277">
    <title>Dr</title>
    <forename>Pascal</forename>
    <surname>Ringwald</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>World Health Organization
Avenue Appia 20</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 3469</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ringwaldp@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53806">
    <organisation>World Health Organization (WHO) (Switzerland) </organisation>
    <website>http://www.who.int/malaria/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Avenue Appia 20</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 3469</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ringwaldp@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder17277-0">
    <name>World Health Organization (WHO) (Switzerland)</name>
    <fundRef>http://dx.doi.org/10.13039/100004423</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-06T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-11-06T00:00:00.000Z">94348100</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The influence of surgical interventions with and without cardiopulmonary bypass on Ca2+ signalling in alveolar macrophages</title>
      <scientificTitle/>
      <acronym>Cacao</acronym>
      <studyHypothesis>A direct G-protein-stimulated ratiometric calcium ion (Ca2+) signal in alveolar macrophages decreases after surgical interventions with cardiopulmonary bypass.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Calcium signal intensity, measured immediately preoperatively and after the surgical procedure.</primaryOutcome>
      <secondaryOutcome>Postoperative pulmonary infection, measured on day of discharge.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Charite - Universitaetsmedizin Berlin ethikkommission on the 8th March 2003 (ref: EA1/146/06).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN94348100</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>VO 741/6-1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective cohort trial with two control groups.</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Cohort study</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-05-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="73ba5a82-5919-40a1-8d7d-91a9dcad47cc">
	  <name>Klinik fur Anaesthesiologie und Operative Intensivmedizin</name>
	  <address/>
	  <city>Berlin</city>
	  <state/>
	  <country>Germany</country>
	  <zip>10117</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Elective coronary bypass graft surgery
2. Elective panendoscopy
3. Elective thoracic surgery</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Aged less than 18 years
2. Relevant pulmonary diseases with oxygenation deficit
3. Liver disease stage greater than Child B
4. Human Immunodeficiency Virus (HIV)-infection
5. Corticosteroid therapy
6. Organ transplantation
7. Perioperative infection
8. Chronic inflammatory disease
9. Pregnancy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-05-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Pulmonary dysfunction after surgery</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Postprocedural respiratory disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Bronchoscopy with Broncho-Alveolar Lavage (BAL) and blood samples before and after surgery. Routine bronchoscopy is used as recommended in a guideline. Duration of treatment is defined by the length of hospital stay. Duration of the diagnostic procedure is approximately 10 minutes. Total duration of follow up also is defined by the length of the hospital stay.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16964-0</funderId>
      <contactId>Contact54925_16964</contactId>
      <sponsorId>Sponsor53490</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54925_16964">
    <title>Prof</title>
    <forename>Thomas</forename>
    <surname>Volk</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Klinik fur Anaesthesiologie und Operative Intensivmedizin
Charite Campus Mitte und Campus Virchow Klinikum
Chariteplatz 1</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>10117</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53490">
    <organisation>Charite - University Medicine Berlin (Charite - Universitaetsmedizin Berlin) (Germany) </organisation>
    <website>http://www.charite.de</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Chariteplatz 1</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>10117</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.6363.0</gridId>
    <rorId>https://ror.org/001w7jn25</rorId>
  </sponsor>
  <funder id="Funder16964-0">
    <name>Humboldt University of Berlin (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-06T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-11-06T00:00:00.000Z">22416062</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>An open-label, prospective, non-comparative clinical trial to evaluate the efficacy and safety of rosuvastatin in high risk Indian population with diabetes and dyslipidemia</title>
      <scientificTitle/>
      <acronym>RESIDD</acronym>
      <studyHypothesis>Rosuvastatin is effective in treating high risk Indian population of diabetic patients who have abnormal lipid levels.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Mean change in total cholesterol
2. Mean change in LDL cholesterol
3. Mean change in High Density Lipoprotein (HDL) cholesterol
4. Mean change in triglycerides
5. Number of patients achieving ATP III target LDL of less than 100 mg/dl

Primary and secondary time points will be measured by evaluating the blood parameters on week 6 and week 12 against the baseline collected at the time of enrolment.</primaryOutcome>
      <secondaryOutcome>1. Mean change in the level of hs-CRP
2. Mean change in level of apoprotein B
3. Mean change in apoB/apoA1 ratio
4. Mean change in apoprotein A1
5. Mean change in lipoprotein a
6. Change in glycosylated haemoglobin at the end of study period
7. Incidence of hepatic dysfunction defined by liver enzyme elevation more than three times in the absence of other systemic cause
8. Compliance and side effects
9. Mean change in the level of creatinine kinase

Primary and secondary time points will be measured by evaluating the blood parameters on week 6 and week 12 against the baseline collected at the time of enrolment.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Dhanvantry Independent Ethics Committee on the 11th June 2007 (ref: RANB11/06/2007).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN22416062</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CT/RNBX &#150; CV-LIFE/07</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open label, prospective, non-comparative clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-09-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>India</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f130b798-6dec-4cc2-8d53-6976e1e04790">
	  <name>Ranbaxy Laboratories Ltd</name>
	  <address/>
	  <city>Gurgaon</city>
	  <state/>
	  <country>India</country>
	  <zip>122001</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Diabetes type II defined by American Diabetes Association criteria of fasting venous plasma glucose of greater than or equal to 126 mg/dl, two-hour post prandial plasma glucose of greater than or equal to 200 mg/dl or already on treatment of diabetes
2. Dyslipidemia defined by Low Density Lipoprotein (LDL) cholesterol more than 100 mg/dl or on prior statin therapy
3. Age of greater than or equal to 30 and less than or equal to 70 years
4. Informed consent by the patient</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>360</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>360</totalTarget>
      <exclusion>1. Failure to give informed consent 
2. A history of hypersensitivity to statins
3. Evidence of fundoscopy grade 2 hypertensive or diabetic retinopathy
4. Serum creatinine greater than 1.5 mg/dl  
5. Overt proteinuria 
6. Pregnant or lactating mothers 
7. Evidence/history of heart failure
8. Systolic blood pressure above 180 mmHg and diastolic blood pressure above 110 mmHg 
9. Recent history of cerebrovascular disease, myocardial infarction, unstable angina, new onset Left Bundle Branch Block (LBBB) in the past 4 weeks
10. Documented case of homozygous familial hypercholesterolemia
11. Type I Diabetes Mellitus (DM)
12. Use of concomitant medications (cyclosporin, systemic itraconazole or ketoconazole, erythromycin, or clarithromycin, glucocorticoids or verapamil) known to affect the lipid profile or with potency safety concern
13. Recent ongoing inter-current infection/high sensitivity C-Reactive Protein (hsCRP) greater than 10 mg/L
14. Active liver disease or hepatic dysfunction (defined as Alanine aminotransferase [ALT], aspartate aminotransferase [AST], Gamma-Glutamyl Transferase [GGT], alkaline phosphate or bilirubin levels greater than or equal to 1.5 the upper limit of normal)
15. Diagnosed to have any other endocrinal or metabolic disease other than Type II DM that is known to influence serum lipids and lipoproteins
16. Patients having history suggestive of myalgia/myositis/arthralgia
17. Serious or unstable medical or psychological condition that could compromise the patient&#146;s safety or successful trial participation
18. History of alcohol consumption greater than 2 drinks/day (30 ml) or 10 drinks per week</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-09-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Diabetes patients with dyslipidemia</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Dyslipidemia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Once the enrolment of the patient is through he will be kept on:
1. Tab. rosuvastatin 10 mg once a day if his LDL level ranges between 100 mg/dL to 130 mg/dL for first 6 weeks, or
2. Tab. rosuvastatin 20 mg once a day if his LDL level is above 130 mg/dL for first 6 weeks

Week 6 (first follow-up):
The patients lipid profile will be evaluated and if the patient&#146;s LDL does not come under 100 mg/dL as per the guidelines of National Cholesterol Education Program (NCEP)-Adult Treatment Panel (ATP) III then the dose will be doubled, i.e., patients on rosuvastatin 10 mg will receive rosuvastatin 20 mg and patients getting rosuvastatin 20 mg will be given rosuvastatin 40 mg. It will remain once a day therapy.

Week 12 (second and last follow-up - end of study):
Patient&#146;s blood will be evaluated for the endpoints and the continuation of therapy will be on the treating clinician.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Rosuvastatin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16894-0</funderId>
      <contactId>Contact54853_16894</contactId>
      <sponsorId>Sponsor53411</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54853_16894">
    <title>Dr</title>
    <forename>Santosh</forename>
    <surname>Jha</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Ranbaxy Laboratories Ltd
Plot-90
Sector-32</address>
      <city>Gurgaon</city>
      <country>India</country>
      <zip>122001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+91 (0)991 003 4380 </telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dr.santoshjha@ranbaxy.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53411">
    <organisation>Ranbaxy Laboratories Ltd (India)</organisation>
    <website>http://www.ranbaxy.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>c/o Dr Santosh Jha
Plot-90
Sector-32</address>
      <city>Gurgaon</city>
      <country>India</country>
      <zip>122001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+91 (0)991 003 4380 </telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dr.santoshjha@ranbaxy.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.418931.6</gridId>
    <rorId>https://ror.org/030yyf771</rorId>
  </sponsor>
  <funder id="Funder16894-0">
    <name>Ranbaxy Laboratories Ltd (India)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-05T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-11-05T00:00:00.000Z">27834915</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluation of the sustained effect of Viniyoga in the rehabilitation of hypertensive patients</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>We hypothesise that patients who receive training in Viniyoga will continue practising the method 15% more often than those who receive training in Progressive Relaxation.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To assess whether more participants in the intervention group will maintain the method taught compared to those in the control group, assessed at three weeks (i.e. at the moment of discharge from our hospital) and six months after the discharge from the hospital.</primaryOutcome>
      <secondaryOutcome>The following will be measured at six months: 
1. Hospital Anxiety and Depression Scale [HADS] 
2. 36-item Short Form health survey (SF-36)
3. Heart rate variability 
4. Blood pressure
5. Use of antihypertensive medication</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Ethics Committee of Arztekammer Nordrhein in May 2007 (ref: 2007113).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN27834915</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-05-07T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-05-06T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4e2a5114-26e8-4988-af08-b62d9c275ec0">
	  <name>Klinik Roderbirken</name>
	  <address/>
	  <city>Leichlingen</city>
	  <state/>
	  <country>Germany</country>
	  <zip>D-42799</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Arterial Hypertension.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>300</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>300</totalTarget>
      <exclusion>1. Congestive heart failure (New York Heart Association [NYHA] II or more)
2. Relevant rhythm disorders
3. Relevant pulmonary disease
4. Dialyses
5. Surgery within the last four weeks
6. ST-elevation myocardial infarction within the last four weeks</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-05-07T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-05-06T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Arterial hypertension</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Arterial hypertension</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Viniyoga or Progressive Relaxation group training (maximum 10 people per group), 45 minutes per session, five days a week for three weeks.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16602-0</funderId>
      <contactId>Contact54560_16602</contactId>
      <sponsorId>Sponsor53115</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54560_16602">
    <title>Mrs</title>
    <forename>Claudia</forename>
    <surname>Fusshoeller</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Klinik Roderbirken</address>
      <city>Leichlingen</city>
      <country>Germany</country>
      <zip>D-42799</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)2175 824310</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Claudia.Fusshoeller@klinik-roderbirken.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53115">
    <organisation>Refonet (Germany)</organisation>
    <website>http://refonet.de</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Burgweg 3</address>
      <city>Bad Neuenahr-Ahrweiler</city>
      <country>Germany</country>
      <zip>D-53474</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Claudia.Fusshoeller@klinik-roderbirken.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487444.f</gridId>
    <rorId>https://ror.org/04yeh2x21</rorId>
  </sponsor>
  <funder id="Funder16602-0">
    <name>Refonet (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-31T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-10-31T00:00:00.000Z">44961472</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Pycnogenol® to reduce use of commercial anti-hypertensive medications: a randomised, double-blind, placebo-controlled, prospective, 15-week study</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Pycnogenol®, a natural product, a  "complementary or alternative medicine", will reduce the use of antihypertensive medicines (Angiotensin Converting Enzyme [ACE] inhibitors) and Cardiovascular Disease (CVD) risk factors in subjects with both hypertension and type 2 diabetes.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Measured at 12th week of treatment:
1. Blood pressure, measured on the left arm after 10 minutes rest (Korotkoff sounds I and V were taken as the systolic and diastolic blood pressures)
2. Serum endothelin-1
3. Fasting Low Density Lipoprotein (LDL)-cholesterol
4. Glycosylated haemoglobin (HbA1c)
5. Fasting plasma glucose
6. Urinary albumin concentration</primaryOutcome>
      <secondaryOutcome>Measured at 4th and 8th week of treatment:
1. Blood pressure, measured on the left arm after 10 minutes rest (Korotkoff sounds I and V were taken as the systolic and diastolic blood pressures)
2. Serum endothelin-1
3. Fasting Low Density Lipoprotein (LDL)-cholesterol
4. Glycosylated haemoglobin (HbA1c)
5. Fasting plasma glucose
6. Urinary albumin concentration</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Human Subjects Protection Program at University of Arizona on the 16th August 2003 (ref: 03-129).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN44961472</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single-centre, interventional, randomised double-blind placebo-controlled study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-08-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="2fa26299-0db8-4134-b100-0a56346418d8">
	  <name>Mel and Enid Zuckerman College of Public Health</name>
	  <address/>
	  <city>Tucson</city>
	  <state/>
	  <country>United States of America</country>
	  <zip>85724-5155</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Men and women, 40 - 75 years of age
2. Non-insulin dependent type 2 diabetes
3. Receiving pharmaceutical treatment (ACE-inhibitors) for hypertension 
4. Pre-trial systolic blood pressure of 130 - 150 mmHg</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>80</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>80</totalTarget>
      <exclusion>1. Type 1 diabetes
2. Use of insulin
3. Any supplements other than single daily multivitamin
4. Having any major illness such as cancer, asthma, or heart failure
5. Any previous cardiac events
6. Pregnancy, or being nursing mother</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-08-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Cardiovascular risk factors in diabetes</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Cardiovascular risk factors</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Oral administration of Pycnogenol® pills (25 mg, 5 times a day) or matched inactive placebo for 12 weeks. Total duration of follow-up is 15 weeks.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Pycnogenol®</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17202-0</funderId>
      <contactId>Contact55163_17202</contactId>
      <sponsorId>Sponsor53729</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55163_17202">
    <title>Prof</title>
    <forename>Ronald</forename>
    <surname>Watson</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Mel and Enid Zuckerman College of Public Health
University of Arizona, Health Science Center
1295 N. Martin
P. O. Box 245155 [FedEx building 202 room 252]</address>
      <city>Tucson</city>
      <country>United States of America</country>
      <zip>85724-5155</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53729">
    <organisation>Horphag Research Ltd (Switzerland) </organisation>
    <website>http://www.horphag.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>P.O. Box 80
Avenue Louis-Casai 71
Cointrin</address>
      <city>Geneva</city>
      <country>Switzerland</country>
      <zip>CH-1216</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487164.8</gridId>
    <rorId>https://ror.org/003n34405</rorId>
  </sponsor>
  <funder id="Funder17202-0">
    <name>Horphag Research Ltd (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-30T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-10-30T00:00:00.000Z">03887874</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Imaging-based Thrombolysis trial in Acute Ischemic Stroke -III</title>
      <scientificTitle/>
      <acronym>ITAIS- III</acronym>
      <studyHypothesis>Whether the patients without occlusion or significant stenosis of the large vessels should receive thrombolysis had been focused on and questioned for a long time. However, there is still no large Randomised Controlled Trial (RCT) to prove if these patients can benefit from thrombolysis. The objective of this trail is to investigate: 
1. For the selected acute ischemic stroke patients without large vessels occlusion or significant stenosis, whether the IntraVenous (IV) thrombolysis can improve the clinical outcome if the mismatch exists on CTP/Computed Tomography Angiography-Source Images (CTA-SI) scan in 3-9 hr time-window
2. For the selected acute ischemic stroke patients without large vessels occlusion or significant stenosis, whether the IV thrombolysis can improve the blood perfusion of brain if the mismatch exists on CT perfusion (CTP)/CTA-SI scan in 3-9 hr time-window
3. For the selected acute ischemic stroke patients without large vessels occlusion or significant stenosis, but the mismatch exists on CTP/CTA-SI scan in 3-9 hr time-window, whether the safety of IV thrombolysis is better than the NINDS trial which was in 3 hr window or implemented on the patients with large vessels occlusion or significant stenosis in 3-9 hr time-window.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Proportion of participants who achieve the following: 
1. Reperfusion improvement, assessed 24 to 48 hours post-treatment and defined as either greater than or equal to 30% reduction of Mean Transit Time (MTT) volume of abnormality
2. Good clinical outcome at 90 days defined as a modified Rankin score (mRS) of 0-1
3. Intracerebral haemorrhage within 24-36 h after thrombolysis</primaryOutcome>
      <secondaryOutcome>Proportion of participants who achieve the following: 
1. mRS 0 to 2 at 90 days 
2. Barthel Index (BI) score 75 to 100 at 90 days 
3. NIHSS 4 points improvement or 0-1 at 2 hours after treatment 
4. NIHSS 4 points improvement or 0-1 at 24 to 48 hours 
5. NIHSS 4 points improvement or 0-1 at day 7</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval gained from the Beijing Tiantan Hospital Capital Medical University Ethics Board on October 10, 2006.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN03887874</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>5</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A prospective, multi-center, assessor-blind controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>China</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b9a281d3-ee60-428f-b959-e23ff373ca0e">
	  <name>Neurology Department</name>
	  <address/>
	  <city>Beijing</city>
	  <state/>
	  <country>China</country>
	  <zip>100050</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Female or male inpatients 
2. Age 18-80 years 
3. Clinical diagnosis of ischaemic stroke 
4. Onset of symptoms within 3-9 hours prior to initiation of thrombolysis treatment 
5. Stroke symptoms present for at least 30 minutes and has not significantly improved before treatment 
6. The National Institutes of Health Stroke Scale (NIHSS) score greater than or equal to 4 
7. m-CT screening to be started within 8.5 hrs after stroke onset 
8. Perfusion abnormality of CT scan &gt;2cm in diameter involving hemisphere 
9. CT Perfusion/CTA source image mismatch greater than or equal to 20% 
10. CTA shows occlusion or significant stenosis of large vessels (Thrombolysis In Cerebral Ischemia [TICI] grade is 0 or 1) 
11. Patients are willing to receive thrombolysis treatment and to give informed consent 
12. Patients are willing and able to comply with the study protocol</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="80.0"/>
      <gender>Both</gender>
      <targetEnrolment>200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>200</totalTarget>
      <exclusion>1. Evidence of IntraCranial Haemorrhage (ICH), brain tumors, vascular malformation, aneurysm, SubArachnoid Hemorrhage (SAH) 
2. Major infarct involving greater than 1/3 of Middle Cerebral Artery (MCA) territory on the CTA-SI 
3. Presenting obvious neurologic deficits because of past stroke (mRS &gt;2) 
4. Severe stroke as assessed clinically (e.g. The National Institute of Health Stroke Scale [NIHSS] &gt;25) and/or by appropriate magnetic imaging techniques. 
5. Seizure at onset of stroke 
6. Prior stroke within the last 3 months 
7. Patients with any history of prior stroke and concomitant diabetes 
8. Administration of heparin within the previous 48 hours and a thromboplastin time exceeding the upper limit of normal for laboratory 
9. Platelet count of below 100,000/mm3
10. Uncompensated hypertension at study entry or hypertension requiring aggressive treatment to reduce blood pressure to nonhypertensive limits. Uncompensated hypertension is defined as systolic blood pressure &gt;185 mm Hg or diastolic blood pressure &gt;=110 mm Hg on 3 repeated measures at least 10 minutes apart 
11. Blood glucose &lt;50 or &gt;400 mg/dl 
12. Known haemorrhagic diathesis within the last 6 months 
13. Patients receiving oral anticoagulants e.g. warfarin sodium, and coagulant response time (INR) &gt;1.5 
14. Known history of or suspected intracranial haemorrhage including subarachnoid haemorrhage 
15. Pregnancy or lactation 
16. Any history of severe central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery) 
17. Haemorrhagic retinopathy,e.g. in diabetes (vision disturbances may indicate haemorrhagic retinopathy) 
18. Bacterial endocarditis, pericarditis
19. Prolonged traumatic external heart massage, or recent (less than 10 days) obstetrical delivery or recent puncture of a non-compressible blood-vessel (e.g. subclavian or jugular vein puncture) 
20. Acute pancreatitis 
21. Documented ulcerative gastrointestinal disease during the last 3 months, 
22. Oesophageal varices, arterial aneurysm, arterial/venous malformation 
23. Neoplasm with increased bleeding risk 
24. Severe liver disease including hepatic failure, cirrhosis, portal hypertension, oesophageal varices and active hepatitis 
25. Major surgery or significant trauma in past 10 days 
26. Known serious sensitivity to alteplase</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute ischemic stroke</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Acute ischemic stroke</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients included were divided into recombinant tissue Plasminogen Activator (rt-PA) (0.9 mg/kg) intravenous thrombolysis group and regular treatment group according to the intention of doctors and patients.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Recombinant tissue Plasminogen Activator (rt-PA)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17196-0</funderId>
      <contactId>Contact55157_17196</contactId>
      <sponsorId>Sponsor53722</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55157_17196">
    <title>Prof</title>
    <forename>Yongjun </forename>
    <surname>Wang</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Neurology Department
Beijing Tiantan Hospital 
Tiantan Xili 6 
Chongwen District </address>
      <city>Beijing</city>
      <country>China</country>
      <zip>100050</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">yongjunwang111@yahoo.com.cn</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53722">
    <organisation>Beijing Tiantan Hospital (China) </organisation>
    <website>http://www.bjtth.com/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Beijing Tiantan Hospital 
Tiantan Xili 6 
Chongwen District</address>
      <city>Beijing</city>
      <country>China</country>
      <zip>100050</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">yongjunwang111@yahoo.com.cn</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.411617.4</gridId>
    <rorId>https://ror.org/003regz62</rorId>
  </sponsor>
  <funder id="Funder17196-0">
    <name>The Ministry of Science and Technology and the Ministry of Health of the People's Republic of China - the key scientific research program of the 11th National Five-Year Planning of China</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-30T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-10-30T00:00:00.000Z">05620936</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Development of a simple protocol to enhance compliance in home management of malaria</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Malaria is a disease caused by the protozoan plasmodium falciparum. It is still rampant in sub-Saharan Africa and endemic in Nigeria with perennial transmission. It causes febrile illness which could be severe in children accounting for 25% of infant mortality and 8-12% of death under age of five years. Malaria is responsible for 40-60% of out patient consultation. It presents in two clinical types - uncomplicated and severe malaria. 

Study Domain: Parasitic infection; child care and health education/behaviour change

Study hypotheses:  
1. There will be no significant difference in the outcome of malaria in children whose mothers or caregivers used treatment protocol to treat malaria at home and those whose mothers did not use the protocol. 
2. There will be no significant difference in the correctness of use of chloroquine by mothers who used the treatment protocol and those who did not use the protocol. 
3. There will be no significant difference in the correctness of use of chloroquine by trained mothers and mothers who were not trained.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The mothers/caregivers were asked about the treatment given to the child during visits by the research assistants. The mothers/caregivers were asked to record these details in their diary, which was checked on Day 7 from recruitment at the time of collecting Day 7 blood sample for microscopy examination. These data were used to assess the following: 

1. Correct use of chloroquine, measured in terms of dose, frequency and duration 
2. Timeliness of commencing treatment (commencing treatment within 24 hours of noticing fever in child) 
3. Treatment outcome, measured by mean parasite clearance time, fever clearance time, and progression of illness as reported by mothers/caregivers 
4. Use of the protocol. Proportion of mothers who referred to the treatment protocol in the treatment of last episode of malaria in children</primaryOutcome>
      <secondaryOutcome>1. Attack rate of malaria over a period of one year 
2. Sensitivity and specificity of presumptive diagnosis of malaria by mothers/caregivers</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The joint University of Ibadan/University College Hospital Institutional Ethical Review Board. Date of Approval: 29th June 2000</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN05620936</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single-centre, single-blind, randomised controlled field study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-06-16T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Nigeria</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="773fd67e-3d02-42e4-aba1-c87a70aaee4e">
	  <name>Department of Epidemiology</name>
	  <address/>
	  <city>Ibadan</city>
	  <state/>
	  <country>Nigeria</country>
	  <zip>PMB 5116</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Mothers with children 10 years or less who have febrile illness presumed to be malaria 
2. Willingness of mothers to allow their child remain in study for a period of 14 days 
3. Mothers who consent to their child having finger prick to collect blood for blood smears</inclusion>
      <ageRange>Child</ageRange>
      <upperAgeLimit unit="Years" value="10.0"/>
      <gender>Both</gender>
      <targetEnrolment>152</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>152 children (76 in each arm)</totalTarget>
      <exclusion>1. Child with severe illness or requiring parenteral medication 
2. Child with other diseases, co-morbid with febrile illness 

Withdrawal Criteria: 
1. Parents of children choosing not to continue with the study 
2. Progression of illness in child</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-06-16T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Malaria</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Malaria</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Randomisation of the communities to the intervention and control groups was done by ballots. 

Interventions carried out at the intervention site: 
1. Training of 'mother trainers' and community members about cause, symptoms and signs of the clinical types, treatment and prevention of malaria including referral. 

2. Development of a treatment protocol using participatory approach and distribution of the protocol to households. The development of the protocol was done in phases using modified focus group sessions with several community checks at different stages of development. The participants were the 'mother trainers', selected community members, research team and a graphic artist. The treatment protocol consists of treatment guidelines for each of the clinical types of malaria compiled together on a cardboard. The protocol illustrated the presentation of clinical types of malaria, the appropriate steps to take for each type and the correct dose and schedule of treatment of uncomplicated malaria using chloroquine according to the age of the child. The protocol was in cartoon format and the local language was used. 

Mothers/caregivers in both arms of the study were requested to purchase the chloroquine used for treatment from their regular source which in most instances are the drug hawkers and patent medicine sellers. 

Control arm of the study: 
They were passive controls. The communities in the control arm of the study were left to continue their usual treatment practice for malaria in their children. No training or guideline was provided.

Duration of intervention: One year</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder17213-0</funderId>
      <contactId>Contact55174_17213</contactId>
      <sponsorId>Sponsor53740</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact55174_17213">
    <title>Dr</title>
    <forename>Ikeoluwapo </forename>
    <surname>Ajayi</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Epidemiology
Medical Statistics and Environmental Health
College of Medicine
University of Ibadan </address>
      <city>Ibadan </city>
      <country>Nigeria</country>
      <zip>PMB 5116</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ikeajayi2003@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53740">
    <organisation>University of Ibadan (Nigeria)</organisation>
    <website>http://www.ui.edu.ng/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>c/o Dr Ikeoluwapo Oyeneye Ajayi
Department of Epidemiology
Medical Statistics and Environmental Health
College of Medicine
University of Ibadan</address>
      <city>Ibadan </city>
      <country>Nigeria</country>
      <zip>PMB 5116</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+234 8 023 268431</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ikeajayi2003@yahoo.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.9582.6</gridId>
    <rorId>https://ror.org/03wx2rr30</rorId>
  </sponsor>
  <funder id="Funder17213-0">
    <name>Investigator funded (Nigeria)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-10T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-10-10T00:00:00.000Z">79667806</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The differential effects of visceral fat reduction compared with subcutaneous fat reduction on parameters of the metabolic indices and adipocytokines</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The weight reduction with the change of fat distribution influence on the adipokines and metabolic indices.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The changes of body fat distribution and adipocytokines, determined by computed tomography scan and measured both before and 16 weeks after the weight reduction program.</primaryOutcome>
      <secondaryOutcome>The relationship of body fat distribution and adipocytokines, determined by computed tomography scan and measured both before and 16 weeks after the weight reduction program.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Institutional Review Board of Yondong Severance Hospital, Yonsei University College of Medicine (South Korea) on the 6th September 2006 (ref: 3-2006-0044).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN79667806</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A prospective intervention study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-09-06T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-05-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Korea, South</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8c6ddf10-9d3c-41c5-a239-5d99a0200273">
	  <name>Department of Family Medicine</name>
	  <address/>
	  <city>Seoul</city>
	  <state/>
	  <country>Korea, South</country>
	  <zip>135-270</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Apparently healthy, either sex, aged 18 - 60 years
2. Non-smokers 
3. Low alcohol consumers
4. Overweight or obese with an average Body Mass Index (BMI) of 23 kg/m^2 or greater</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <upperAgeLimit unit="Years" value="60.0"/>
      <gender>Both</gender>
      <targetEnrolment>52</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>52</totalTarget>
      <exclusion>1. A past history of cardiovascular disease
2. Diabetes
3. Moderate to severe hypertension (resting blood pressure greater than 170/100 mmHg)
4. Renal impairment (serum creatinine greater than 120 µmol/L) or overt proteinuria
5. Obesity caused by an endocrine disorder
6. Psychiatric disorders
7. Current pregnancy or breast-feeding
8. A body weight fluctuation of more than 5 kg in the previous six months
9. Taking any kind of medication</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-09-06T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-05-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Obesity</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Obesity</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All patients received all three interventions for 16 weeks:
1. The subjects visited an obesity clinic twice per month and restricted their caloric intake to less than their usual intake by 600 kcal/day
2. All patients were encouraged to achieve the goal of five hours of aerobic exercise (physical activity of moderate intensity, such as brisk walking, light jogging or stationary ergometer usage) per week
3. They were also administered 10 - 15 mg of sibutramine (in the morning)</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Sibutramine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16940-0</funderId>
      <contactId>Contact54901_16940</contactId>
      <sponsorId>Sponsor53466</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54901_16940">
    <title>Dr</title>
    <forename>Ji-Won</forename>
    <surname>Lee</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Family Medicine
Yonsei University College of Medicine
Yongdong Severance Hospital
Kangnam 
P.O. Box 1217</address>
      <city>Seoul</city>
      <country>Korea, South</country>
      <zip>135-270</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53466">
    <organisation>Yonsei University College of Medicine (South Korea) </organisation>
    <website>http://medicine.yonsei.ac.kr/en/index.asp</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>250 Sungsan-Ro 
Seodaemoon-gu</address>
      <city>Seoul </city>
      <country>Korea, South</country>
      <zip>120-752 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.15444.30</gridId>
    <rorId>https://ror.org/01wjejq96</rorId>
  </sponsor>
  <funder id="Funder16940-0">
    <name>Yonsei University College of Medicine (South Korea) - faculty research grant (2006)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-10T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-10-09T00:00:00.000Z">68305337</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The efficacy of chiropractic spinal adjustments as a treatment protocol in the management of infantile colic: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Chiropractic manipulation is more effective than placebo for the treatment of infantile colic.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Parental questionnaire at baseline, each subsequent treatment session and follow-up consultation. The questionnaire asked the following quetisons: 
1. Measured from the parents' perception, how long does the baby cry with each attack of colic?  
2. How often does the colic occur in 24 hours?  
3. Does the colic attack occur at any particular time of day or night?  
4. Does anything seem to precipitate an attack?  
5. For how long does the baby sleep between colic attacks?  
6. Does the baby still require medicine to relieve the colic?  
7. How would you rate the baby's response to treatment (1-5)?  
8. Has the baby had any other illnesses?</primaryOutcome>
      <secondaryOutcome>Increased joint motion assessed at baseline, each subsequent treatment session and follow-up consultation.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Responsible Committee on Human Experimentation, and the Research Ethics Committee of Technikon Natal, Durban, South Africa. Approved in 1998.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN68305337</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1998-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1998-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Australia</country>
	<country>South Africa</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0ef1a2e0-2797-44f9-950b-f1da42f66641">
	  <name>Murdoch University</name>
	  <address/>
	  <city>Murdoch</city>
	  <state/>
	  <country>Australia</country>
	  <zip>6150</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. The infant was to undergo a thorough examination by the consulting paediatrician to determine the health of the infant and to exclude any underlying organic problem, thereby ensuring a strict diagnosis of infantile colic
2. The infant was to be 0 to 8 weeks of age at the commencement of treatment to exclude the possibility of spontaneous cessation of the colic at 3 months
3. Apart from the colic, the infant was to suffer from no other condition/disease
4. If any medication had been administered to the infant to relieve the symptomatology of colic prior to the commencement of treatment (whether prescribed or over-the-counter drugs) the infant was required to remain on the same medication for the duration of the study, if the medication was required
5. Written informed consent was to be obtained from a parent before participation in the study</inclusion>
      <ageRange>Neonate</ageRange>
      <gender>Both</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>Any participant that did not meet the inclusion criteria.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1998-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1998-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Infantile colic</description>
	<diseaseClass1>Neonatal Diseases</diseaseClass1>
	<diseaseClass2>Infantile colic</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Chiropractic manipulation/mobilization for spinal adjustments vs placebo treatment. One hour per session, 6 sessions over a 2-week period with a follow-up consultation after 1 month.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16103-0</funderId>
      <contactId>Contact54049_16103</contactId>
      <sponsorId>Sponsor52603</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54049_16103">
    <title>Dr</title>
    <forename>Brian</forename>
    <surname>Nook</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Murdoch University
School of Chiropractic
Room ECL 1.009
South Street</address>
      <city>Murdoch</city>
      <country>Australia</country>
      <zip>6150</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+61 08 9360 7690</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">b.nook@murdoch.edu.au</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52603">
    <organisation>Technikon Natal School of Chiropractic (South Africa)</organisation>
    <website>http://www.dut.ac.za/front%20page.aspx</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Durban University Of Technology - Durban Central Offices
41/43 Centenary Road</address>
      <city>Durban</city>
      <country>South Africa</country>
      <zip>4001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+27 (0)31 308 5111</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">CharmaK@dut.ac.za</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.412114.3</gridId>
    <rorId>https://ror.org/0303y7a51</rorId>
  </sponsor>
  <funder id="Funder16103-0">
    <name>Technikon Natal School of Chiropractic (South Africa)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-03T00:00:00.000Z" version="17">
    <isrctn dateAssigned="2007-10-03T00:00:00.000Z">25515380</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Occupational orientation in medical neurorehabilitation (Berufliche Orientierung in der Medizinischen Neurorehabilitation [BOMeN])</title>
      <scientificTitle/>
      <acronym>BOMeN</acronym>
      <studyHypothesis>The trial studies survivors of stroke or brain injury with a special occupational difficulty concerning the reintegration to work. For these patients return-to-work is accompanied by explicit strains because of the coincidence of physical and cognitive impairments. Furthermore patients with acquired brain injury often focus only on the physical deficits and do not show adequate awareness for cognitive constraints. 

Hypotheses: 
1. Until 15 months after rehabilitation the ratio of (re-)employed persons in the intervention group is significantly higher than the ratio of (re-)employed persons in the control group
2. Until 15 months after rehabilitation the ratio of (re-)employable persons in the intervention group is significantly higher than the ratio of (re-)employable persons in the control group
3. Patients of the intervention group can be re-integrated significantly quicker than patients of the control group
4. Re-integrated patients who participated in the intervention group show significantly less days of incapacity for work than re-integrated patients who participated in the control group
5. Patients who participated in the intervention group show a significantly higher satisfaction with life and health than patients who participated in the control group
6. Patients who participated in the intervention group show a significantly higher motivation for rehabilitation than patients who participated in the control group
7. The intervention treatment will gain a higher valuation than the control treatment by the parties involved  (patients and rehabilitation workers)</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following variables are measured by standardized or self-developed questionnaires: 
1. Re-employment (patients) 15 months after rehabilitation
2. (Re-)employability (patients) 15 months after rehabilitation
3. Days of incapacity to work (patients), measured using the Indicators of the Status of Rehabilitation questionnaire (Indikatoren des Reha-Status [IRES]) 15 months after rehabilitation
4. Expectations concerning the rehabilitation (patients), measured using the Questionnaire on Expectations and Motivation Concerning Rehabilitation (Fragebogen zu Reha-Erwartungen und Reha-Motivation [FREM]) at the start and end of rehabilitation
5. Motivation for rehabilitation (patients), measured using the Diagnostic Investigation of Motivation Concerning Work questionnaire (Diagnostik von Arbeitsmotivation [DIAMO]) at the start and end of rehabilitation, 6, 12 and 15 months after rehabilitation
6. Satisfaction with life and health (patients) (the 36-item Short Form health survey [SF-36]/the World Health Organization Quality of Life Questionnaire [WHO-QoL-BREF]) at the start and end of rehabilitation, 6, 12 and 15 months after rehabilitation
7. Satisfaction with rehabilitation procedure and contents (patients and rehabilitation workers). Timepoints for patients: at the start and end of rehabilitation, 6, 12 and 15 months after rehabilitation. Timepoints for workers: once in Summer 2008.</primaryOutcome>
      <secondaryOutcome>1. Cognitive functional status at the start and end of rehabilitation, 6, 12 and 15 months after rehabilitation
2. Motivation for work at the start and end of rehabilitation, 6, 12 and 15 months after rehabilitation</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee of the Arztekammer Westfalen-Lippe and the Medical Faculty of the Westfalischen Wilhelms Unitersigy of Munster. Approved on 24th May 2007 (ref: 2007-235-f-S)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN25515380</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>GfR 06/006</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="750eeeaf-3705-4a02-b7ce-7b0eea1010ac">
	  <name>Johanniterstrasse 7</name>
	  <address/>
	  <city>Bad Oeynhausen</city>
	  <state/>
	  <country>Germany</country>
	  <zip>32545</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All participants must meet all of the following conditions: 
1. Positive prognostic estimation of occupational ability 
2. Stroke or craniocerebral trauma 
3. Estimated Functional Independence Measure (FIM) greater than or equal to 90 
 
Also, all participants must meet at least one of the following conditions: 
1. Advice for medical rehabilitation based on paragraph 51.1 of the Social Security Statutes, Book No. 5 (SGB V)
2. Inability to work for 3 months during the last 12 months 
3. Ability to work is less than 6 hours 
4. Not in paid work before start of rehabilitation 
5. Necessary occupational reorientation 
6. Application for a pension 
7. Risk of early retirement</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>306</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>306</totalTarget>
      <exclusion>1. Older than 60 years 
2. Acute psychiatric disorder 
3. Acute addiction 
4. Restrictive aphasic disorder
5. Insufficient knowledge of German language 
6. Estimated FIM &lt;90 
7. Neurological diseases other than stroke or craniocerebral trauma</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Neurorehabilitation for survivors of stroke and brain injury</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Neurorehabilitation for survivors of stroke and brain injury</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention group: Patients of the intervention group take part in a newly developed rehabilitation concept called Occupational Orientation in Medical Neurorehabilitation (BOMeN) which consists of nine sessions of 3 hours during a 4-week rehabilitation. In this therapy the patients get to know relevant information about stress, perspectives, motivation and the relevance of attention, memory, planning functions and motor skills for everyday working life. The contents are mediated by patient education, experiments of perception and ergotherapeutic exercises. Furthermore the neuropsychological, socialmedical and ergotherapeutical assessments are more related to work and therapy is integrated in a fixed schedule. Finally different disciplines show a higher degree of interworking. 

Control group: Medical Neurorehabilitation (MeN) patients of the control group take part in the conventional rehabilitation concept (MeN) which contains shorter units of assessment and therapy without an explicit relation to work. The average duration of treatment in both groups is controlled.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16876-0</funderId>
      <funderId>Funder16876-1</funderId>
      <contactId>Contact54835_16876</contactId>
      <sponsorId>Sponsor53393</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54835_16876">
    <title>Dr</title>
    <forename>Anke</forename>
    <surname>Menzel-Begemann</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Johanniterstrasse 7</address>
      <city>Bad Oeynhausen</city>
      <country>Germany</country>
      <zip>32545</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 5731 151 773</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">anke.menzel-begemann@ahb-klinik.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53393">
    <organisation>Association for Rehabilitation Sciences Nordrhein-Westfalen e.V. (Germany)</organisation>
    <website>http://www.rehaforschung-nrw.de</website>
    <sponsorType>Not defined</sponsorType>
    <contactDetails>
      <address>Königsallee 71</address>
      <city>Düsseldorf</city>
      <country>Germany</country>
      <zip>40215 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder16876-0">
    <name>Association for Rehabilitation Sciences Nordrhein-Westfalen e.V. (Gesellschaft für Rehabilitationswissenschaften Nordrhein-Westfalen e.V.) (ref: GfR 06006 / 623-06)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16876-1">
    <name>Houses of Holy Order of Johanniter Rehabilitation Centre (Johanniter-Ordenshäuser Bad Oeynhausen gemGmbH) (ref: BOMeN 98410)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-03T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-10-03T00:00:00.000Z">46330948</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled trial comparing group to individual prenatal care</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>It was hypothesised that group prenatal care would improve maternal mental health (depression and anxiety), psychosocial health (social support, stress, parenting morale, parenting self-efficacy) and infant birth outcomes (low birth weight, small for gestational age and preterm birth rates) compared to individual prenatal care among a community sample of women in Calgary, Alberta.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Maternal mental health: depression and anxiety - measured at study intake (prior to 20 weeks gestation), third trimester (32 - 36 weeks gestation) and 4 months postpartum 
2. Maternal psycho-social health:
2.1. Social support and stress - measured at study intake (prior to 20 weeks gestation) and 4 months postpartum 
2.2. Parenting morale and parenting self efficacy - measured at 4 months postpartum</primaryOutcome>
      <secondaryOutcome>1. Rates of infant birth outcomes (low birth weight, small for gestational age, preterm birth) - measured at birth 
2. Rates of breast feeding, uptake of parenting classes/supports, attendance at well child visits, immunisation rates - measured at 4 months postpartum</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Conjoint Health Research Ethics Board, University of Calgary and Calgary Health Region on the 7th June 2007 (ref: E-20821).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN46330948</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2011-07-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8ab309bc-ee9f-4272-a795-3d8feb2be694">
	  <name>Alberta Children's Hospital (ACH)</name>
	  <address/>
	  <city>Calgary</city>
	  <state/>
	  <country>Canada</country>
	  <zip>T3B 6A8</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Pregnant woman living in Northeast Calgary
2. Less than 20 weeks gestation at study intake
3. Able to communicate in English, Punjabi, Mandarin, Hindi, Arabic, Urdu or Spanish</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Female</gender>
      <targetEnrolment>1200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1200</totalTarget>
      <exclusion>1. Pregnant woman living outside Northeast Calgary
2. Greater than 20 weeks gestation at study intake
3. Unable to communicate in English, Punjabi, Mandarin, Hindi, Arabic, Urdu or Spanish</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2011-07-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Maternal mental health</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Post-natal mental disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Pregnant women are randomised to: 
1. Standard individual prenatal care
2. Group prenatal care

Control: Standard Prenatal Care 
Women randomly assigned to individual prenatal care will receive a standard schedule of one-on-one prenatal visits with a physician. The timing and frequency of visits will be decided by each womens' physician, although it is anticipated that they will follow the clinical practice guidelines, Healthy Beginnings: Guidelines for Care during Pregnancy and Childbirth provided by the Society for Obstetrics and Gynaecologists of Canada (SOGC). Women with high medical risk pregnancies will be referred for obstetrical care. 

Intervention: Group Prenatal Care 
Women randomly assigned to group prenatal care will receive an initial individual prenatal visit with a physician to confirm their pregnancy and subsequently will be grouped with 8 - 12 other women who are at a similar stage in pregnancy. Each group will meet with a health care provider for nine group sessions including one-on-one time with the provider for a prenatal check-up, time to conduct self measurements of their weight and blood pressure and a group discussion covering a topic appropriate to their stage of pregnancy. The group discussion will be co-facilitated by the physician and a perinatal educator who will encourage group members to participate in discussing topics of interest related to pregnancy, childbirth, parenting, and personal growth. These group sessions will take place at approximately 16, 20, 24, 28, 32, 34, 36, 38 weeks gestation and 2 weeks postpartum. Women will also receive individual prenatal visits at 37 and 39 weeks gestation. Women with high medical risk pregnancies will be referred for obstetrical care.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16761-0</funderId>
      <funderId>Funder16761-1</funderId>
      <contactId>Contact54719_16761</contactId>
      <sponsorId>Sponsor53275</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54719_16761">
    <title>Dr</title>
    <forename>Suzanne</forename>
    <surname>Tough</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Alberta Children's Hospital (ACH)
c/o Decision Support Research Team, Room C4-301
2888 Shaganappi Trail NW</address>
      <city>Calgary</city>
      <country>Canada</country>
      <zip>T3B 6A8</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53275">
    <organisation>Calgary Health Region (Canada) - Three Cheers for the Early Years </organisation>
    <website>http://www.calgaryhealthregion.ca/3cheers/home.htm</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>5th Floor
1509 Centre Street South</address>
      <city>Calgary</city>
      <country>Canada</country>
      <zip>T2G 2E6</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.413574.0</gridId>
    <rorId>https://ror.org/02nt5es71</rorId>
  </sponsor>
  <funder id="Funder16761-0">
    <name>Calgary Health Region (Canada) - Three Cheers for the Early Years</name>
    <fundRef/>
  </funder>
  <funder id="Funder16761-1">
    <name>Alberta Heritage Foundation for Medical Research (Canada)</name>
    <fundRef>http://dx.doi.org/10.13039/501100003179</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-27T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-09-27T00:00:00.000Z">52466525</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Phase III trial of gemcitabine concurrent with radiation for locally advanced squamous cell carcinoma of the head and neck</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Cisplatin concurrent with radiation therapy has been used in stage IV head and neck cancer. One previous study has reported that the combination of low-doses of gemcitabine with radiotherapy has a similar response in terms of overall survival and progression-free survival to that of cisplatin concurrent with radiation in patients with III, IVa, IVb stage disease. Based on these facts we decided to perform a randomised phase III trial to compare cisplatin concurrent with radiation versus low-dose gemcitabine concurrent with radiation for locally advanced squamous cell carcinoma of the head and neck. The hypothesis being a similar response in both conditions, but better control of adverse effects with low-dose gemcitabine/radiotherapy.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Data of interest (haematologic toxicity, presence of mucositis, skin rash, nausea/vomiting, dysphagia, odynophagia, etc) is assessed and collected at the time of each visit. The first timepoint at which the outcomes will be measured will be at 6 months after inclusion in the study. Toxicity is evaluated according to the National Cancer  Institute - Common Toxicity Criteria version 3 (NCI-CTC v.3.0).</primaryOutcome>
      <secondaryOutcome>Efficacy in terms of overall and progression free-survival, will be determined with clinical examination, Computed Tomography (CT)-scans, medical lab tests (metabolic profile, Complete Blood Count [CBC], blood chemistry), endoscopy and biopsy studies.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the National Cancer Institute of Mexico Ethics and Scientific Committee (Comite de Etica y Científico del Instituto Nacional de Cancerologia) on the 5th March 2007 (ref: CB/341/06).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN52466525</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>007/022/OMI</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Mexico</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d1b610ec-b094-448c-9bef-944e0676f3e6">
	  <name>St. Fernando Avenue No. 22</name>
	  <address/>
	  <city>Mexico City</city>
	  <state/>
	  <country>Mexico</country>
	  <zip>14080</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. International Union Against Cancer (UICC) classification stage IVb
2. Histologically proven and measurable squamous cell carcinoma of the head and neck (oral cavity, oropharynx, larynx, hypopharynx)
3. Previously untreated
4. Unresectable disease (when surgical resection was considered technically not feasible or surgical resection with clear margins was estimated to produce significant organ and/or function loss) or refused surgery
5. Aged 18 to 70 years
6. Squamous cell carcinoma of the head and neck without distant metastases
7. Karnofsky performance status score greater than or equal to 70%
8. Normal renal, hepatic and haematological function
9. Negative pregnancy 
10. Informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>216</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>216</totalTarget>
      <exclusion>1. Surgery and chemotherapy previously
2. Previous malignancy except non-melanoma skin cancer and cervical carcinoma in situ
3. Any clinical manifestation of distant metastases
4. Therapy concurrent 30 days previous with other experimental anti-neoplastic treatment
5. Systemic and/or uncontrolled disease that precludes the use of chemotherapy
6. Hypersensibility to gemcitabine or cisplatin</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Advanced squamous cell carcinoma of the head and neck</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Squamous cell carcinoma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients with squamous cell carcinoma of the head and neck staged IVb will be randomised to either:

Arm 1: cisplatin at 50 mg/m^2, administered intravenously over 60 minutes with 125 ml mannitol once weekly, 3 hours before radiation. The total dose of radiation will be administered to the macroscopic tumour and to potential sites of microscopic spread was 70 Gy, over 7 weeks.

Arm 2: gemcitabine at 100 mg/dl, administered intravenously over 30 minutes once weekly, 3 hours before radiation. The total dose of radiation will be administered to the macroscopic tumour and to potential sites of microscopic spread was 70 Gy, over 7 weeks.

The maximal dose to the spinal cord was restricted to 45 and 54 Gy to the brain stem and optic nerves, respectively. Total treatment time is seven weeks; overall time of this trial is three years.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase III</phase>
	<drugNames>Gemcitabine, cisplatin, mannitol</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16786-0</funderId>
      <contactId>Contact54744_16786</contactId>
      <sponsorId>Sponsor53300</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54744_16786">
    <title>Dr</title>
    <forename>Jose Luis</forename>
    <surname>Aguilar Ponce</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>St. Fernando Avenue No. 22
Sec. XVI</address>
      <city>Mexico City</city>
      <country>Mexico</country>
      <zip>14080</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53300">
    <organisation>National Cancer Institute of Mexico (Instituto Nacional de Cancerologia [INCAN]) (Mexico) </organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>c/o Dr Jose Luis Aguilar Ponce
St. Fernando Avenue No. 22
Sec. XVI  
Mexico, D.F.</address>
      <city>Mexico City</city>
      <country>Mexico</country>
      <zip>14080</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.419167.c</gridId>
    <rorId>https://ror.org/04z3afh10</rorId>
  </sponsor>
  <funder id="Funder16786-0">
    <name>National Cancer Institute of Mexico (Instituto Nacional de Cancerologia [INCAN]) (Mexico)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-24T00:00:00.000Z" version="17">
    <isrctn dateAssigned="2007-09-24T00:00:00.000Z">88124420</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Pharmacological modulation of heterosynaptic LOng-TErm POtentiation in humans by LOrazepam and METHylphenidat</title>
      <scientificTitle/>
      <acronym>LOTEPOLOMETH</acronym>
      <studyHypothesis>Long-Term Potentiation (LTP) within the nociceptive system is one of the mechanisms underlying central sensitisation, which accounts for some hyperalgesic pain states in chronic pain patients. In the study we will use a human surrogate model of nociceptive LTP to study the involvement of the GABAergic and the catecholaminergic system in the induction of hyperalgesia following high-frequency electrical stimulation of nociceptive afferents in the skin. 

We will study the contribution of GABAA-receptors (by lorazepam, a GABAA-receptor agonist) and receptors of catecholamines (by methylphenidat, a dopamine/noradrenaline re-uptake inhibitor) in plastic changes within the nociceptive system, which occur typically after a tissue injury, but in contrast to a real lesion we mimic an injury by high-frequency electrical stimulation of nociceptive afferents in the skin. This conditioning stimulation will lead to pain to light tactile stimuli (dynamic mechanical allodynia) and to an increase of pain to punctuate mechanical pain stimuli (static mechanical hyperalgesia). Both phenomena can typically been found in a subset of neuropathic pain patients.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following outcomes will be assessed based on the sensory changes determined by QST during the intervention: 
1. Spread of the area of dynamic allodynia and static hyperalgesia 
2. Combined analgesic and anti-hyperalgesic effect to mechanical and electrical stimuli on the site of conditioning stimulation</primaryOutcome>
      <secondaryOutcome>The following outcomes will be assessed based on the sensory changes determined by QST during the intervention:
1. Anti-hyperalgesic effect to electrical and mechanical test stimuli 
2. Analgesic effect to electrical and mechanical test stimuli 
3. Anti-wind up pain, tested by mechanical pinprick stimuli</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by the Local Ethics Committee (Ethikkommission der Landesärztekammer Rheinland-Pfalz) on 15 March 2003 (ref: 837.002.03[3664]) and was conducted in accordance with the declaration of Helsinki, the German Medicines Act (AMG), and the guidelines of the International Conference on Harmonisation (ICH) for Good Clinical Practice (GCP).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN88124420</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Tr 236/16-2/LTP-Methyl-Lora</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A double-blind, randomized, placebo-controlled, three-way cross-over study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-10-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="92923fa3-82b3-4864-84ba-020b07ae0247">
	  <name>Institute of Physiology and Pathophysiology</name>
	  <address/>
	  <city>Mainz</city>
	  <state/>
	  <country>Germany</country>
	  <zip>55128</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Healthy volunteer</participantType>
      </participantTypes>
      <inclusion>1. Healthy volunteers of full age
2. Subject familiarized with the experimental procedure prior to experimentation and had given written informed consent
3. At least a 50% increase of pain to pinprick stimuli and a 25% increase of pain to electrical stimuli following high-frequency electrical stimulation in a screening visit</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>18</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>18</totalTarget>
      <exclusion>1. Skin lesions at the test and/or control site
2. Use of any medication within one day prior to study onset except contraceptives
3. Known hypersensitivity to histamine or methylphenidate and lorazepam and their derivates
4. Any history of allergy or drug hypersensitivity
5. Chronic use of analgesics or Central Nervous System (CNS) active drugs
6. Pregnancy or nursing
7. Any acute or chronic disease</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-10-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Hyperalgesic pain</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Hyperalgesic pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The effect of 40 mg methylphenidate and 2.5 mg lorazepam orally (p.o.) will be compared to placebo in a three-way cross-over design (placebo-methylphenidate-lorazepam). Sensory changes will be determined by Quantitative Sensory Testing (QST) using non-nociceptive and low-intensity painful mechanical and electrical stimuli. 

The QST-protocol consists of mildly painful and non-painful mechanical and electrical stimuli, which were applied in runs alternating between two skin sites on the forearms (a test site and a control site). In addition, we will apply a moderate painful high-frequency electrical stimulation protocol to induce nociceptive LTP (only at the test site). All test stimuli will last between 0.5 - 2 seconds depending on the modality tested. 

The QST will be carried out over 30 min before the application of the conditioning stimulus and over 90 min at the beginning and immediately after the stimulus.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Methylphenidate, Lorazepam</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16831-0</funderId>
      <contactId>Contact54789_16831</contactId>
      <sponsorId>Sponsor53345</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54789_16831">
    <title>Prof</title>
    <forename>Rolf-Detlef</forename>
    <surname>Treede</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Institute of Physiology and Pathophysiology
The Johannes Gutenberg University of Mainz
Duesbergweg 6</address>
      <city>Mainz</city>
      <country>Germany</country>
      <zip>55128</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">treede@uni-mainz.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53345">
    <organisation>Individual sponsor (Germany)</organisation>
    <website>http://www.uni-mainz.de/eng/index.php</website>
    <sponsorType>Other</sponsorType>
    <contactDetails>
      <address>c/o Prof Rolf-Detlef Treede
Institute of Physiology and Pathophysiology
The Johannes Gutenberg University of Mainz
Duesbergweg 6</address>
      <city>Mainz</city>
      <country>Germany</country>
      <zip>55128</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)61313925715</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">treede@uni-mainz.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder16831-0">
    <name>German Research Foundation (Deutsche Forschungsgemeinschaft) (Grant ref: Tr236/16-2)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-19T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-09-19T00:00:00.000Z">72183044</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised double-blind parallel-group study evaluating effcacy and safety on MEGA tablets compared to Kalcipos® tablets in adult subjects</title>
      <scientificTitle/>
      <acronym>MEGA</acronym>
      <studyHypothesis>The treatment to be tried will result in recommended levels of serum 25-hydroxy-vitamin D.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Serum levels of 25-hydroxyvitamin D, measured at baseline, 3, 6, 9 and 12 months.</primaryOutcome>
      <secondaryOutcome>1. Serum levels of parathyroid hormone and biochemical bone markers, measured at baseline, 6 and 12 months
2. Safety, measured at baseline, 3, 6, 9 and 12 months</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from Regionala Etikprovningsnamnden i Linkoping, Sweden (one of six regional ethical boards in Sweden) on the 11th October 2006 (ref: Dnr M150-06 [EudraCT-nr: 2006-002595-17]).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN72183044</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CT06-MEGA-001</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A prospective randomised double-blind parallel group study evaluating efficacy and safety of a one year treatment.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-01-05T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="bd016961-2691-40c3-b628-919994cb5984">
	  <name>Department of Endocrinology</name>
	  <address/>
	  <city>Linköping</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>S-58185</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Men and women 55 to 85 years of age 
2. Mild or moderate vitamin D insufficiency (serum 25-hydroxy-vitamin D 10-70 nmol/L)</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>56</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>56</totalTarget>
      <exclusion>1. Subjects with severe vitamin D deficiency (serum 25-hydroxy-vitamin D below 10 nmol/L)
2. Suspected osteomalacia
3. Serious diseases or drug treatments that may interfere with study results</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-01-05T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Mild or moderate vitamin D deficiency</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Vitamin D deficiency</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Supplementation with either calcium and vitamin D or calcium alone. The subjects will be treated with two tablets per day for twelve months. The allocation of subjects to treatment, study product (vitamin D and calcium) or reference product (calcium), will be done by randomisation at start of the study.</description>
	<interventionType>Supplement</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Kalcipos®, vitamin D</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16584-0</funderId>
      <contactId>Contact54542_16584</contactId>
      <sponsorId>Sponsor53097</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54542_16584">
    <title>Dr</title>
    <forename>Goran</forename>
    <surname>Toss</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Endocrinology
EM-kliniken
University Hospital</address>
      <city>Linköping</city>
      <country>Sweden</country>
      <zip>S-58185</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 (0)13 222 000</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Goran.Toss@lio.se</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53097">
    <organisation>Recip AB (Sweden)</organisation>
    <website>http://www.recip.se/</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Lagervagen 7</address>
      <city>Haninge</city>
      <country>Sweden</country>
      <zip>S-13650</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.496608.5</gridId>
    <rorId>https://ror.org/01apnjb23</rorId>
  </sponsor>
  <funder id="Funder16584-0">
    <name>Recip AB (Sweden)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-07T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2007-09-13T00:00:00.000Z">21996121</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Impact of In-exsufflator Treatment on hospitalisation for Respiratory Exacerbation in Neuromuscular Disease</title>
      <scientificTitle/>
      <acronym>In-ex TREND study</acronym>
      <studyHypothesis>We will be looking specifically at a heterogeneous group of neuromuscular disorders which, either as a secondary consequence of degeneration of the spinal nerves (spinal muscular atrophy, amyotrophic lateral sclerosis) or as a primary muscle defect (muscular dystrophies, myopathies) result in progressive loss of muscle strength. Respiratory complications are the primary cause of morbidity and mortality associated with these diseases, as involvement of the respiratory muscles leads to either progressive hypoventilation or recurrent atelectasis and pneumonia secondary to decreased cough efficacy.

For this study we will look at those children with neuromuscular disorders who are admitted to hospital with a respiratory deterioration (hypoxemia and/or the presence of new onset radiologically proven atelectasis or consolidation).

Hypotheses:
We expect that the addition of the Emerson in-exsufflator to a standard treatment regimen for acute respiratory deterioration:
1. Will result in a decreased duration of hospitalisation in a population of children with neuromuscular disease
2. Resulting in hospitalisation will decrease the time requiring supplemental oxygen in a population of children with neuromuscular disease
3. Resulting in hospitalisation will result in a more rapid improvement in chest X-ray changes in a population of children with neuromuscular disease
4. Resulting in hospitalisation will decrease the length of stay in intensive care unit or days invasively ventilated in a population of children with neuromuscular disease</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Time to discharge: an estimate of the primary end-point, time to discharge with standard care, was based on the clinical experience of the principal investigators and is currently being verified with a three-year retrospective chart review at Childrens Hospital of Eastern Ontario (CHEO). The mean length of stay in these patients is estimated to be 10 days. Discussions with several paediatric respirologists have taken place, focusing on what magnitude of difference in time to discharge would be clinically important between treatment and control groups. The consensus was a Minimally Clinically Important Difference (MCID) of three days' reduction from the average current length of stay in the study population. These numbers translate to a hazard ratio of 1.4. A two-sided time-to-event test at a = 0.05 will be used to detect a significant difference in time to discharge between the two arms.</primaryOutcome>
      <secondaryOutcome>1. Time (in days) to improvement in oxygenation (no longer requiring supplemental oxygen for 24 hours)
2. X-ray changes: improvement or progression (increasing atelectasis, consolidation)
3. Development of acute hypercapnic respiratory failure requiring intubation and mechanical ventilation
4. Days in intensive care unit</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Each site will submit to their local hospital ethics boards. Ethics approval received from the Children's Hospital of Eastern Ontario Research Ethics Board (REB) on the 2nd October 2007 (ref: 07/24E).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN21996121</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multi-centre randomised unblinded controlled trial of the mechanical inexsufflator. Randomisation sequence will be stratified by centre with a block-size randomisation protocol.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f835c857-2436-4192-ab3d-fb30544e6fe5">
	  <name>Children's Hospital of Eastern Ontario</name>
	  <address/>
	  <city>Ottawa</city>
	  <state/>
	  <country>Canada</country>
	  <zip>K1H 8L1</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients aged 3 to 17 years
2. Patients have a known neuromotor disorder affecting respiratory muscles  
3. Admitted to hospital with a respiratory deterioration (hypoxemia in the presence of new onset radiologically proven atelectasis or consolidation)</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="3.0"/>
      <upperAgeLimit unit="Years" value="17.0"/>
      <gender>Both</gender>
      <targetEnrolment>128</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>128</totalTarget>
      <exclusion>1. Refusal to participate
2. Already using the Emerson in-exsufflator at home on a regular basis
3. Development of new uncompensated hypercapnic respiratory failure requiring intubation and mechanical ventilation
4. History of bullous emphysema, known susceptibility to pneumothorax or pneumomediastinum, or known to have had any recent barotraumas</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Children with neuromuscular disorders who are admitted to hospital with a respiratory deterioration (hypoxemia and/or the presence of new onset radiologically proven atelectasis or consolidation).</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Neuromuscular disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Conventional treatments, as deemed appropriate by the treating physician:
1.1. Physiotherapy 
1.2. Nutritional support
1.3. Antibiotics (fever, elevated White Blood Cells [WBC])
1.4. Non-invasive positive pressure ventilation
2. Conventional treatments and Emerson in-exsufflator

Using Friedman's formula for survival analysis study design, 62 patients per arm would achieve 80% power to detect a hazard ratio of 1.4.  To account for potential withdrawals and withdrawal of consent, estimated at about 2.5%, four additional participants will be recruited for a grand total of 128 participants.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16646-0</funderId>
      <contactId>Contact54604_16646</contactId>
      <sponsorId>Sponsor53159</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54604_16646">
    <title>Dr</title>
    <forename>Sherri</forename>
    <surname>Katz</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Children's Hospital of Eastern Ontario
401 Smyth Road
w1406</address>
      <city>Ottawa</city>
      <country>Canada</country>
      <zip>K1H 8L1</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 613 737 7600 ext. 2868</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">skatz@cheo.on.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53159">
    <organisation>Children's Hospital of Eastern Ontario (Canada)</organisation>
    <website>http://www.cheo.on.ca/english/hub.shtml</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>c/o Sherri Katz, MD
401 Smyth Road
W1406</address>
      <city>Ottawa</city>
      <country>Canada</country>
      <zip>K1H 8L1</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 613 737 7600 ext. 2868</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">skatz@cheo.on.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.414148.c</gridId>
    <rorId>https://ror.org/05nsbhw27</rorId>
  </sponsor>
  <funder id="Funder16646-0">
    <name>Fight Spinal Muscular Atrophy (FightSMA) (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-11T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2007-09-11T00:00:00.000Z">58825135</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Early diagnosis of colorectal cancer by faecal occult blood detection - the Goteborg trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>By detection of early stages of colorectal tumours in the "healthy population", mortality from colorectal cancer is reduced. 

Underlying this hypothesis is a further hypothesis that colorectal tumours develop over a time sequence, probably several years, from benign adenomas through localised cancer to cancer with spread growth, and that tumours in this sequence of development can be detected before they give symptoms observed by the individual.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Mortality in colorectal cancer.

Time points were: after invitation, after screening participation, after work-up of positive screen test and after treatment for patients with positive work-up.</primaryOutcome>
      <secondaryOutcome>1. Overall mortality
2. Quality of life
3. Sensitivity and specificity of screening procedure
4. Sensitivity and specificity of work up procedure
5. Stage distribution of adenomas and cancers

The questionnaires used were specifically designed for this trial, with face validation and tested in pilot populations before use. Time points were: after invitation, after screening participation, after work-up of positive screen test and after treatment for patients with positive work-up.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from the ethical committee of Goteborg University, Goteborg (Sweden) in 1982 (ref: 21-82).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN58825135</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, controlled, single centre, population based, interventional trial; control group not invited for screening.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Screening</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1982-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="466114cf-e1c7-4a7e-9e6b-e4ce9a52020c">
	  <name>Bruna Straket 11B</name>
	  <address/>
	  <city>Goteborg</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>SE 413 45</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>The entire population was born between 1918 and 1931, men and women, in Goteborg, Sweden. Only those randomised to "intervention, i.e., screening for occult faecal blood" were invited to participate, the control group was not contacted. Initial invitation to the trial was when each individual was between the ages of 60 to 64 years, thus inclusion from 1982 to 1995 in cohorts of five years.</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>68000</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>68,000</totalTarget>
      <exclusion>Does not meet the above criteria.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1982-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Colorectal cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Colorectal cancer</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention: detection of faecal blood by Haemoccult analyses of samples from three consecutive stools, in the group randomised to "screening"
Control: no contact/information

If blood was detected, there was a continued intervention involving consultation with colorectal surgeon, sigmoidoscopy (60 cm) and barium enema. If found at sigmoidoscopy, adenomas were removed. If cancer/suspected cancer found at either investigation, surgery was followed at earliest possible date. 

Total duration of follow-up was 11 - 19 years, mean of 15 years.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>1986 Other publications in https://pubmed.ncbi.nlm.nih.gov/3790958
1987 Other publications in https://pubmed.ncbi.nlm.nih.gov/3792765
1988 Other publications in https://pubmed.ncbi.nlm.nih.gov/3292038
1989 Other publications in https://pubmed.ncbi.nlm.nih.gov/2720326
1990 Other publications in https://pubmed.ncbi.nlm.nih.gov/2322788
1990 Other publications in https://pubmed.ncbi.nlm.nih.gov/2276015 .
1991 Other publications in https://pubmed.ncbi.nlm.nih.gov/2056836 .
1992 Other publications in https://pubmed.ncbi.nlm.nih.gov/1439536 .
1994 Other publications in https://pubmed.ncbi.nlm.nih.gov/8306829
1994 Other publications in https://pubmed.ncbi.nlm.nih.gov/8036464
1995 Other publications in https://pubmed.ncbi.nlm.nih.gov/7601048 .
1995 Other publications in https://pubmed.ncbi.nlm.nih.gov/7732341 .
1996 Other publications in https://pubmed.ncbi.nlm.nih.gov/8646956
1997 Other publications in https://pubmed.ncbi.nlm.nih.gov/9085461</publicationDetails>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="50f732e7-699f-445f-9f82-1be69dbb5784" outputType="otherpublications" artefactType="ExternalLink" dateCreated="1986-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/3790958"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="07f98f83-4da9-40a3-be2e-b15b372af63a" outputType="otherpublications" artefactType="ExternalLink" dateCreated="1987-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/3792765"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="7a51b317-acab-47e4-b09f-ded689d13610" outputType="otherpublications" artefactType="ExternalLink" dateCreated="1988-08-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/3292038"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="fa0fec52-f7c6-4fca-92e8-9b5b75a3b909" outputType="otherpublications" artefactType="ExternalLink" dateCreated="1989-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/2720326"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="f41adbfb-bf1e-47f7-969a-898965ead581" outputType="otherpublications" artefactType="ExternalLink" dateCreated="1990-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/2322788"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="4e583c69-14d4-46e3-a18f-e4b0daee6006" outputType="otherpublications" artefactType="ExternalLink" dateCreated="1990-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/2276015"/>
	<description>.</description>
	<productionNotes/>
      </output>
      <output id="e4e4cfcd-458a-470b-b3ed-7eb8d5fe3a47" outputType="otherpublications" artefactType="ExternalLink" dateCreated="1991-06-12T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/2056836"/>
	<description>.</description>
	<productionNotes/>
      </output>
      <output id="e4810e71-f78f-44d7-a6f9-011796194a44" outputType="otherpublications" artefactType="ExternalLink" dateCreated="1992-10-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/1439536"/>
	<description>.</description>
	<productionNotes/>
      </output>
      <output id="8688b5ee-09ad-45e7-87e5-c56e7482b6c0" outputType="otherpublications" artefactType="ExternalLink" dateCreated="1994-02-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/8306829"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="11df0a51-ae90-4e02-9996-3a7f229ca201" outputType="otherpublications" artefactType="ExternalLink" dateCreated="1994-05-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/8036464"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="305f87cd-836d-457d-ac55-7fd39da17e99" outputType="otherpublications" artefactType="ExternalLink" dateCreated="1995-02-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/7601048"/>
	<description>.</description>
	<productionNotes/>
      </output>
      <output id="788afdb3-10ee-464f-9dcb-4dfdd5ff051e" outputType="otherpublications" artefactType="ExternalLink" dateCreated="1995-02-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/7732341"/>
	<description>.</description>
	<productionNotes/>
      </output>
      <output id="037863a1-84f5-4273-b55d-5f842eabc2e9" outputType="otherpublications" artefactType="ExternalLink" dateCreated="1996-06-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/8646956"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="60716711-ad13-4012-85e6-3af9c69c992a" outputType="otherpublications" artefactType="ExternalLink" dateCreated="1997-03-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/9085461"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16819-0</funderId>
      <funderId>Funder16819-1</funderId>
      <funderId>Funder16819-2</funderId>
      <funderId>Funder16819-3</funderId>
      <funderId>Funder16819-4</funderId>
      <funderId>Funder16819-5</funderId>
      <funderId>Funder16819-6</funderId>
      <contactId>Contact54777_16819</contactId>
      <sponsorId>Sponsor53333</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54777_16819">
    <title>Prof</title>
    <forename>Eva</forename>
    <surname>Haglind</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Bruna Straket 11B
Sahlgrenska University Hospital</address>
      <city>Goteborg</city>
      <country>Sweden</country>
      <zip>SE 413 45</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 (0)31 3426096</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">eva.haglind@vgregion.se</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53333">
    <organisation>Swedish Cancer Society (Sweden)</organisation>
    <website>http://www.cancerfonden.se</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>David Bagares Gata 5</address>
      <city>Stockholm</city>
      <country>Sweden</country>
      <zip>SE 101 55</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 (0)8 6771000</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@cancerfonden.se</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.453026.6</gridId>
    <rorId>https://ror.org/0527jb766</rorId>
  </sponsor>
  <funder id="Funder16819-0">
    <name>Swedish Cancer Society (Sweden)</name>
    <fundRef>http://dx.doi.org/10.13039/501100002794</fundRef>
  </funder>
  <funder id="Funder16819-1">
    <name>Assar Gabrielsson Foundation (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16819-2">
    <name>Goteborgs Lakarsallskap, Inga-Britt and Arne Lundberg Research Foundation (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16819-3">
    <name>Magnus Bergvall Foundation (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16819-4">
    <name>Gunnar and Elisabeth Nilsson Foundation (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16819-5">
    <name>Jubileumsklinikens Foundation (Sweden)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16819-6">
    <name>Sahlgrenska University Hospital Foundation (Sweden)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-10T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2007-09-10T00:00:00.000Z">55976458</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Workplace AIDS prevention - a randomised controlled trial of community engagement by employees of motor dealers</title>
      <scientificTitle/>
      <acronym>CIET-BM1</acronym>
      <studyHypothesis>Engaging motor dealership employees community outreach education increases their Human Immunodeficiency Virus (HIV)-protective attitudes and practices.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>HIV-related protective attitudes and practices among dealership employees, measured after one year.</primaryOutcome>
      <secondaryOutcome>1. Work absenteeism
2. Work performance
3. HIV related knowledge
4. Attitudes
5. Positive deviation from subjective norms
6. Intention to change
7. Sense of agency to implement prevention measures
8. Discussion of HIV prevention

All secondary outcomes measured after one year.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from CIET Africa Ethics Board on the 30th April 2007 (ref: BM2-2007).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN55976458</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CIET-BM1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Pragmatic randomised controlled cluster trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Botswana</country>
	<country>South Africa</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f5fee87b-2061-4bb7-8967-9255cf043bd9">
	  <name>CIET Trust Botswana</name>
	  <address/>
	  <city>Gaborone</city>
	  <state/>
	  <country>Botswana</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All employees of participating dealerships</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>3000</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>3000 employees</totalTarget>
      <exclusion>Dealerships declining to participate prior to randomisation</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>HIV/Acquired Immune Deficiency Virus (AIDS) prevention</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>HIV/AIDS</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The unit of randomisation is the dealership, each dealership employing a staff of 40 - 100 people and an adjacent community where a large number of the staff live. Some 20 participating dealerships nationally will be allocated randomly to first wave or second wave of intervention. Although the dealerships are typically in well-to-do or commercial areas, the linked communities tend to be much more modest.

Workplaces are randomised after baseline survey, to early and late initiation of intervention.

Intervention:
1. AIDS prevention education
2. Sexual violence education
3. Participant involvement in community outreach education

The intervention lasts 4 - 6 months in each dealership, although aspects of this will continue well beyond the investment. For example, employees will be trained to implement the sexual violence prevention education, which they will continue to implement on an ongoing basis, once a week.

Control:
Usual education

The impact of the first wave of dealerships will be assessed after one year, while the second wave (controls for the first wave) will be assessed a year later.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16524-0</funderId>
      <contactId>Contact54482_16524</contactId>
      <sponsorId>Sponsor53037</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54482_16524">
    <title>Dr</title>
    <forename>Neil</forename>
    <surname>Andersson</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>CIET Trust Botswana
PO Box 1240</address>
      <city>Gaborone</city>
      <country>Botswana</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53037">
    <organisation>Community Information, Empowerment and Transparency (CIET) Trust (South Africa)</organisation>
    <website>http://www.ciet.org/</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>c/o Neil Andersson
CIET Trust Botswana
PO Box 1240</address>
      <city>Gaborone</city>
      <country>Botswana</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487352.f</gridId>
    <rorId>https://ror.org/02cfx3y90</rorId>
  </sponsor>
  <funder id="Funder16524-0">
    <name>BMW (South Africa)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-10T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2007-09-10T00:00:00.000Z">79325454</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Grannies do AIDS-speak: a randomised controlled trial of empowerment of female elders in rural South Africa</title>
      <scientificTitle/>
      <acronym>Grannies</acronym>
      <studyHypothesis>Empowering female elders through discussion of results for a national youth survey can increase their engagement in and support of young people in their communities.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>HIV-related protective attitudes and practices among youth, measured 12 months after intervention, in a school-based study in communities where the granny groups took place.</primaryOutcome>
      <secondaryOutcome>1. Conscious knowledge of HIV risk and related attitudes
2. Positive deviations from subjective norms
3. Intention to change
4. Sense of agency
5. Discussion of HIV risks

All measured 12 months after intervention, in a school-based study in communities where the granny groups took place.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from Community Information, Empowerment and Transparency (CIET) Africa. Separate ethics approvals were also obtained for Limpopo (ref: LIM2-2006) dated 21st February 2006 and Eastern Cape (ref: CAG1-2006) dated 26th October 2006.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN79325454</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CIET-LPEC</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Cluster pragmatic randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Botswana</country>
	<country>South Africa</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b80c0d26-f79f-4640-af8a-7ae20da728a4">
	  <name>CIET Trust Botswana</name>
	  <address/>
	  <city>Gaborone</city>
	  <state/>
	  <country>Botswana</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Female elders in target community</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>1000</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1000 female elders</totalTarget>
      <exclusion>Men</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) prevention</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>After the baseline surveys, communities were randomised to intervention and control sites (unit of randomisation is the school with its attendant community). In Limpopo, there were 15 such intervention communities, 9 Xitsonga and 6 Sepedi speaking. There were 15 control communities, also 9 of them Xitsonga and 6 Sepedi speaking. In Amathole district in the Eastern Cape, also after the baseline survey, there were 13 intervention and 15 control communities.

Communities were randomised after youth baseline survey to early and late initiation of intervention.

Intervention:
1. AIDS prevention education
2. Sexual violence education 
Based on national youth survey

Control:
Usual education

The intervention lasts 3 - 5 months with follow-up study 12 months after intervention.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16523-0</funderId>
      <funderId>Funder16523-1</funderId>
      <contactId>Contact54481_16523</contactId>
      <sponsorId>Sponsor53036</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54481_16523">
    <title>Dr</title>
    <forename>Neil</forename>
    <surname>Andersson</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>CIET Trust Botswana
PO Box 1240</address>
      <city>Gaborone</city>
      <country>Botswana</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53036">
    <organisation>Community Information, Empowerment and Transparency (CIET) Trust (South Africa)</organisation>
    <website>http://www.ciet.org/</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>c/o Neil Andersson
CIET Trust Botswana 
PO Box 1240 </address>
      <city>Gaborone</city>
      <country>Botswana</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487352.f</gridId>
    <rorId>https://ror.org/02cfx3y90</rorId>
  </sponsor>
  <funder id="Funder16523-0">
    <name>Australia's Overseas Aid Program (AusAID) (Australia) - Addressing Domestic Violence in Limpopo</name>
    <fundRef/>
  </funder>
  <funder id="Funder16523-1">
    <name>The Conflict and Governance Facility (CAGE) (South Africa) - funded by the South African Government and The European Commission</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-05T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2007-09-05T00:00:00.000Z">19709160</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Analyses of PAThogen and HOSt determinants in hospitalised patients with a laboratory confirmed infection caused by Staphylococcus aureus: the PATHOS study</title>
      <scientificTitle/>
      <acronym>PATHOS study</acronym>
      <studyHypothesis>To identify candidate antigens for the development of a prophylactic Staphylococcus aureus vaccine by studying expression profiles of host and pathogen determinants during natural infection.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Putative antigen targets for the development of a Staphylococcus aureus vaccine.</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN19709160</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, non-randomised, non-controlled, single armed clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4efae4cd-8d58-4209-ac05-dea2340bb5fe">
	  <name>Vrije University Medical Centre</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1007 MB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Adult patients (greater than 18 years) with S. aureus bacteraemia or wound infection
2. Diagnosis of S. aureus infection within 48 hours after initial cultures
3. Informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>50</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>50</totalTarget>
      <exclusion>1. Incapacitated patients (Glasgow Coma Scale [GSC] less than 15)
2. Patients with neutropenia (less than 500x 10^6 neutrophils/L)
3. Patients with haematological malignancy
4. Transplantation patients
5. Patients who are treated with immunosuppressive drugs</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Staphylococcus aureus infection and vaccination</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Vaccination</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Blood will be drawn at days 2, 7 and 14 after the moment that the initial blood and wound cultures were obtained. This will be done simultaneously to drawing blood for routine haematology and chemistry investigations according good clinical practice, so no extra venapuncture is required for participation in the study. At day 2 two nasal swabs will be obtained for assessment of Staphylococcus aureus nasal carriage.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16901-0</funderId>
      <contactId>Contact54860_16901</contactId>
      <sponsorId>Sponsor53418</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54860_16901">
    <title>Prof</title>
    <forename>J.A.J.W. </forename>
    <surname>Kluytmans</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Vrije University Medical Centre
Department of Medical Microbiology and Infection Control
P.O. Box 7057</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1007 MB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 444 0552</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jan.kluytmans@vumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53418">
    <organisation>Wyeth Pharmaceuticals B.V. (The Netherlands)</organisation>
    <website>http://www.wyeth.nl/</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>P.O. Box 255</address>
      <city>Hoofddorp</city>
      <country>Netherlands</country>
      <zip>2130 AG  </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)23 567 2567</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info-nl@wyeth.com </email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487416.8</gridId>
    <rorId>https://ror.org/02bzf1224</rorId>
  </sponsor>
  <funder id="Funder16901-0">
    <name>Wyeth Pharmaceuticals B.V. (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-05T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-09-05T00:00:00.000Z">45091963</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Preventing early language delay: a pilot study</title>
      <scientificTitle/>
      <acronym>LLL (Let's Learn Language)</acronym>
      <studyHypothesis>To determine the feasibility of conducting a randomised controlled trial investigating a preventative approach to improve children's language development and behaviour problems at two years of age. Aims of this pilot were to:
1. Examine whether families whose children score at or below the 20th percentile on a standardised vocabulary measure agree to be randomised to a six-week Parent Language Program and to a non-intervention group
2. Compare the usefulness of two standardised vocabulary measures for post-test assessment: the SureStart 100 word Vocabulary Checklist (adapted from the MacArthur Bates Communicative Development Inventories [MBCDI] by Roy, Kersley and Law [2005]) or the Vocabulary Checklist from the complete MBCDI (approx 680 words divided into semantic categories)
3. Trial the videotaping of post-test assessment at 21 - 24 months
4. Solicit parents' evaluations of the program's content and format to provide information about program changes that may increase the feasibility of the Parent Language Program for families in Victoria

This is the pilot study to the randomised trial assigned to ISRCTN20953675.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcomes are to pilot and refine: 
1. Parent interest in, and attendance at, a six-week parent language promotion program 
2. Organisation and format of the Parent Language Program sessions, adapted from You Make The Difference™ program
3. The sensitivity of the assessment tools used during the follow-up</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite>http://www.rch.org.au/emplibrary/ccch/TheLetsLearnLanguage.pdf</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Received ethics approval from The Royal Children's Hospital Ethics in Humans Research Committee (EHRC) on the 7th June 2007 (ref: 26073A).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN45091963</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Pilot randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>GP practice</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-06-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Australia</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b375517e-4400-4ab2-9456-99848c2decb8">
	  <name>Royal Children's Hospital</name>
	  <address/>
	  <city>Melbourne</city>
	  <state/>
	  <country>Australia</country>
	  <zip>3052</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Parents of 18 - 21 month-old toddlers 
2. Attending any of eight well-child clinics within one Melbourne local government area
3. Identified by a brief, parent-reported vocabulary questionnaire as having minimal or no expressive vocabulary (e.g., scoring at or below the 20th percentile relative to age and sex norms)</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Target sample size was 100 to identify 20 eligible children. Recruitment status achieved was 103, which identified 30 eligible children.</totalTarget>
      <exclusion>1. Children with already-diagnosed (or a referral for) cognitive delay or major medical conditions
2. Children with symptoms of Autism Spectrum Disorder
3. Parents with insufficient English to attend a parent language program and complete brief written questionnaires</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-06-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Early delay in acquiring expressive vocabulary</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Vocabulary disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>For each pair of eligible families recruited, one was randomly allocated to the Parent Language Program Group and one to the Usual Care Group. Masking occurred at randomisation, with group allocation concealed from the principal researcher and participants until allocation was complete. Group allocation was concealed from the researcher conducting follow-up direct assessments with intervention (Parent Language Program) families until data collection was complete.  

Arm A - Parent Language Program Group: 
A six-week parent language promotion program (six two-hour group sessions) adapted from the Hanen You Make The Difference™ program, offered to parents when children were 19 - 22 months old. The Parent Language Program teaches child-centred, interaction-promoting and language-modelling responsive interaction strategies targeting the development of vocabulary and multi-word phrases. The Parent Language Program was conducted within the family's local community, facilitated by an early childhood professional.

Arm B - Usual Care Group:
Usual care from the Maternal and Child Health (MCH) nurses who provide a universal and free surveillance service to Melbourne families in the first five years of life (active control).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16684-0</funderId>
      <contactId>Contact54642_16684</contactId>
      <sponsorId>Sponsor53197</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54642_16684">
    <title>Dr</title>
    <forename>Melissa </forename>
    <surname>Wake</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Royal Children's Hospital
Flemington Road
Parkville</address>
      <city>Melbourne</city>
      <country>Australia</country>
      <zip>3052</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+61 (0)3 9345 5761</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">melissa.wake@rch.org.au</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53197">
    <organisation>Murdoch Childrens Research Institute, Parkville (Australia)</organisation>
    <website>http://www.rch.org.au/rch/index.cfm?doc_id=1495</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>c/o Associate Professor Melissa Wake
Royal Children's Hospital
Flemington Road
Parkville</address>
      <city>Melbourne</city>
      <country>Australia</country>
      <zip>3052</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+61 (0)3 9345 5761</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">melissa.wake@rch.org.au</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.1058.c</gridId>
    <rorId>https://ror.org/048fyec77</rorId>
  </sponsor>
  <funder id="Funder16684-0">
    <name>Murdoch Childrens Research Institute, Parkville (Australia)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-03T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2007-09-03T00:00:00.000Z">07857866</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The  Effectiveness of Acupuncture for Insomnia</title>
      <scientificTitle/>
      <acronym>EAI</acronym>
      <studyHypothesis>Traditional Chinese Medicine (TCM) Meridian Theory.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Pittsburgh Sleep Quality Index (PSQI) records (PSQI assessment will be carried out on a weekly basis).</primaryOutcome>
      <secondaryOutcome>Serious adverse events.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Institutional Review Board at Taipei City Hospital (IRB/TCH) (ref: 960302)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN07857866</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>096XDAA00028</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-08-03T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-05-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Taiwan</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="995a6e0b-892b-4f97-a103-2ba3934d61e9">
	  <name>145 Zhengzhou Road</name>
	  <address/>
	  <city>Taipei City</city>
	  <state/>
	  <country>Taiwan</country>
	  <zip>10341</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Participants suffering from insomnia who have not taken any sleep medications associated with psychiatric disorders within 30 days.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>90</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>90</totalTarget>
      <exclusion>1. Pregnancy 
2&#129;. Central nervous system disease such as seizure disorder, cerebrovascular disease, dementia etc.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-08-03T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-05-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Insomnia</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Insomnia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. Acupuncture 
2. Stilnox® (non-benzodiazepines) 5 mg/day at bedtime (hs) for 4 weeks</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16826-0</funderId>
      <contactId>Contact54784_16826</contactId>
      <sponsorId>Sponsor53340</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54784_16826">
    <title>Dr</title>
    <forename>Yu-Yang </forename>
    <surname>Chiang</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>145 Zhengzhou Road
Datong District</address>
      <city>Taipei City</city>
      <country>Taiwan</country>
      <zip>10341</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+886 2 25523234 ext 5207</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">chiang3940@yahoo.com.tw</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53340">
    <organisation>Taipei City Hospital (Taiwan)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>145 Zhengzhou Road
Datong District</address>
      <city>Taipei City</city>
      <country>Taiwan</country>
      <zip>10341</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+886 2 25523234</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">chiang3940@yahoo.com.tw</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.410769.d</gridId>
    <rorId>https://ror.org/02gzfb532</rorId>
  </sponsor>
  <funder id="Funder16826-0">
    <name>Taipei City Government (Taiwan)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-03T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2007-09-03T00:00:00.000Z">82127342</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Metabolic control of hospitalized diabetes mellitus patients: Application of standardised insulin protocols to hospitalized diabetes mellitus patients</title>
      <scientificTitle/>
      <acronym>COMETADIH</acronym>
      <studyHypothesis>Type 2 Diabetes Mellitus (DM2) is the leading cause of death and the most common diagnosis in hospitalized patients in Mexico. The economic burden that DM2 imposes to the public health system is onerous. Strategies focused on improving medical care and optimising resources are of paramount importance.

In-patient hyperglycemia negatively affects related comorbidities and has been linked to negative outcomes when compared to strategies that attain good glycemic control. Traditional insulin sliding scales are still widely used to treat in-patient hyperglycemia, even though this approach has been questioned and at present time is not considered good clinical practice. Novel strategies must be explored and compared to traditional insulin sliding scales.

Hypothesis of this study: Glycemic control of in-patients can be improved by the implementation of standardised insulin protocols. Glycemic control achieved by standardised insulin protocols will be better compared to traditional insulin sliding scales.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Mean CBG during study period 
2. Mean VBG during study period
3. Hypoglycemic episodes</primaryOutcome>
      <secondaryOutcome>1. Clinical condition at the end of study period
2. Health team acceptance and adherence to the protocol guidelines
3. In-hospital morbidity and mortality registered during hospitalization</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The Human Biomedical Research Institutional Committee (an internal regulatory organisation for clinical research and ethics) approved this trial on June 10th, 2005 (ref: 1434).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN82127342</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CIBH-1434</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Single-centre, interventional, randomized, unblinded trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-05-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Mexico</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="32721684-a377-4b88-bd42-da9d01d01924">
	  <name>Direccion Medica</name>
	  <address/>
	  <city>Mexico City</city>
	  <state/>
	  <country>Mexico</country>
	  <zip>14000</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Adult hospitalized patients of any age or gender 
2. Diabetes mellitus (World Health Organization criteria) and uncontrolled hyperglycemia on admission (capillary blood glucose &gt;200 mg/dL or HbA1c &gt;7.0)
3. Signed informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>90</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>Forty five patients on each protocol. Al teast ninety patients overall.</totalTarget>
      <exclusion>1. Good glycemic control on oral medication
2. Refusal to participate</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-05-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Type 2 Diabetes Mellitus</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Type 2 Diabetes Mellitus</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Two general wards of a tertiary care hospital were randomly assigned to one of two standardised insulin protocols. 

The two protocols consist of different proportions of intermediate and regular unmodified human insulin. One of the protocols was delivered in 4 daily injections and the other in 3. At initiation total daily insulin dose was calculated with the same guidelines for both protocols, further dose titration was provided according to pre-stablished glycemic goals and individual requirements. 

Training was provieded to the nursing and medical staff and adherence to the protocol guidelines was supervised by the research team.

After inclusion to this study the patient was treated with the protocol assigned to the ward. Capillary Blood Glucose (CBG) was measured 4 times a day. Fasting Venous Blood Glucose (VBG) was measured according to the attending physician decision. All hypoglycemic episodes were registered in one of two categories: 

1. Laboratory hypoglycemia (CBG &lt;60 mg/dL) 
2. Clinical hypoglycemia (Presence of adrenergic or neuroglycopenic symptoms with CBG &gt;60 mg/dL that reverted after the ingestion of food)

Cause of the hypoglycemic episode was tracked and registered.

The patient was followed until discharge or until transfered to other areas such as the intensive care unit.

Glycemic control was compared in both protocols and, in a secondary analysis, the best protocol was compared with historical controls.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>insulin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16820-0</funderId>
      <contactId>Contact54778_16820</contactId>
      <sponsorId>Sponsor53334</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54778_16820">
    <title>Dr</title>
    <forename>Armando</forename>
    <surname>Villegas-Jimenez</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Direccion Medica
Vasco de Quiroga 15
Seccion XVI
Tlalpan</address>
      <city>Mexico City</city>
      <country>Mexico</country>
      <zip>14000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+52 55 56 55 90 68</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">armandov@quetzal.innsz.mx</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53334">
    <organisation>The National Institute of Medical Sciences and Nutrition (Mexico)</organisation>
    <website>http://www.innsz.mx</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Vasco de Quiroga 15
Seccion XVI
Tlalpan</address>
      <city>Mexico City</city>
      <country>Mexico</country>
      <zip>14000</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+52 55 54 87 09 00</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">acabral@quetzal.innsz.mx</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.416850.e</gridId>
    <rorId>https://ror.org/00xgvev73</rorId>
  </sponsor>
  <funder id="Funder16820-0">
    <name>This trial was funded by an unrestricted grant from institutional research budget of the National Institute of Medical Sciences and Nutrition (Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran). The National Institute of Medical Sciences and Nutrition is a non-profit organization, and its parental organizations are the Mexican Health Ministry (Secretaria de Salud de Mexico) and the Mexican National Autonomous University (Universidad Nacional Autonoma de Mexico). The National Institute of Medical Sciences and Nutrition is a tertiary care academic hospital.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-30T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2007-08-30T00:00:00.000Z">16469166</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Nutrition and wasting in tuberculosis (TB): Can nutritional supplementation in TB patients improve body weight gain, body composition and treatment outcome?</title>
      <scientificTitle/>
      <acronym>TBGIZI ("GIZI" means "nutrition" in Indonesian)</acronym>
      <studyHypothesis>Th hypothesis is that supplementation of TB patients with macro- and micronutrients patients during the first 2 months of treatment increases body weight gain, as compared to TB patients on standard TB treatment. Secondary hypothses include that above supplementation will increase the production of pro-inflammatory cytokines as measured by ex-vivo whole blood stimulation assay and that lean body mass increases more in patients receiving micro- and macronutrient supplementation.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Body weight gain and body composition between start of TB treatment and end of the active phase of treatment (2 months later)</primaryOutcome>
      <secondaryOutcome>The following will be assessed at baseline and 2 months: 
1. Micronutrient status
2. Production of inflammatory cytokines</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>1. The Ethical Review Board of Hasan Sadikin University, University of Padjajaran, Bandung, Indonesia, approved in August 2006 
2. The Ethical Advisory Board, Radboud University Nijmegen, The Netherlands, approved on 16 Feb 2007</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN16469166</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>WV93-411</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-05-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-01-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Indonesia</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8f561fe7-ba16-41e6-9fd4-30eb1951ecfa">
	  <name>Dept. of Internal Medicine</name>
	  <address/>
	  <city>Bandung</city>
	  <state/>
	  <country>Indonesia</country>
	  <zip>40161</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Subjects must meet all of the following inclusion criteria to be eligible for participation in this study:
1. Patients with Ziehl-Neelsen (ZN) staining - positive pulmonary TB 
2. Patients starting, or started &lt;2 weeks ago, with the intensive phase of TB treatment 
3. Subject is &gt;18 years of age
4. Willing to participate in the study, and signing the informed consent form</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>150</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>150</totalTarget>
      <exclusion>No informed consent.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-05-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-01-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Tuberculosis / nutritional status and wasting / nutrition and public health</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Tuberculosis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Newly diagnosed TB patients who fullfil the eligiblity criteria will be randomly allocated according to a previously made random list (randomization in blocks of 4) to either standard treatment + nutritional supplementation (75 patients) or standard treatment only (75 patients). Patients allocated to the nutritional supplementation group will receive 3 biscuits per day for 2 months, containg macro- and micronutriets in addition to their standard TB treatment. These 3 biscuits will provide approximately 450 KCal of energy (or approximately 20% of the daily energy requirements), as well as a wide range of minerals and vitamins, in a doses of approximately half the Daily Required Intakes (DRI&#146;s), and NOT containing iron. Patients will be followed up according to standard clinical practice by the health services until the end of the intensive TB drug treatment phase (2 months).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16468-0</funderId>
      <contactId>Contact54426_16468</contactId>
      <sponsorId>Sponsor52981</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54426_16468">
    <title>Dr</title>
    <forename>Frank</forename>
    <surname>Wieringa</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Dept. of Internal Medicine
Hasan Sadikin Hospital
Jl. Pasir Kaliki 191</address>
      <city>Bandung</city>
      <country>Indonesia</country>
      <zip>40161</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+62 22 2038 986</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">wieringa@tiscali.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52981">
    <organisation>NWO/WOTRO - Netherlands Organisation for Scientific Research (The Netherlands) </organisation>
    <website>http://www.nwo.nl/nwohome.nsf/pages/NWOA_6UB9S8</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Anna van Saksenlaan 51   </address>
      <city>The Hague</city>
      <country>Netherlands</country>
      <zip>2593 HW </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)70 3440763 </telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">WOTRO@nwo.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.420488.2</gridId>
    <rorId>https://ror.org/04jsz6e67</rorId>
  </sponsor>
  <funder id="Funder16468-0">
    <name>NWO/WOTRO - Netherlands Organisation for Scientific Research (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-30T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-08-30T00:00:00.000Z">91251359</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The use of magnetic resonance in non-invasive pancreatic beta-cell imaging: the relation between pancreatic triglyceride accumulation and beta-cell function in human (pre)diabetes</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Pancreatic triglyceride accumulation, measured by magnetic resonance spectroscopy, is related to beta-cell function in subjects with Impaired Glucose Tolerance and/or Impaired Fasting Glucose.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Triglyceride content of the human pancreas in vivo assessed using non-invasive 1H-MRS
2. Relation between pancreatic triglyceride accumulation and beta-cell function
3. Relation between triglyceride accumulation in the pancreas and other fat compartments within the abdomen</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Committee VU University Medical Center 18-12-2006 (ref: 2006/219)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN91251359</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2006/219 sub1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Observational study.</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="067ddee4-402d-41ac-9e8e-78de8ba9972d">
	  <name>VU University Medical Center</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1081 HV</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Male and female subjects (aged 35-70 years) 
2. Impaired Fasting Glucose (IFG; plasma glucose &gt; = 6.1 and &lt; 7.0 mmol/l) and/or 
3. IFG (plasma glucose &gt;= 5.6 and &lt; 7.0 mmol/l) and a family history of Diabetes Mellitus type two (DM2; i.e. first and second degree [i.e. grandparents] relatives) and/or 
4. Impaired Glucose Tolerance (IGT; 2-hour plasma glucose during 75 g Oral Glucose Tolerance Test  [OGTT] 7.8-11.1 mmol/l)</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. Known diabetes
2. History or present liver, exocrine pancreatic or renal disease
3. Drug-/alcohol abuse
4. Acute cardiovascular disease &lt;3 months prior to screening
5. Malignant disease
6. Claustrophobia and metal implants or pacemakers (MRI)
7. Lack of capacity to understand the aim of the research
8. Use of the following: 
8.1.  Glucocorticoids
8.2. Cytostatic drugs
8.3. Thiazolidinediones
8.4. Metformin
8.5. Oral contraceptives
8.6. Fibrates
8.7. Anti epileptic drugs
8.8. Centrally acting drugs for neurologic and/or psychiatric indications</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Subjects with impaired glucose tolerance and/or impaired fasting glucose</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Glucose Tolerance , Fasting Glucose</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The following will be performed in each subject: 
1. A modified euglycaemic hyperglycaemic clamp with arginine stimulation (After an euglycaemic clamp [120 minutes, 5 mmol/L], there is an hour rest period followed by a hyperglycaemic clamp [110 minutes, 15 mmol/L with 5 grams arginine stimulation])
2. Magnetic Resonance Imaging (MRI) of the abdominal fat compartments 
3. Proton Magnetic Resonance Spectroscopy (1H-MRS)</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16609-0</funderId>
      <contactId>Contact54567_16609</contactId>
      <sponsorId>Sponsor53122</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54567_16609">
    <title>Dr</title>
    <forename>M</forename>
    <surname>Diamant</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>VU University Medical Center
Deparment of Endocrinology/ Diabetes Center
De Boelelaan 1117</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 HV</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53122">
    <organisation>VU University Medical Center, Diabetes Center (The Netherlands)</organisation>
    <website>http://www.vumc.nl/english/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>c/o Dr M Diamant
VU University Medical Center 
Deparment of Endocrinology / Diabetes Center 
De Boelelaan 1117 </address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 HV</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.16872.3a</gridId>
    <rorId>https://ror.org/00q6h8f30</rorId>
  </sponsor>
  <funder id="Funder16609-0">
    <name>Merck Sharp &amp; Dohme B.V. Protocol number: P 2129 V1 (International)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-28T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-08-23T00:00:00.000Z">58162568</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The surplus value of doppler in haemorrhoid artery ligation procedure</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Standard localised ligations are as feasible as doppler-guided ligations of haemorrhoid arteries.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Incontinence at four months postoperatively.</primaryOutcome>
      <secondaryOutcome>1. Operative variables
2. Visual Analogue Scale (VAS)-pain scores, analgesics (seven days, month one and four)
3. Cleveland Incontinence Score, Complaints (month one and four)
4. Costs</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee (Medisch-Ethische toetsingscommissie) on the 24th of May 2007 (ref: METC number M071729).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN58162568</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double-blind, active controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0161b6f0-62d4-4799-b7f2-af99aef0b66f">
	  <name>Canisius-Wilhelmina Hospital</name>
	  <address/>
	  <city>Nijmegen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>6500 GS</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged greater than 18 years
2. Symptomatic grade II/III/IV haemorrhoids
3. At least one unsuccessful rubber band ligation
4. Informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>92</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>92</totalTarget>
      <exclusion>1. Previous anal surgery
2. Bleeding disorder</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Haemorrhoid arteries</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Artery diseases</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Doppler-guided and standard localised haemorrhoidal artery ligation.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16861-0</funderId>
      <contactId>Contact54819_16861</contactId>
      <sponsorId>Sponsor53376</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54819_16861">
    <title>Dr</title>
    <forename>S.</forename>
    <surname>Nienhuijs</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Canisius-Wilhelmina Hospital
P.O. Box 9015</address>
      <city>Nijmegen</city>
      <country>Netherlands</country>
      <zip>6500 GS</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)24 365 7657</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">s.nienhuijs@hccnet.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53376">
    <organisation>Catharina Hospital Eindhoven (The Netherlands)</organisation>
    <website>http://www.catharina-ziekenhuis.nl/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Surgery
P.O. Box 1350</address>
      <city>Eindhoven</city>
      <country>Netherlands</country>
      <zip>5602 ZA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.413532.2</gridId>
    <rorId>https://ror.org/01qavk531</rorId>
  </sponsor>
  <funder id="Funder16861-0">
    <name>Catharina Hospital Eindhoven (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-26T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-08-23T00:00:00.000Z">82467578</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Bacterial Translocation and intestinal permeability in patients undergoing open or laparoscopic total colectomy: open, right side or left side first laparoscopically</title>
      <scientificTitle/>
      <acronym>BactTrans</acronym>
      <studyHypothesis>We hypothesise that bacterial translocation is the least in open colectomy followed by laparoscopic colectomy starting the devascularisation on the left side followed by laparoscopic colectomy starting the devascularisation on the right side. 

The longer period of devascularisation results in an increased permeability and higher risk of bacterial translocation.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Intestinal permeability, measured before, during and directely after surgery
2. Amount of bacterial translocation, measured before, during and directely after surgery</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Medical Ethics Committee AMC, Amsterdam on the 26th April 2006 (ref: MEC 06/045).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN82467578</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double-blind, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7006bb6e-a835-4547-a664-3c4bb561b772">
	  <name>Academic Medical Centre (AMC)</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1100 DD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged greater than 18 years
2. Patients planned for laparoscopic total colectomy for inflammatory bowel diseases or familial adenomatous polyposis or patients undergoing subtotal colectomy
3. Informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>1. Antibiotics within a week prior to surgery (perioperative antibiotics are allowed)
2. Use of probiotic products four weeks before or during the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Bacterial translocation and intestinal permeability</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Bacterial translocation</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Devascularisation beginning left or right in case of laparoscopic colectomy. In case of open colectomy mobilisation from lateral to medial.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16863-0</funderId>
      <contactId>Contact54821_16863</contactId>
      <sponsorId>Sponsor53378</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54821_16863">
    <title>Dr</title>
    <forename>W.A.</forename>
    <surname>Bemelman</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Academic Medical Centre (AMC)
Department of Surgery
P.O. Box 22660</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 566 9111</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">W.A.Bemelman@amc.uva.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53378">
    <organisation>Academic Medical Centre (AMC) (The Netherlands)</organisation>
    <website>http://www.amc.uva.nl/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Surgery
P.O. Box 22660</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5650.6</gridId>
    <rorId>https://ror.org/03t4gr691</rorId>
  </sponsor>
  <funder id="Funder16863-0">
    <name>Academic Medical Centre (AMC) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-26T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-08-23T00:00:00.000Z">52352361</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Implementation of a strategy of osteoporosis screening in patients over 50 years of age with a first fracture</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The nurse practitioner will actively approach all fracture patients above the age of 50 for screening and intensive treatment of osteoporosis. This will improve the number of fracture patients screened and treated for osteoporosis.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Percentage of patients with a fracture of 50 years and older that is screened by a fracture nurse for osteoporosis (the goal is 70%)
2. Percentage of patients that are screened and treated and still use their medication after one year (the goal is 70%)</primaryOutcome>
      <secondaryOutcome>1. Percentage of patients that present with a fracture within a year of the initial fracture
2. Percentage screened patients and percentage compliant patients in the fracture nurse group compared to the parallel group
3. The costs and barriers to implement a fracture nurse

The final follow up will take place after one year, the patients will be contacted every three months.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from VU University Medical Center Ethics Board, Amsterdam, on the 21st June 2007 (ref: 2007/132).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN52352361</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, parallel group clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Screening</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="80b28810-84b4-441f-91d7-9e0729cd1896">
	  <name>Vrije University Medical Centre</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1081 HV</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All patients 50 years of age or older, who have a clinical fracture and a low Bone Mineral Density (BMD) defined as a T score greater than or equal to 2.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>1650</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1650</totalTarget>
      <exclusion>1. Patients with a fracture after a traffic accident
2. Patients with a pathological fracture
3. Patients with fractures of hand, foot or scull
4. Serious co-morbidity or dementia
5. Incapable of visiting the out patient clinic</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Osteoporosis screening</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Osteoporosis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>In the implementation group the patients will be screened for osteoporosis by Dual energy X-ray Absorptiometry (DXA) measurement, and a spine X-ray will be performed. At baseline and after 12 months a blood sample will be taken. At baseline, after 3, 6, 9 and 12 months questionnaires will be performed. The follow up period is 1 - 1.5 years (depending on the time it takes to include enough patients). Patients will be treated with anti-osteoporosis medication according to the CBO guidelines (first choice bisphosphonates).

In the parallel group only the questionnaires will be performed.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16869-0</funderId>
      <contactId>Contact54827_16869</contactId>
      <sponsorId>Sponsor53384</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54827_16869">
    <title>Dr</title>
    <forename>D.A.</forename>
    <surname>Eekman </surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Vrije University Medical Centre
Department of Rheumatology, 4a-42
Boelelaan 1117</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 HV</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 444 3432</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">d.eekman@vumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53384">
    <organisation>Vrije University Medical Centre (VUMC) (The Netherlands)</organisation>
    <website>http://www.vumc.nl/english/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Rheumatology</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 BT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.16872.3a</gridId>
    <rorId>https://ror.org/00q6h8f30</rorId>
  </sponsor>
  <funder id="Funder16869-0">
    <name>The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-01T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-08-23T00:00:00.000Z">73594603</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Neurocognitive functioning and brain plasticity in high-grade glioma patients: a magnetoencephalography pilot</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>We hypothesise that a relationship is present between functional connectivity, network features and neurocognitive performance in Glioblastoma Multiforme (GBM) patients. We also expect treatment and recurrence of the tumour to lead to remodelling of the neuronosynaptic maps and network features (i.e. plasticity), and hypothesise that these dynamic changes correlate with improvements of cognition.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Main study parameters are neurocognitive functioning and Magnetoencephalogram (MEG)-measures (synchronisation likelihood and small-world features).</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from ethics boards of two centres participating in the study:
1. Academic Medical Centre (AMC) Medisch Ethische Commissie, received on the 16th July 2007 (ref: MEC 07/134) 
2. VU University Medical Center Medical Ethical Board, received on the 12th June 2007 (ref: 2007/108)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN73594603</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>NWOpilot01</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, observational, case-control study</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Case-control study</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Screening</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e55e6895-8e36-4e25-bfe3-16a4843cdfcd">
	  <name>Department of Medical Psychology, D343</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1081 BT</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>For newly diagnosed patients: 
1. Adult (greater than 18 years)
2. Radiologically suspected GBM prior to surgery
3. Histologically confirmed GBM after surgery
4. Treatment consisting of surgery followed by combined radiotherapy and chemotherapy
5. Written informed consent

For patients with GBM recurrence: 
1. Adult (greater than 18 years)
2. Histologically confirmed GBM
3. Treatment consisting of surgery followed by chemotherapy
4. Written informed consent

For matched healthy controls: 
1. Adult (greater than 18 years)
2. Written informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>For patient groups: 
1. Use of centrally acting drugs, including corticosteroids, other than antiepileptic drugs
2. Psychiatric disease or symptoms
3. Insufficient mastery of the Dutch language
4. Inability to communicate adequately

For controls: 
1. Use of centrally acting drugs (including analgesics)
2. Psychiatric disease or symptoms
3. Disorders of the central nervous system
4. Insufficient mastery of the Dutch language</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Glioblastoma multiforme, high grade Glioma</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Glioma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Using prospective cognitive data and MEG recordings of ten newly diagnosed glioblastoma multiforme patients and ten glioblastoma multiforme patients with tumour recurrence we will investigate:
1. The impact of tumour- and treatment-related factors on functional connectivity and neural network features, and
2. The correlation between changes in these measures and cognitive function

If such treatment- and/or tumour-related cerebral plasticity and its correlation with cognition can be established in this pilot, future prospective studies will focus in more detail on:
1. The effects of different treatment modalities (e.g. less or more extensive surgery, radiotherapy), and 
2. The contribution of tumour-related symptoms (e.g. epilepsy) and their treatment (e.g. anti-epileptic drugs) on neural network function and cognition

This knowledge will eventually assist in the guidance of clinical decision-making in these patients.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16852-0</funderId>
      <contactId>Contact54810_16852</contactId>
      <sponsorId>Sponsor53367</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54810_16852">
    <title>Dr</title>
    <forename>M.</forename>
    <surname>Klein</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Medical Psychology, D343
Vrije University Medical Centre</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 BT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 444 8432</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">m.klein@vumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53367">
    <organisation>Vrije University Medical Centre (VUMC) (The Netherlands)</organisation>
    <website>http://www.vumc.nl/english/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Medical Psychology</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1081 BT</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.16872.3a</gridId>
    <rorId>https://ror.org/00q6h8f30</rorId>
  </sponsor>
  <funder id="Funder16852-0">
    <name>Vrije University Medical Centre (VUMC) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-29T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-08-23T00:00:00.000Z">87502236</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effects of SCH 351125 on mononuclear cell trafficking to joints, synovial inflammation and expression of chemokines in subjects with rheumatoid arthritis</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>SCH 351125 50 mg twice daily (BID) 2/days is an effective treatment for Rheumatoid Arthritis (RA).

Primary objectives of the study are to determine the effects of SCH 351125 on mononuclear cell migration into synovial tissue in subjects with rheumatoid arthritis, and to evaluate the safety and tolerability of multiple-dose administration of SCH 351125 50 mg BID in subjects with rheumatoid arthritis when administered for 28 days.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. To determine the effects of SCH 351125, a CCR5 receptor antagonist, on  mononuclear cell migration into synovial tissue in subjects with rheumatoid arthritis 
2. To evaluate the safety and tolerability of multiple-dose administration of SCH 351125 50 mg twice-daily in subjects with rheumatoid arthritis when administered for 28 days</primaryOutcome>
      <secondaryOutcome>1. To explore the effects of SCH 351125 on:  
1.1. Synovial inflammation via MRI 
1.2. Chemokine expression and concentrations in the plasma, synovial tissue and synovial fluid (messenger Ribonucleic Acid [mRNA] expression only)
1.3. Mononuclear cell concentrations in the peripheral blood
1.4. Clinical signs and symptoms of rheumatoid arthritis
1.5. To determine the single-dose and multiple dose pharmacokinetic profile of SCH 351125 in subjects with rheumatoid arthritis</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Medical Ethics Committee of the Academic Medical Centre (University of Amsterdam) on the 21st January 2004 (ref: 03/267).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN87502236</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>P03653</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double-blind, placebo controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-03-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-05-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="19cc24de-e7d6-46b4-bf80-38c48be918af">
	  <name>Academic Medical Centre (AMC)</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1100 DD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Subjects 18 to 70 years of age, of either sex, and of any race
2. Diagnosis of RA according to the American College of Rheumatology (ACR) criteria, for at least six weeks prior to entry in the study
3. Active RA defined as: 
3.1. Three or more tender joints
3.2. Three or more swollen joints, and 
3.3. At least one of the following three:  
3.3.1. Duration of morning stiffness equal to or greater than 45 minutes 
3.3.2. Erythrocyte sedimentation rate equal to or greater than 28 mm/hour
3.3.3. C-reactive protein equal to or greater than 10 mg/L
4. Functional class I, II or III
5. Subjects must be free of any clinically significant disease (other than rheumatoid arthritis) that would interfere with the study evaluations and/or safety
6. Subjects must be willing to give written informed consent and able to adhere to dose and visit schedules
7. Females must not be breast-feeding, and either be of non-childbearing potential (i.e., sterilised via hysterectomy or bilateral tubal ligation or at least one year postmenopausal) or if of child bearing potential, must be practicing effective double barrier contraceptive methods from at least two weeks prior to day 1 and until 30 days following cessation of dosing
8. Female subjects of childbearing potential must have a negative serum pregnancy test (beta human Chorionic Gonadotropin [beta-hCG]) at screening
9. Males must practice an effective barrier method of contraception from day 1 until 30 days following cessation of dosing
10. A physical examination must be without clinically significant findings with exception of those finding related to rheumatoid arthritis
11. At screening, Electrocardiogram (ECG) conduction intervals must be within the gender specific normal range (i.e., QTc for males less than 430 msec and females less than 450 msec)</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>1. Individuals with a history of any significant medical disorder which require a physician's care (excluding rheumatoid arthritis) and would interfere with the study evaluations or compromise subject safety
2. Individuals who have a history of any clinically significant local or systemic infectious disease within four weeks prior to drug administration
3. Any subject with an allergy to gadolinium
4. Any subject with a pacemaker, metal object implanted their body or any other device or condition which may interfere with a subject's safety during the Magnetic Resonance Imaging (MRI) procedure
5. Any subject who has received Disease Modifying Anti-Rheumatic Drug (DMARD) treatment within 30 days prior to enrolment (leflunomide requires a charcoal or cholestyramine washout)
6. Any subject who has received anti-Tumour Necrotising Factor (anti-TNF) therapy (except enteracept) or any biologic therapy within the previous 90 days
7. Any subject whose baseline Disease Activity Score (DAS-28) has significantly changed since screening to indicate unstable disease
8. Any individual who does not comply with the requirement that he should not have used:
8.1. Any drugs (including herbal and mineral supplements or vitamins), other than acetaminophen or an approved stable regimen of low dose prednisone (10 mg/day) and/or Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), for at least two weeks prior to study drug administration
8.2. Alcohol in amounts of greater than 50 grams a day throughout the study
9. Subjects that have been diagnosed with Juvenile RA
10. A history of systemic lupus erythematosus, or signs and symptoms suggesting systemic lupus erythematosus
11. Subjects who are positive for hepatitis B surface antigen, hepatitis C Ribonucleic Acid (RNA) or for Human Immunodeficiency Virus (HIV) antibodies
12. Individuals who have participated in a clinical trial of an investigational drug within 90 days prior to the start of study drug administration, or have received prior treatment with a CCR5 receptor antagonist
13. Individuals with a positive screen for drugs of abuse
14. Individuals who have donated blood (greater than 300 mL) within the preceding 90 days
15. Males who are unwilling to use/practice an effective method of contraception (i.e., condom in conjunction with spermicide from study start until 30 days after the last study treatment
16. Females who are unwilling to use/practice an effective method of contraception (i.e., condom in conjunction with spermicide from two weeks prior to study start until 30 days after the last study treatment
17. Individuals who have received any vaccinations within 30 days prior to screening
18. Individuals with any clinically significant history of food or drug allergy or allergy to any component of SCH 351125
19. Subjects who are not willing to follow the study restrictions or procedures</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-03-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-05-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Rheumatoid arthritis</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Arthropathies</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Subjects with active Rheumatoid Arthritis (RA) were enrolled in a randomised double-blind, placebo-controlled, parallel-group study exposed  to either SCH 351125 50 mg BID or matched placebo, in a 2:1 ratio, for 28 days.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>SCH 351125</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16857-0</funderId>
      <contactId>Contact54815_16857</contactId>
      <sponsorId>Sponsor53372</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54815_16857">
    <title>Prof</title>
    <forename>P.P.</forename>
    <surname>Tak</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Academic Medical Centre (AMC)
Department of Clinical Immunology and Rheumatology
P.O. Box 22660</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 566 2171</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">p.p.tak@amc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53372">
    <organisation>Schering Plough Research Institute (USA)</organisation>
    <website>http://www.schering-plough.com/schering_plough/research/research_institute.jsp</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Schering-Plough Corporation Headquarters
2000 Galloping Hill Road
Kenilworth</address>
      <city>New Jersey</city>
      <country>United States of America</country>
      <zip>07033-0530</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.417993.1</gridId>
    <rorId>https://ror.org/02891sr49</rorId>
  </sponsor>
  <funder id="Funder16857-0">
    <name>Schering Plough Research Institute (USA)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-04T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-08-23T00:00:00.000Z">68179235</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Treatment of itch with naltrexon in patients with burns</title>
      <scientificTitle>Treatment of itch with naltrexone in patients with burns: an explorative, randomised, double blind, placebo-controlled, cross-over clinical trial</scientificTitle>
      <acronym>BITE (Burns Itch TreatmEnt study)</acronym>
      <studyHypothesis>The primary objective of this study is to evaluate the efficacy and safety of naltrexone in the treatment of itch in patients with burn wounds.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Mean itch intensity score at endpoint, defined as the mean of the last 7 diary entries while the patient is receiving study medication. The percentage change in itch intensity score from baseline is calculated as:
1 - (mean itch intensity score end point/mean itch intensity score baseline) x 100%</primaryOutcome>
      <secondaryOutcome>1. Additional aspects of itch (e.g. frequency, duration) 
2. The effect of treatment as perceived by the patient, pain, and various aspects of anxiety and sleep:
2.1. Itch presence, measured at baseline 1
2.2. Demographics, measured at baseline 1	 
2.3. Burn injury characteristics, measured at baseline 1
2.4. Polymorphism µ-receptor (DNA), measured at intervention week 2
2.5. Blood plasma level, measured at intervention week 2 and intervention week 4
2.6. Scar: 
2.6.1. Patient and Observer Scar Assessment Scale (POSAS), measured at baseline 1 and intervention week 4
2.6.2. Dermaspect, measured at baseline 1 and intervention week 4
2.7. Itch: 	
2.7.1. Visual Analogue Scale (VAS) measured daily throughout treatment
2.7.2. Body-Image Ideals Questionnaire (BIQ), measured at baseline 1, intervention week 1, intervention week 2, baseline 2, intervention week 3, intervention week 4
2.8. Sleep:	
2.8.1. Visual Analogue Scale (VAS) measured daily throughout treatment	
2.8.2. Medical Outcomes Study (MOS)-Sleep, measured at baseline 1, intervention week 1, baseline 2, intervention week 3	
2.9. Pain: Visual Analogue Scale (VAS) measured daily throughout treatment	
2.10. Anxiety: Hamilton Anxiety and Depression Scale (HADS), measured at baseline 1, intervention week 1, baseline 2, intervention week 3	
2.11. Treatment effect: Patient Global Impression of Change (PGIC), measured at intervention 2 and intervention 4
2.12. Adverse Drug Reaction, measured daily during the intervention and wash out periods

Timepoints:
Baseline 1: 7 days
Intervention week 1: 7 days
Intervention week 2: 7 days
Wash-out 1: three days
Baseline 2: 7 days
Intervention week 3: 7 days
Intervention week 4: 7 days
Wash-out 2: 3 days</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local ethics board (Stichting Beoordeling Ethiek Biomedisch Onderzoek, Medisch Ethische toetsingscommissie [METC Assen]) on the 4th July 2007 (ref: MZH 2007-20).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN68179235</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double-blind, placebo controlled, crossover group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="82152da2-0c53-4642-aff0-31c64f0e709b">
	  <name>Martini Hospital</name>
	  <address/>
	  <city>Groningen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>9700 RM</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Eligible for inclusion are patients:
1. With (almost) healed burns who have been admitted to the burn centre
2. Who are 18 years of age or older with itch 4 - 6 weeks post burn</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>Patients will be excluded when meeting one of the following exclusion criteria: 
1. Total Body Surface Area (TBSA) of more than 20%
2. Liver insufficiency (in this study that means more than two times the normal range of the liver enzymes: Aspartate Aminotransferase [ASAT] greater than 80 U/L and/or Alanine Aminotransferase [ALAT] greater than 80 U/L and/or Alkaline Phosphatase [AP] greater than 250U/L and/or Gamma Glutamyl Transpeptidase [GGT] greater than 100U/L)
3. Acute hepatitis
4. History of drug/alcohol abuse
5. Known sensitivity for any of the following substances: naltrexonehydrochloride, lactose monohydrate, crospovidone, powder cellulose, microcrystalline cellulose, colloid silicon dioxide, magnesium stearate, hypromellose, macrogole 4000, Titanium dioxide (E171), Black iron oxide (E172), Red iron oxide (E172), Yellow iron oxide (E172), carboxymethylamylum sodium type A, precirole
6. Pregnant
7. Breast feeding
8. Having used opioids 10 days prior to the start of treatment
9. Using itch medication other than the study medication and unwilling to stop
10. Psychiatric disorder
11. Other disease associated with itch (e.g. eczema, atopic dermatitis, cholestatic pruritus)
12. Insufficiently proficient in Dutch to give informed consent and/or fill out the questionnaires</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Burns</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Burns</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients will take either naltrexone or placebo for two weeks and are randomised to start with one or the other. Before the two treatment periods a baseline measurement of 7 days will be done. In between the two treatment periods there will be a wash-out period of 3 days. The naltrexone dose will be 50 mg once daily. On the first day patients will receive two times 25 mg of naltrexone with at least one hour in between. The procedure on the first day will be mimicked where the placebo is concerned.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16867-0</funderId>
      <contactId>Contact54825_16867</contactId>
      <sponsorId>Sponsor53382</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54825_16867">
    <title>Dr</title>
    <forename>A.</forename>
    <surname>Wieringa</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Martini Hospital
Department of Pharmacy
P.O. Box 30033</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>9700 RM</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)50 524 5771</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">andre.wieringa@mzh.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53382">
    <organisation>Martini Hospital (The Netherlands)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Surgery
P.O. Box 30033</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>9700 RM</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.416468.9</gridId>
    <rorId>https://ror.org/017b69w10</rorId>
  </sponsor>
  <funder id="Funder16867-0">
    <name>Association of Dutch Burn Centres (ADBC) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-19T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-08-23T00:00:00.000Z">74137878</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A study to evaluate the different levels of attention and VALence direction for erotic stimuli, in relation to genital and subjective sexual arousal in healthy female subjects and healthy female subjects with female sexual dysfunction</title>
      <scientificTitle/>
      <acronym>VAL</acronym>
      <studyHypothesis>In the present placebo controlled study we will investigate the influence of valence on attention when viewing visual erotic stimuli. Especially when under the treatment condition of testosterone with sildenafil. In addition, we will investigate the effects of testosterone in combination with sildenafil on vaginal and subjective sexual arousal induced by visual erotic stimuli in females with Female Sexual Dysfunction (FSD) and control subjects, for individual motivational and emotional differences (valence). In earlier study's we've found a distinction between groups that differ in colour naming of erotic words compared to neutral words. These two groups also differed in their benefit from testosterone combined with sildenafil. 

We expect that for some women this treatment, testosterone with sildenafil will work adequately. For the other group, we expect that negative sexual experiences and personality differences and therefore the negative/defensive motivational neural circuit is responsible for the more diffuse reaction to the treatment of testosterone and sildenafil, in women with FSD.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Evaluation of the women's judgment of valence (negative or positive) for erotic stimuli under placebo condition and the condition of 0.5 mg sublingual testosterone combined with sildenafil (50 mg) and the influence of positive and/or negative valence on attention for erotic cues, in healthy female subjects with and without Female Sexual Dysfunction. 

Data for analysis:
1. Attention for erotic stimuli (strooptask: speedrate). A masked version of the Emotional Stroop Task comparing colour-naming latencies on neutral and erotic words will be used. The word is presented before and after the erotic film excerpts in the attention condition for about 24 ms and then masked by randomly cut, reassembled signs in the same colour (red, green, yellow or blue). The colour of the mask has to be assigned, and subjects are asked to verbally name the colours as quickly as possible. The stimuli are presented in the centre of the screen. An extra set of stimuli will be prepared for practice-trials. A trial consists of a fixation point, which will be shown for 750 ms, followed by the target stimulus (the coloured neutral or erotic word and mask). Vocal responses will be recorded and will terminate the trials. The order of these 2 blocks will be randomly assigned. Attention will be measured on both the experimental days in the morning (pre-dose) and in the afternoon (post-dose).
2. Vaginal Pulse Amplitude (VPA. A vaginal photoplethysmograph will be used to measure Vaginal Pulse Amplitude (VPA) (the AC component of the signal), which is a reliable index for genital vasocongestion. Changes in the amplitude of the signal reflect changes in vaginal vasocongestion. The Vaginal Photoplethysmograph (VP) is a clean tampon shaped device, which contains an infrared Light-Emitting Diode (LED) as a light source and a photosensitive light detector (photodiode). It measures the blood volume in the tissue surrounding the plethysmograph. The light emitted by the LED is reflected by the blood vessels in the tissue. This light is measured by the photodiode. The output signal of the photodiode varies with changes in the amount of blood in the vessels. VPA will be measured on both the experimental days in the morning (pre-dose) and in the afternoon (post-dose)
3. Valence for erotic stimuli. Perceived emotional valence of erotic stimuli will be measured and compared to neutral, pleasant and unpleasant stimuli. Facial expressions reveal emotions with corresponding appetitive and defensive motivational circuits. The amygdala projects to the facial motor nucleus, which reflects the chosen motivational circuit; appetitive or defensive. Therefore, Electromyographic (EMG) activity will be measured over the corrugator, zygomatic major and orbicularis oculi muscles. Activation of the zygomatic muscle reveals a smile, but co-activation of the zygomatic and orbicularis mirrors a major smile. Activation of the corrugator muscle alone is correlated with viewing unpleasant events. More specifically, co-activation of the corrugator and orbicularis oculi reflects the emotion of repulsion and aversion. While viewing International Affective Picture System (IAPS) pictures (eight pictures for each domain; pleasant, neutral, unpleasant and erotic) and an additional category of sexually explicit pictures (depicting vaginal coitus), activation of the three muscles will be measured two seconds before picture onset and for six seconds during picture presentation. The activation of the orbicularis oculi muscle is also a component of the startle reflex. When viewing the pictures, half of all pictures will be accompanied by a startle stimulus. The acoustic startle stimulus consists of a 50-ms burst of white noise, presented at 95 dB. The startle stimuli will be presented through earplugs, between 3 and 5 seconds following picture onset. Prior to the first block, six startle sounds will be presented to allow habituation of the startle reflex. After the presentation of the pictures subjects are instructed to give a subjective rating of the emotional pictures by finger pointing at a touch screen. Each emotional picture will be followed by a picture of five figures with expressions ranging from happy (smiling) to unhappy (frowning). Subjects are instructed to rate on a 9-point scale how their feeling towards the preceding picture was reflected by one of the figures. The same was done for arousal, with excited, wide-eyed figures to sleepy, relaxed figures. Valence be measured on both the experimental days in the morning (pre-dose) and in the afternoon (post-dose).</primaryOutcome>
      <secondaryOutcome>1. To evaluate the correlation between subjective ratings of sexual functioning and physiological sexual responses
2. To evaluate the changes in differences in direction of valence when viewing visual erotic stimuli under the placebo condition and the condition with testosterone combined with sildenafil
3. To evaluate the individual differences in attention in relation to positive and/or negative valence induced by visual erotic stimuli
4. To evaluate the influence of personality traits on the differences in vaginal &amp; subjective sexual arousal, EMG, valence direction and startle reflex
5. Subjective ratings of sexual functioning
6. Startle reflex
7. EMG activation
8. Personality traits
9. Negative sexual experiences will be assessed with a questionnaire and in the clinical interview, both during screening</secondaryOutcome>
      <trialWebsite>http://www.emotionalbrain.nl</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval gained from the local ethics committee (Stichting Therapeutische Evaluatie Geneesmiddelen, Medische Etische Toetsingscommissie [STEGMETC]) on the 13th June 2007 (ref: R07-013).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN74137878</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>EB069 (VAL)</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double-blind, placebo controlled, crossover trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1978-06-21T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-11-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7746c3a3-1740-4e82-b154-de06d8b6700c">
	  <name>Emotional Brain BV</name>
	  <address/>
	  <city>Almere</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1311 RL</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>40 Subjects must meet the following criteria:
1. Subjects must have a heterosexual orientation
2. Subjects must be between 21 and 65 years of age
3. Subjects with normal sexual functioning
4. Subjects must have signed the Informed Consent Form
5. Inclusion will be following the selection criteria including, but not limited to, a physical examination, gynaecological examination, medical history, vital signs, pregnancy test and Electrocardiogram (ECG)

80 Subjects must meet the following criteria:
1. Subjects must have a heterosexual orientation
2. Subjects must be between 21 and 65 years of age
3. Subjects must have experienced low sexual arousal and/or low sexual desire for at least six months prior to study entry according to Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM IV) criteria. The diagnosis will be made by an experienced psychologist/sexologist
4. Subjects must have signed the Informed Consent Form
5. Inclusion will be following the selection criteria including, but not limited to, a physical examination, gynaecological examination, medical history, vital signs, pregnancy test and ECG, and by the scoring on the strooptask during familiarization trial</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>120</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>120</totalTarget>
      <exclusion>Subjects will not be eligible for inclusion if one of the following criteria applies: 
1. Use of oral contraception containing anti-androgens (Like Diane 35 or Minerva)
2. Use of oral contraception containing 50 µg oestrogen or more
3. Pregnancy, or intention to become pregnant during this study (note: a serum or urine pregnancy test will be performed in all women prior to the administration of study medications)
4. A pelvic inflammatory disease or an untreated vaginal infection at screening
5. Lactating or subjects who have given birth in the previous six months
6. Previous prolapse and incontinence surgery affecting the vaginal wall
7. Women with other unexplained gynaecological complaints, such as abnormal uterine bleeding patterns;
8. History of endocrinological treatment or current endocrinological treatment (with the exception of the use oral contraceptives and of  fertility-promoting treatment)
9. History of neurological treatment or current neurological treatment
10. History of  serious psychiatric treatment or current psychiatric treatment
11. Any underlying cardiovascular condition including unstable angina pectoris, that would preclude sexual activity
12. History of myocardial infarction, stroke or life-threatening arrhythmia within the prior six months
13. Uncontrolled atrial fibrillation/flutter at screening (ventricular response rate greater than 100 bpm), or other significant abnormality observed on Electrocardiogram (ECG)
14. Systolic blood pressure greater than 140 mmHg and/or diastolic blood pressure greater than 90 mmHg. For subjects with age greater than 60 years and without diabetic mellitus, familiar hypercholesterolemia or cardiovascular disease: systolic blood pressure greater than 160 mmHg and/or diastolic blood pressure greater than 90 mmHg (according to the CBO-guideline hypertension [CBO.2000a])
15. Subjects who are taking strong CYP3A4-inhibitors:  ritonavir (Human Immunodeficiency Virus [HIV] Protease inhibitor), ketoconazole and itraconazole 
16. Subjects who are taking less strong CYP3A4-inhibitors: clarithromycin, erythromycine and saquinavir
17. Subjects who are taking CYP3A4-inducers: carbamazepine, phenytoin, phenobarbital, St Johns Wort, rifampicine
18. Severe chronic or acute liver disease, history of moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment
19. Use of medicinal herb as Ginkgo Biloba and nutrition containing grapefruit
20. Subjects who are taking nitrates or nitric oxide donors
21. A substance abuse disorder that in the opinion of the investigator is likely to affect the subject's ability to complete the study or precludes the subject's participation in the study; mild or moderately alcohol drinking behaviour is allowed, only 12 hours before the experimental days is alcohol drinking not allowed. Three weeks before the start of the experimental day is the taking of any recreational drug not allowed. Smoking is allowed
22. Use of any treatment for FSD within the seven days before visit one or during the study, including oral medications or constrictive devices
23. Subjects who are illiterate, unwilling or unable to understand and complete the questionnaires
24. Any other clinically significant abnormality or condition which in the opinion of investigator would interfere with the participant's ability to provide informed consent, comply with study instructions, possibly confound interpretation of study results, or endanger the participant if she took part in the trial
25. Moderate and severe hearing impairment
26. Subjects who are colour blinded
27. Subjects who are having botox® (or other equivalents of botox, like dysport) in the facial area within six months before the first experimental day</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1978-06-21T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-11-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Female sexual dysfunction</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Female sexual dysfunction</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Testosterone, administered as a solution sublingually (0.5 mg) and sildenafil, type 5 phosphodiesterase (PDE5) inhibitor, administered as an encapsulated tablet orally (50 mg):

Treatment A: 0.5 mg testosterone and sildenafil 50 mg 
Treatment P: placebo testosterone and placebo sildenafil 

The two treatments (A and P) will be randomised across the 120 subjects. Two different drug combinations will be given on separate days: (day 1) placebo, (day 2) sildenafil plus testosterone. Drug administration will be divided into two parts. Testosterone will be administered first. Two hours after testosterone administration, sildenafil (Viagra) will be administered. Testosterone will have a behavioural effect, increasing sexual desire and arousal, after four hours of intake. Sildenafil will have a physical effect, increasing blood flow to the genitals, after 1 hour of intake. It's duration is about six hours.

Two separate experimental days are separated by a three to ten day period.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Testosterone, sildenafil</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16846-0</funderId>
      <contactId>Contact54804_16846</contactId>
      <sponsorId>Sponsor53361</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54804_16846">
    <title>Dr</title>
    <forename>D.</forename>
    <surname>van Ham</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Emotional Brain BV</address>
      <city>Almere</city>
      <country>Netherlands</country>
      <zip>1311 RL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)36 546 8346</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">d.vanham@emotionalbrain.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53361">
    <organisation>Emotional Brain B.V. (The Netherlands)</organisation>
    <website>http://www.emotionalbrain.nl/</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Louis Armstrongweg 78</address>
      <city>Almere</city>
      <country>Netherlands</country>
      <zip>1311 RL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.476322.6</gridId>
    <rorId>https://ror.org/03vy5fy74</rorId>
  </sponsor>
  <funder id="Funder16846-0">
    <name>Emotional Brain B.V. (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-17T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-08-17T00:00:00.000Z">83770226</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Impact of Spirulina platensis supplementation on general health status of HIV infected patients in Burkina Faso</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Daily Spirulina platensis supplementation can improve clinical, nutritional and immunobiological status of HIV infected patients.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The impact of active daily supplementation of Spirulina platensis on the clinical, nutritional and immunological status of HIV infected patients will be assessed by the following: 
1. Measurement of CD4, viral load, hematological and biochemical parameters at the start, 6 and 12 months of trial
2. Monthly measurement of anthropometric parameters</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Institutional Ethics Committee of Centre Muraz (Institut de Recherche en Sciences de la Santé [IRSS]), approved on 20 December 2005 (ref: 022/2005/CEI-CM)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN83770226</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Double-blind randomized controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-05-20T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-01-20T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Burkina Faso</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="94467c70-9df4-49f3-a6fa-da5c49dad463">
	  <name>Institut de Recherche en Sciences de la Santé</name>
	  <address/>
	  <city>Bobo-Dioulasso</city>
	  <state/>
	  <country>Burkina Faso</country>
	  <zip>545</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. HIV infected 
2. At least 18 years old 
3. Willing to be followed up for at least 12 months 
4. Informed consent to be provided by the patient</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>180</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>180</totalTarget>
      <exclusion>1. Patients who do not consent to be involved in the trial
2. Under the age of 18 years
3. Patients who are pregnant 
4. Cardiopathy or cancer
5. Currently receiving Spirulina platensis spplementation</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-05-20T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-01-20T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>HIV / AIDS</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>HIV / AIDS</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group 1: 60 Patients with 200 CD4/µl of peripheric blood or lower (patients who are currently receiving antiretroviral treatment) 
Sub-group 1 (30 patients): four capsules (a capsule contains 420 mg of spiruline) three times daily per os (orally) for each patient for 12 months 
Sub-group 2 (30 patients): The same number of capsules as in sub-group 1 but placebo instead of active supplement 

Group 2: 60 Patients with 200 &lt; CD4 &lt; 400 (patients who are currently receiving antiretroviral treatment) 
Sub-group 1 (30 patients): four capsules (a capsule contains 420 mg of spiruline) three times daily per os for each patient for 12 months 
Sub-group 2 (30 patients): The same number of capsules as in sub-group 1 but placebo instead of active supplement 

Group 3: 60 Patients with CD4 &gt;400 (some of these patients are currently receiving antiretroviral treatment) 
Sub-group 1 (30 patients): four capsules (a capsule contains 420 mg of spiruline) three times daily per os for each patient for 12 months 
Sub-group 2 (30 patients): The same number of capsules as in sub-group 1 but placebo instead of active supplement 

Each included patient in the trial will be followed up monthly by a physician. 
Anthropometric parameters of the participants will be measured monthly and their CD4, viral load, hematological and biochemical parameters will be measured semestrially.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Spirulina platensis</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16577-0</funderId>
      <contactId>Contact54535_16577</contactId>
      <sponsorId>Sponsor53090</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54535_16577">
    <title>Prof</title>
    <forename>Jean Bosco</forename>
    <surname>Ouedraogo </surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Institut de Recherche en Sciences de la Santé
Direction Régionale de l'Ouest
399, Avenue de la Liberté
01 BP 545 Bobo-Dioulasso 01</address>
      <city>Bobo-Dioulasso</city>
      <country>Burkina Faso</country>
      <zip>545</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+226 20 98 18 80</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jbouedraogo.irss@fasonet.bf</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53090">
    <organisation>Ministry of Health of Burkina Faso, Drug Directorate (DGPML)</organisation>
    <website/>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Projet Spiruline Nayalgue 
S/C Pr Jean-Baptiste Nikiema </address>
      <city>Ouagadougou</city>
      <country>Burkina Faso</country>
      <zip>03 BP 7009 Ouaga</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+226 50 32 46 60 / 61</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jbnikiema@yahoo.fr</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.491199.d</gridId>
    <rorId>https://ror.org/03h83vk17</rorId>
  </sponsor>
  <funder id="Funder16577-0">
    <name>Ministry of Health of Burkina Faso, Drug Directorate (DGPML)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-11T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-08-15T00:00:00.000Z">45665690</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy and safety of artesunate and sulfadoxine-pyrimethamine and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in low to moderate sentinel sites in Sudan</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To assess the efficacy of the first (artesunate and sulfadoxine-pyrimethamine) and second line treatment (artemether-lumefantrine) for the treatment of uncomplicated Plasmodium falciparum infections in different sentinel sites in Sudan.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Adequate clinical and parasitological response Polymerase Chain Reaction (PCR) corrected.</primaryOutcome>
      <secondaryOutcome>Incidence of adverse events.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from:
1. Federal Ministry of Health (Sudan) on the 3rd May 2007
2. Ethical Research Committee of the World Health Organization (WHO) on the 11th June 2007 (ref: RPC220)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN45665690</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RPC220</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>One-arm surveillance study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-11-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sudan</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="cfa40408-67db-4481-81a5-4eea739e4e09">
	  <name>World Health Organization</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH-1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged over 6 months old
2. Infection with P. falciparum
3. Parasitaemia, 1000 - 100 000 asexual forms per µl
4. Axillary temperature of 37.5°C or oral/rectal temperature of 38°C
5. Ability to swallow oral medication
6. Ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule
7. Informed consent from the patient or from a parent or guardian in case of children</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>180</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>180</totalTarget>
      <exclusion>1. Presence of general danger signs among children less than 5 years old or other signs of severe and complicated falciparum malaria according to current WHO definitions
2. Mixed or mono-infection with another Plasmodium species
3. Presence of severe malnutrition (defined as a child whose weight-for-height is below -3 standard deviation or who has symmetrical oedema involving at least the feet)
4. Presence of febrile conditions due to diseases other than malaria (measles, acute lower tract respiratory infection, severe diarrhoea with dehydration, etc.), or other known underlying chronic or severe diseases
5. History of hypersensitivity reactions to any of the drug(s) being tested or used as alternative treatment
6. Pregnancy or lactation</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-11-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Malaria</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Malaria</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Each patient will receive both:
1. Artemether-lumefantrine six consecutive doses according to manufacturer recommendation over three days orally (per os)
2. Artesunate 12 mg/kg over three days per os and sulfadoxine-pyrimethamine 1/2 tablet 500 mg - 25 mg/10 kg single dose per os

Principal Investigator:
Dr Khalid A. Elmardi
National Malaria Control Programme
Federal Ministry of Health
P.O. Box 1204
Khartoum
Sudan
Tel: +249 (0)183 776809
Fax: +249 (0)183 770397
Email: khalidmrd9@hotmail.com</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Artesunate, sulfadoxine-pyrimethamine, artemether-lumefantrine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16808-0</funderId>
      <contactId>Contact54766_16808</contactId>
      <sponsorId>Sponsor53322</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54766_16808">
    <title>Dr</title>
    <forename>Pascal</forename>
    <surname>Ringwald</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>World Health Organization
20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 34 69</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ringwaldp@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53322">
    <organisation>World Health Organization (WHO)/HIV/AIDS, Tuberculosis and Malaria (HTM) - Global Malaria Programme</organisation>
    <website>http://www.who.int/malaria/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder16808-0">
    <name>World Health Organization (WHO) (Sudan)</name>
    <fundRef>http://dx.doi.org/10.13039/100004423</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-09T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2007-08-08T00:00:00.000Z">67123277</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Circadian intraocular pressure, blood pressure and diastolic ocular perfusion pressure with timolol-dorzolamide fixed combination compared with latanoprost in newly-diagnosed glaucoma patients</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To evaluate the short-term effect of Timolol-Dorzolamide Fixed Combination (TDFC), and latanoprost 0.005% on the 24-hour Intraocular Pressure (IOP), ambulatory Blood Pressure (BP), and Diastolic Ocular Perfusion Pressure (DOPP), in newly-diagnosed Primary Open-Angle Glaucoma (POAG) patients.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The following were measured at baseline, and at the end of each treatment period: 
1. 24-hour IOP
2. Ambulatory BP
3. Calculated DOPP</primaryOutcome>
      <secondaryOutcome>Adverse events</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Institutional Review Board of Clinica Oculistica Università degli studi Brescia (ref: 02/2005/03)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN67123277</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized, observer-masked, two-treatment, two-period cross-over study.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Italy</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8e3b6778-ef98-4ef0-ba21-ac7cd7366c21">
	  <name>Centro per lo studio del glaucoma</name>
	  <address/>
	  <city>Brescia</city>
	  <state/>
	  <country>Italy</country>
	  <zip>25123</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>We enrolled in the present study consecutive newly diagnosed and previously untreated POAG patients who demonstrated typical optic disc excavation and visual field abnormalities. We included POAG patients older than 45 years with no previous history of ocular surgery or laser. Additional inclusion criteria were: 
1. Open-angle by gonioscopy (Grade III-IV according to Shaffer&#146;s grading system)
2. Untreated diurnal IOP between 23 and 32 mm Hg (mean of the two highest values recorded in a daytime IOP curve with measurements every 2 hours between 08:00 and 18:00 by a calibrated Goldmann applanation tonometry)
3. Visual acuity 20/40 or better
4. Mean defect &gt;6 dB using the Humphrey 24-2 program (Humphrey Visual Field Analyzer model 745 perimeter, Humphrey Instruments, Inc., USA)
5. No history of allergy to the ingredients of any of the study drugs
6. No history of cardiovascular disease (e.g. arterial hypertension, heart disease, arrhythmia)
7. No concomitant systemic treatment (e.g. beta-blockers, angiotensin-converting enzyme inhibitors) that could modify IOP, or blood pressure. 
8. Females were enrolled in the study only if they were postmenopausal or were using contraceptives</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>27</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>27</totalTarget>
      <exclusion>See inclusion criteria</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Primary open-angle glaucoma</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Primary open-angle glaucoma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Following the monitoring of the baseline or washout IOP and BP all study patients were randomly assigned to receive either one drop of TDFC twice daily (08:00 and 20:00) or one drop of latanoprost once in the evening (20:00). 

Twenty-four hour IOP and ambulatory BP were measured at the beginning after the interim washout and at the end of each treatment period, thus obtaining 4 circadian curves. At the time of 24-hour IOP and BP assessments patients were hospitalized, and the drugs were administered by the dosing coordinator of the study according to the protocol. 

The IOP was measured every two hours. A calibrated Goldmann applanation tonometer (Haag-Streit, Switzerland) was employed to measure sitting IOP at the slit lamp between 08:00 and 22:00, while supine IOP was measured between 24:00 and 06:00, with the patient in bed, by means of a calibrated handheld electronic tonometer (TonoPen XL; Bio-Rad, USA). At each timepoint, the mean of 3 consecutive readings was calculated. 

Ambulatory blood pressure monitoring was recorded by means of an automated portable BP device, TM-2430 (A&amp;D Co, Saitama, Japan). Ambulatory BP monitoring units indirectly measure BP through oscillometric measurement of the vibratory signals associated with blood flow in the brachial artery. The BP device satisfies the recommendation by the British Hypertension Society and Association for Advancement of Medical Instrumentation on accuracy levels for both systolic and diastolic blood pressures. A cuff of appropriate size was placed in the subject&#146;s non-dominant arm and BP measurements were taken automatically every 15 minutes between 08:00 to 22:00, and every 30 minutes from 22:00 to 08:00. If a certain reading was not performed properly the 
device was programmed to repeat it. The recorded BP values throughout the 24-hour period were later recovered from the recording chip and stored in a personal computer. 

During the study BP and IOP readings were monitored in the hospital on two separate days, so as to not influence BP readings by the process of IOP measurements, or by waking the patient during the night for IOP evaluation. 
IOP measurements were performed by three well-trained masked observers who were unaware of the treatment assignments; their agreement was previously tested on a pilot sample of 15 patients, resulting in an intraclass correlation coefficient of 0.97 and 0.99 for Tonopen and Goldmann tonometry, respectively. 
A comprehensive ocular and systemic examination was performed at baseline and at the conclusion of each phase of the trial, and any ocular or systemic adverse events were noted.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16799034 Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="5694185f-4941-4d9d-a941-04122fbf9ee3" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-07-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16799034"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16738-0</funderId>
      <contactId>Contact54696_16738</contactId>
      <sponsorId>Sponsor53252</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54696_16738">
    <title>Prof</title>
    <forename>Luciano</forename>
    <surname>Quaranta</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Centro per lo studio del glaucoma
Piazzale Spedali Civili 1 </address>
      <city>Brescia</city>
      <country>Italy</country>
      <zip>25123</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+39 (0)30 3995 847</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">quaranta@med.unibs.it</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53252">
    <organisation>Clinica Oculistica (Italy)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Piazzale Spedali Civili 1 </address>
      <city>brescia</city>
      <country>Italy</country>
      <zip>25123</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+39 (0)30 3995 847</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">quaranta@med.unibs.it</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder16738-0">
    <name>Ministry of Education, University and Research  (Ministero dell&#146;Università e della Ricerca; MIUR) (Italy)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-02T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2007-07-30T00:00:00.000Z">35782567</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Applications of body surface mapping in cardiac resynchronisation therapy and ventricular tachycardia</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>1. Electrocardiographic Imaging (ECGI) using potentials derived from the body surface can be used to identify electrical dyssynchrony within the Left Ventricle (LV), along with activation patterns and regions of slow conduction. It could therefore be used to predict response to cardiac resynchronisation therapy, and ultimately to guide placement of the LV pacing lead to the optimal site.
2. ECGI using body surface potentials acquired noninvasively is of comparable accuracy to endocardial data acquired invasively in determining sites of pacing of the LV endocardium and patterns of activation.
3. ECGI is comparable to endocardial data acquired invasively in locating the origin of Ventricular Tachycardia (VT) substrates and may provide useful information over and above endocardial data to aid radiofrequency ablation of this tachyarrhythmia.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>CRT study: 
Response to CRT (assessed clinically using echo, 6 minute walk distance, cardiopulmonary stress testing, and functionally using quality of life questionnaire and NYHA symptom class). This can be assessed in conjunction with pacing site localisation using ECGI in relation to regions of slow conduction/scar tissue. 

ECGI validation and VT studies: These are qualitative studies whereby ECGI data and data acquired invasively are compared directly. Therefore there is no discrete end-point.</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The Office for Research Ethics Committees in Northern Ireland (ORECNI), approved on 16/09/2005 (ref: 05/NIR01/139)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN35782567</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RGHT000233</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Non randomised controlled trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-07-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Northern Ireland</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="55431f13-2a0b-419e-a74b-acee2a2b0231">
	  <name>Regional Medical Cardiology Centre</name>
	  <address/>
	  <city>Belfast</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>BT12 6BA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Cardiac Resynchronization Therapy (CRT) study: 
1. Poor LV function with ejection fraction on echocardiogram (ECHO) &lt;35%
2. Symptomatic with New York Heart Association (NYHA) class 2-4
3. Dilated LV (&gt;55 mm)
4. Any QRS duration (representing the duration of ventricular depolarisation)
LV dysfunction can be of any aetiology. All patients must be able and willing to give writted informed consent. 

ECGI validation study: 
Patients must require EPS/ablation of tachyarrhythmias requiring LV access e.g. VT ablation/EPS, Brugada EPS, left sided pathways. All must be willing and able to give written informed consent. 

VT study: 
All patients must require EPS for induction of LV tachyarrhythmias or ablation of VT. Again all must give written informed consent.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>70</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>70 (CRT study, 50; ECGI validation study, 10; VT study, 10)</totalTarget>
      <exclusion>CRT study:
1. Ejection fraction on ECHO &gt;35%
2. Unable or unwilling to come back for 6 month follow-up
3. Unable or unwilling to give written informed consent

ECGI validation and VT studies:
1. Procedures not requiring access to the LV
2. Bleeding conditions
3. Clotting disorders
4. Unwilling to give written informed consent
5. Age &lt;18 years</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-07-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Left ventricular dysfunction</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Left ventricular dysfunction</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. CRT study 
This is a pilot study during which 50 consecutive patients undergoing CRT implantation will be identified and worked up appropriately (there is no control group in this study and all participants will be given the same intervenions). All participants will undergo baseline assessment to include echocardiography, 6 minute walk testing, cardiopulmonary stress testing, quality of life assessment (questionnaire) and N-terminal Pro-BNP measurement. Body Surface Mapping (BSM) will be performed at baseline and the day following device implantation during different pacing modalities. They will then be followed up with a single visit at 6 months, at which time all of these tests will be repeated. 

2. ECGI validation study: 
A qualitative study comparing ECGI with data acquired invasively using noncontact endocardial mapping as gold standard. 10 patients undergoing invasive ElectroPhysiological Studies (EPS) requiring access to the left ventricle will be recruited. All patients will have an ECHO at baseline and undergo simultaneous body surface mapping and invasive endocardial mapping during muti-site pacing of the LV endocardium. BSM utilises a plastic 80-electrode mapping harness applied to the anterior and posterior torso. Noncontact endocardial mapping uses the previously validated EnSite 3000 system. This study will enable a qualitative comparison of both imaging modalities for localisation of pacing sites as well as activation sequences. There will be no follow-up for the patients in this sub-study.

3. VT study: 
10 patients requiring VT ablation or simply EPS for induction of ventricular arrhythmias will be studied using both invasive and noninvasive modalities. This is a purely qualitative study.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17993307 results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="1134c235-a071-4c2c-b0be-73b3f73c68e6" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-11-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17993307"/>
	<description>results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16486-0</funderId>
      <contactId>Contact54444_16486</contactId>
      <sponsorId>Sponsor52999</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54444_16486">
    <title>Prof</title>
    <forename>Jennifer</forename>
    <surname>Adgey</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Regional Medical Cardiology Centre
1st Floor West Wing
Royal Victoria Hospital</address>
      <city>Belfast</city>
      <country>United Kingdom</country>
      <zip>BT12 6BA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52999">
    <organisation>Royal Victoria Hospital (UK)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>c/o Professor Ian Young
Royal Research Office
Royal Victoria Hospital
Grosvenor Road</address>
      <city>Belfast</city>
      <state xmlns:isrctn="http://www.67bricks.com/isrctn">Northern Ireland</state>
      <country>United Kingdom</country>
      <zip>BT12 6BA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.416232.0</gridId>
    <rorId>https://ror.org/03rq50d77</rorId>
  </sponsor>
  <funder id="Funder16486-0">
    <name>Frances and Augustus Newman Foundation (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-22T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2007-07-16T00:00:00.000Z">38727701</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Determinants of thiazide induced hyponatraemia in pre-exposed elderly - a controlled experiment</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Thiazide-induced hyponatraemia is caused by impaired free water excretion either due to alterations in the Arginine Dihydrolase (ADH) - Arginine Vasopressin Receptor 2 (AVPR2) - Aquaporin-2 (AQP2) pathway or impaired renal sodium handling.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Effect of a single oral dose hydrochloorthiazide 50 mg intake on the serum and urine sodium, serum ADH, prostaglandin E2 and urinary aquaporin-2 excretion in elderly patients (aged 60 - 80 years) with previous thiazide-induced hyponatraemia (sodium less than 125 mmol/l) without another cause for their hyponatraemia and matched controls receiving a thiazide diuretic without hyponatraemia. 

Urinary hydrochlorothiazide concentrations are measured to analyse differences in thiazide metabolism. The response to ADH will be assessed by expression of AVPR2 in a cell-culture and determine its activity by measurement of cyclic Adenosine Monophospahte (cAMP).

Outcomes will be measured at baseline (n = 0) and after 4, 8 and 24 hours.</primaryOutcome>
      <secondaryOutcome>To identify (elderly) patients who are at risk of thiazide induced hyponatraemia.

Outcomes will be measured at baseline (n = 0) and after 4, 8 and 24 hours.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Medical Ethics Committee of the AMC on the 16th August 2007 (ref: MEC 07/059).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN38727701</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Non-randomised, controlled experimental study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-08-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="cf52a276-32d1-4353-8f9b-dda39ffe2677">
	  <name>Academic Medical Centre</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1105 AZ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age 60 - 80 years
2. Previously admitted with thiazide-induced hyponatraemia
3. Patients must be willing and medically able to discontinue anti-hypertensive therapy six weeks before the study and for the duration of the study
4. Patients must be willing to be admitted for 24 hours and must be medically able to take the study medication
5. Patients must be willing to give informed consent</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>36</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>36</totalTarget>
      <exclusion>1. Other causes for hyponatraemia (e.g. heart failure, pulmonary disease, medication associated with hyponatraemia)
2. Renal dysfunction (estimated clearance less than 50 ml/min according to Cockroft-Gault)
3. Liver cirrhosis
4. Heart failure
5. Medication: antipressiva (Selective Serotonin Reuptake Inhibitors [SSRI&#146;s]), antiepileptica, prednisone, Non-Steroidal Anti-Inflammatory Drugs (NSAID&#146;s), opioids, other diuretics (e.g. lasix, burinex, chloorthalidon, dytac)
6. Allergy for sulphonamide derivates
7. Therapy resistant hypertension (Blood Pressure [BP] greater than 140/90 mmHg while using three or more anti-hypertensive drugs)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-08-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Thiazide induced hyponatraemia</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Metabolic disorders</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>All subjects included in this controlled experiment will receive a single dose of Hydrochloorthiazide 50 mg. After that they will be monitored for 24 hours.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Hydrochloorthiazide</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16729-0</funderId>
      <contactId>Contact54687_16729</contactId>
      <sponsorId>Sponsor53243</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54687_16729">
    <title>Dr</title>
    <forename>Nanne </forename>
    <surname>Frenkel</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Academic Medical Centre
Department of Vascular Medicine</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1105 AZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">w.j.frenkel@amc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53243">
    <organisation>Academic Medical Centre (AMC) (The Netherlands)</organisation>
    <website>http://www.amc.uva.nl#http://www.amc.uva.nl/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Vascular Medicine
P.O. Box 22660</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5650.6</gridId>
    <rorId>https://ror.org/03t4gr691</rorId>
  </sponsor>
  <funder id="Funder16729-0">
    <name>Dutch Kidney Foundation (Nierstichting Nederland) (The Netherlands)</name>
    <fundRef>http://dx.doi.org/10.13039/501100002997</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-09T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2007-07-12T00:00:00.000Z">96658320</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Inhaled fluticasone in acute severe asthma</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>High dose inhaled fluticasone is superior to standard treatment with intravenous hydrocortisone in patients with acute severe asthma.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>FEV1 and PEF at 90 minutes and 180 minutes from the time of administering the drug.</primaryOutcome>
      <secondaryOutcome>1. Symptom assessment, at 90 minutes and180 minutes from the time of administering the drug
2. Adverse effect of fluticasone at 90 minutes and180 minutes from the time of administering the drug</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by Christian Medical College Ethics committee on the 18th October 2005 (ref: IRB(EC)23/10/05).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN96658320</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RES/10/2005</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double blind, double dummy, single centre, parallel group design.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-05-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>India</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c11cad31-f27a-4f7b-9887-bf4d7cc61328">
	  <name>Department of Pharmacology</name>
	  <address/>
	  <city>Vellore</city>
	  <state/>
	  <country>India</country>
	  <zip>632002</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age between 18 to 55
2. Asthma patients with Peak Expiratory Flow (PEF) and Forced Expiratory Volume in one second (FEV1) less than 50% of the predicted
3. Asthmatic for six months or more</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>110</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>110</totalTarget>
      <exclusion>1. Underlying chronic lung disease
2. Fever more than 100.4°F
3. Smoker greater than five pack years
4. Patients with no legal representative or legal representative not willing to give consent
5. Life threatening asthma</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-05-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute severe asthma, acute exacerbation of asthma</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Asthma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Baseline Measurements: 
Subjects, those who are randomised will be asked to perform baseline Peak Expiratory Flow (PEF) and Forced Expiratory Volume at one second (FEV1). Blood samples will be drawn for blood Theophylline level, pre-treatment serum potassium, Haemoglobin (Hb), Total Leucocyte Count (TLC), Differential Leucocyte Count (DLC) and Glucometer Random Blood Sugar (GRBS).  Bedside Electrocardiogram (ECG) will be done before initiation of the treatment.

Drug dose, route and time of administration:
One group will receive two doses of Fluticasone 2 mg via nebulizer half an hour apart and single dose of intravenous (IV) placebo. The other group will receive single dose of Hydrocortisone 200 mg IV and two doses of placebo via nebulizer half an hour apart. In addition, all patients will receive salbutamol 2.5 mg and ipratropium bromide 0.5 mg via nebulizer alternating every 15 minutes for three hours.

Monitoring:
PEF and FEV1 to be measured at 0, 30, 60, 90, 120, 150 and 180 minutes from the time of administering the drug, for close monitoring of the patient although the primary outcome measurement is at 90th and 180th minute.  If there is no improvement at 90th minute, the subject will be withdrawn from the trial and standard care will be given. If there is sign of worsening of the subject's condition from the baseline, at any point of time after the start of the trial, the subject will be immediately admitted into intensive care unit. 

During the period of drug administration the patient will be continuously monitored for adverse effect. At the end of three hours serum potassium level and GRBS level will be assessed. At the end of three hours, those who fulfilled the discharge criteria will be discharged and the rest will be admitted in the ward for further management. 

Follow up: 
At the time of discharge, all subjects will be advised to take Tab. Prednisolone 30 mg Once Daily (OD) and Tab. Ranitidine 150 mg twice daily for seven days along with Metered Dose Inhaler (MDI) Salbutamol 100 mcg two puffs when necessary (PRN) and MDI Fluticasone 250 mcg two puffs twice daily (BD) for one month. All of them will be advised follow up in Pulmonary Medicine Out-Patients Department (OPD) or Pulmonary Function laboratory at one month from the date of admission, to repeat PEF and FEV1.   

If there is any aggravation of symptoms prior to the day of follow up, all patients are advised to report to the Emergency Department immediately.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Fluticasone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16678-0</funderId>
      <contactId>Contact54636_16678</contactId>
      <sponsorId>Sponsor53191</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54636_16678">
    <title>Dr</title>
    <forename>K.R.</forename>
    <surname>Dhanasekar</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Pharmacology 
Christian Medical College
Thorapadi Post
Bagayam, Tamil Nadu</address>
      <city>Vellore</city>
      <country>India</country>
      <zip>632002</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor53191">
    <organisation>Christian Medical College (India)</organisation>
    <website>http://www.cmch-vellore.edu/</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Bagayam
Thorapadi Post
Tamil Nadu</address>
      <city>Vellore</city>
      <country>India</country>
      <zip>632002</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.11586.3b</gridId>
    <rorId>https://ror.org/00c7kvd80</rorId>
  </sponsor>
  <funder id="Funder16678-0">
    <name>Christian Medical College (India) - FLUID research grant (ref: R.C. Min No: 5735, RES/10/2005).</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-21T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-07-02T00:00:00.000Z">20060588</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Palliative pylorus-preserving pancreatic head resection and postoperative chemotherapy versus primary chemotherapy alone for patients with advanced carcinoma of the pancreatic head</title>
      <scientificTitle/>
      <acronym>Palliative Pylorus-Preserving Pancreatododenectomy (Palliative PPPD)</acronym>
      <studyHypothesis>Survival and quality of life after palliative pylorus-preserving pancreatoduodenectomy and postoperative chemotherapy with Gemzar® is increased when compared to Gemzar® chemotherapy alone.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Survival, measured after 3, 6 and 12 months</primaryOutcome>
      <secondaryOutcome>1. Quality of life, measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer patients (EORTC QLQ-C30) and the EORTC Quality of Life Questionnaire for Pancreatic cancer (QLQ PAN26). This will be measured after 3, 6 and 12 months
2. Surgical complications, measured after 3, 6 and 12 months
3. Toxicity of chemotherapy, measured after 3, 6 and 12 months</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from local Institutional Review Board (IRB) (Ethics Board of the Charité, Medical Faculty, Humboldt University, now known as the Ethics Committee State Berlin) on the 30th August 2002.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN20060588</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2002</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open prospective randomised study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-09-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="99fce4ac-6c8c-4e8b-84b8-4b2064cad717">
	  <name>Department of Surgery</name>
	  <address/>
	  <city>Berlin</city>
	  <state/>
	  <country>Germany</country>
	  <zip>13589</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Medical centres experienced in surgical and medical care of patients with pancreatic head carcinoma.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>15 to 20 patients</totalTarget>
      <exclusion>No exclusion criteria.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-09-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Pancreatic head carcinoma</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Pancreatic head carcinoma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group 1: standard pylorus-preserving pancreatic head resection with regional lymphadenectomy (this is an internationally well accepted surgical procedure) and after completion of wound healing (up to four weeks postoperative) standard chemotherapy with gemcitabine is started (see below). The chemotherapy is the same as in group 2.
Group 2: standard gemcitabine chemotherapy alone: 1000 mg/m^2 body surface once per week for four weeks with a one-week break, i.e., three weeks treatment and one week free. This is an internationally accepted standard for gemcitabine in advanced pancreatic carcinoma treatment. 

Drugs will be administered on an out patient basis intravenously (i.v.) through a port system. Follow up period is one year.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Gemcitabine (Gemzar®)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16540-0</funderId>
      <contactId>Contact54498_16540</contactId>
      <sponsorId>Sponsor53053</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54498_16540">
    <title>Prof</title>
    <forename>Jan</forename>
    <surname>Langrehr</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Surgery
Evangelisches Waldkrankenhaus Spandau
Stadtrandstrasse 555</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>13589</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)30 3702 1101</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">j.langrehr@waldkrankenhaus.com</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53053">
    <organisation>Humboldt University Berlin (Germany)</organisation>
    <website>http://www.charite.de/start/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Department of General-, Viszeral- and Transplantational-Surgery
Charite Universitaetsmedizin Berlin
Campus Virchow-Klinikum
Augustenburger Platz 1</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>13353</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)30 450 552001</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jan.langrehr@charite.de</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.7468.d</gridId>
    <rorId>https://ror.org/01hcx6992</rorId>
  </sponsor>
  <funder id="Funder16540-0">
    <name>Humboldt University Berlin (Germany) - Department of Surgery at Charité Campus Virchow Clinic</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-21T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-06-27T00:00:00.000Z">20350801</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Early Endoscopic Ultrasonography (EUS)-guided coeliac plexus neurolysis versus opioids for the treatment of pain in pancreatic carcinoma</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>We want to investigate which treatment modality is better, the fentanyl patches or the Endoscopic Ultrasonography (EUS)-guided Coeliac Plexus Neurolysis (CPN). This has never been investigated before. We think that the latter treatment might be less effective than one would expect according to earlier studies.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Quality of Adjusted Life Years (QALYs) will be the primary outcome parameter. This is a composite endpoint linking survival and quality of life, i.e. the number of quality adjusted life years. These are based on biweekly assessments of health status with the EuroQoL questionnaire (EQ-5D). The utility of each observed health score profile on the EQ-5D will be derived from previous research in which the time trade off based elicitation technique during interviews with adults from the general population has been applied.</primaryOutcome>
      <secondaryOutcome>1. Health-related quality of life (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC-QLQ-C30])
2. Survival
3. Opioid requirement
4. Health status (EQ-5D)
5. Adverse effects
6. Costs</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN20350801</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, active controlled, crossover multicentre trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-08-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="32fbdf85-3dcc-44ee-a0c3-c7e85b72c12e">
	  <name>Academic Medical Centre</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1100 DD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Cytological or histological proven irresectable pancreatic carcinoma
2. Chronic pain unresponsive to non-opioid analgesic drugs and low dose fentanyl (Durogesic®) transdermal patches (Visual Analogue Scale [VAS] score greater than three while using fentanyl transdermal patches maximum 50 ug/h, one patch per three days)
3. Age above 18 years
4. Karnovsky score greater than 30%</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>120</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>120</totalTarget>
      <exclusion>1. Previous coeliac plexus blockade
2. Use of opioids
3. Refusal to sign informed consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-08-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Pancreatic carcinoma</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Pancreatic carcinoma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients will be randomised according to two treatment algorithms. The first &#147;conventional&#148; type treatment algorithms consists of increasing dosages of transdermal fentanyl patches. In this algorithm, EUS-guided CPN (rescue) will only be performed in case of failure of opioid treatment because of insufficient pain relief (VAS score greater than or equal to 4) or unmanageable side effects. The second treatment algorithm consists of early (repeated) EUS-guided CPN. In case of insufficient pain relief after the second CPN, opioid treatment with transdermal fentanyl patches may be started. Adequate response to therapy (either after EUS-guided CPN or opioids) is defined as a pain score less than or equal to 3 on a scale from 0 - 10 (VAS score) and the absence of unmanageable opioid-related side effects.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Transdermal fentanyl patches</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16652-0</funderId>
      <contactId>Contact54610_16652</contactId>
      <sponsorId>Sponsor53165</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54610_16652">
    <title>Dr</title>
    <forename>A.M.C.J.</forename>
    <surname>Voorburg </surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Academic Medical Centre</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 566 8712</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">a.m.voorburg@amc.uva.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53165">
    <organisation>Academic Medical Centre (AMC) (The Netherlands)</organisation>
    <website>http://www.amc.uva.nl#http://www.amc.uva.nl/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Gastroenterology
P.O. Box 22660</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5650.6</gridId>
    <rorId>https://ror.org/03t4gr691</rorId>
  </sponsor>
  <funder id="Funder16652-0">
    <name>Academic Medical Centre (AMC) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-26T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-06-27T00:00:00.000Z">48083859</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>VErtebroplasty versus Radiotherapy As palliative treatment of vertebral metastases of Multiple Myeloma (M. Kahler)</title>
      <scientificTitle/>
      <acronym>VERAMM</acronym>
      <studyHypothesis>Vertebroplasty improves the quality of life of the individual patient by increased pain reduction and restoration of mobility. Vertebroplasty also reduces costs, as it decreases the number of inpatient days, the number of outpatient visits and follow-up treatments, and the need for home care.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Degree of pain (VAS-pain score, scale: 0 - 10), measured at day 0 (pre-treatment), day 0 (post-treatment), day 7, week 4, week 12, month 6 and year 1
2. Use of pain medication, measured at day 0 (pre-treatment), day 0 (post-treatment), day 7, week 4, week 12, month 6 and year 1</primaryOutcome>
      <secondaryOutcome>1. Initial technical success and complications, measured at day 0 (post-treatment) and week 4 respectively
2. Mobility (Oswestry-daily activity scale), measured at day 0 (pre-treatment), day 7, week 4, week 12, month 6 and year 1
3. Quality of life (questionnaires: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire on Myeloma [EORTC QLQ-MY24], 36-item Short Form health survey [SF-36]), measured at day 0 (pre-treatment), day 7, week 4, week 12, month 6 and year 1
4. Collapse of treated vertebrae (lateral X-WK), measured at day 0 (pre-treatment), week 4, week 12, month 6 and year 1
5. Mortality, measured at year 1
6. Direct medical costs (e.g. procedure costs, hospitalisation days, pain medication, secondary interventions, revalidation or nursing home costs, follow-up), measured at year 1</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The VERAMM trial was approved by the Medical Ethics Committee Erasmus MC (METC) on the 15th March 2007 (ref: MEC-2007-033).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN48083859</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CCMO NL14746.078.07; Erasmus MC METC 2007-033</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, active controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-06-04T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b58ac38b-070a-4386-b181-26934a462779">
	  <name>Department of Radiology Hs-220</name>
	  <address/>
	  <city>Rotterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3015 CE</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Persistent pain caused by vertebral metastases from myeloma (including plasmacytoma) with Visual Analogue Scale (VAS) score greater than 4 (scale: 1-10)
2. Informed consent
3. Older than 18 years</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>104</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>104</totalTarget>
      <exclusion>1. Greater than four affected vertebrae
2. Vertebral fracture through back wall with retropulsion that consumes more than 33% of the spinal channel
3. Myelum compression with neurological degeneration: Frankel A/B
4. Epiduritis
5. Incorrigible coagulopathy
6. Karnofsky score less than 30 (moribund)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-06-04T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Spinal metastases, vertebroplasty, multiple myeloma</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Myeloma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Arm I (control): radiotherapy (20 Gy) of affected vertebrae
Arm II: vertebroplasty of affected vertebrae</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16662-0</funderId>
      <contactId>Contact54620_16662</contactId>
      <sponsorId>Sponsor53175</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54620_16662">
    <title>Dr</title>
    <forename>Edwin</forename>
    <surname>van der Linden</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Radiology Hs-220
Erasmus MC - University Medical Center Rotterdam
's Gravendijkwal 230</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3015 CE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 463 2886</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">e.vanderlinden@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53175">
    <organisation>Erasmus Medical Centre (The Netherlands)</organisation>
    <website>http://www.erasmusmc.nl/content/englishindex.htm </website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Radiology
&#146;s-Gravendijkwal 230</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3015 CE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5645.2</gridId>
    <rorId>https://ror.org/018906e22</rorId>
  </sponsor>
  <funder id="Funder16662-0">
    <name>Erasmus Medical Centre (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-21T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2007-06-01T00:00:00.000Z">88423868</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Evaluation of the diagnostic quality of manganese chloride tetrahydrate (CMC-001©) in liver magnetic resonance imaging in patients with liver metastases in comparison to gadolinium benzyloxypropionictetraacetate (BOPTA): a randomised cross-over phase III trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The primary objective is to assess the feasibility of manganese chloride tetrahydrate (CMC-001©) as a contrast medium in liver Magnetic Resonance Imaging (MRI) scanning in patients with liver metastases in comparison with gadolinium Benzyloxypropionictetraacetate (BOPTA) (MultiHance©) MRI.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary objective is to assess the feasibility of CMC-001© as a contrast medium in liver MRI scanning in patients with liver metastases in comparison with gadolinium BOPTA (MultiHance©) MRI.</primaryOutcome>
      <secondaryOutcome>The secondary objectives are to further evaluate the safety and tolerability of CMC-001© in patients:
1. ECG, vital signs, blood for laboratory analyses and urine is drawn at screening and after MRI
2. AEs are asked for during the whole trial as well as at the phone calls 24 and 48 hours after contrast</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from the Regional Ethics Board in Stockholm on the 30th March 2005 (ref: 2005/305-31/1).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN88423868</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CMC-P 004</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>The study will be of a single centre, randomised and open cross-over design.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="7c90e809-f1de-4c19-8067-a31ad84b95f3">
	  <name>Lars Vedin AB</name>
	  <address/>
	  <city>Stockholm</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>SE-114 75</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Signed written informed consent after oral and written information about the study has been given by the investigator
2. Patients with one to six liver metastases from colorectal cancer verified with other methods
3. Men or women over 18 years old
4. The patient is conscious and co-operative</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>1. Clinically relevant medical history or abnormal physical findings which could interfere with the safety or objectives of the study as judged by the investigator
2. Clinically relevant Electrocardiogram (ECG), haematology, clinical chemistry, serology and urine chemistry abnormalities. This is based on the judgement of the treatment physicians
3. Allergy to any of the study product compounds
4. Drug or alcohol abuse by asking the patient at screening
5. Patients who are deemed to be unsuitable for any other reason in the opinion of the investigator
6. Participation in another clinical study concerning another contrast preparation within the last three months or seven days after this study
7. Previous inclusion in this study
8. Pregnancy after randomisation at the day of MRI before contrast
9. The patient is scheduled to receive intravascular iodinated contrast medium within 24 hours after this study
10. The patient is being investigated on an emergency basis
11. The patient has newly discovered unstable diabetes or undergoes haemodialysis or peritoneal dialysis
12. The patient has a known or suspected clinically severe concurrent illness that may influence the renal function or has undergone kidney, liver or bone marrow transplantation
13. The patient has a concurrent severe illness in the Gastrointestinal (GI) tract like paralysis or malabsorption or clinically manifest icterus
14. Known Human Immunodeficiency Virus (HIV) infection or Acquired Immune Deficiency Syndrome (AIDS)
15. Known hepatitis
16. Known cirrhosis
17. The patient has uncompensated cardiac failure (cardiac failure New York Heart Association [NYHA] grade IV)
18. A patient may be excluded during the trial based on the clinical judgement of the clinician or the radiologist</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Colorectal cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Colorectal cancer</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Each patient will have two MRI sessions, one with each product. This means that each patient will be his/her own control. The evaluation of MR images will be performed by two independent observers. The final evaluation will however be made in consensus.

When a suitable patient arrives at the clinic he/she will be informed about the trial both orally and in writing and is offered a to take part in the trial with two different MRI sessions, one with Gadolinium BOPTA and a second MRI with CMC-001© as contrast. After that he/she will sign the informed consent form.

The patients will visit the clinic three times:
1. For screening and eligibility test
2. For MR imaging of the first contrast
3. For MR imaging of the second contrast

After this, they will be called by phone 24 and 48 hours and asked about Adverse Events (AEs).

The order of administration of the two contrast agents is randomised. MRI after CMC-001© is performed three hours after contrast and MRI after MultiHance©, the comparator, is performed two hours after contrast.

Electrocardiogram (ECG), vital signs, blood for laboratory analyses and urine is drawn at screening and after MRI.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Manganese chloride tetrahydrate (CMC-001©) and gadolinium BOPTA (MultiHance©).</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16453-0</funderId>
      <contactId>Contact54411_16453</contactId>
      <sponsorId>Sponsor52966</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54411_16453">
    <title>Dr</title>
    <forename>Lars</forename>
    <surname>Vedin</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Lars Vedin AB
Floragatan 13</address>
      <city>Stockholm</city>
      <country>Sweden</country>
      <zip>SE-114 75</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 (0)8 5064 5751</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">lv@cmc-contrast.se</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52966">
    <organisation>Copenhagen Malmö Contrast AB (CMC Contrast AB) (Sweden)</organisation>
    <website>http://www.cmc-contrast.se</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>c/o Lars Vedin AB
Floragatan 13</address>
      <city>Stockholm</city>
      <country>Sweden</country>
      <zip>SE-11475</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 (0)8 5064 5751</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">lv@cmc-contrast.se</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.476186.a</gridId>
    <rorId>https://ror.org/015x46y72</rorId>
  </sponsor>
  <funder id="Funder16453-0">
    <name>Copenhagen Malmö Contrast AB (CMC Contrast AB) (Sweden)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-22T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2007-05-30T00:00:00.000Z">08206786</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>My story as informal care-giver: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The new preventive intervention will lead to a significant decrease in psychological problems and perceived stress, an improvement in the quality of life of the informal care-givers as compared with a waiting list control group.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Depressive symptoms
2. Perceived stress
3. Quality of life

Outcomes will be measured at:
T0: one week before start of intervention
T1: after three months (directly after intervention)
T2: after six month (three months after intervention)</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local ethics committee (METIGG kamer Noord) on the 23rd January 2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN08206786</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, multicentre, placebo controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b5190312-eef5-4cc5-9fc7-32e717c8ff57">
	  <name>Trimbos-Instituut</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3500 AS</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Adults above the age of eighteen who provide informal care for a parent and feel they are under stress as a result.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>200</totalTarget>
      <exclusion>1. The parent of the informal care-provider is no longer able to take part in the life review, e.g. because of having severe dementia
2. The health situation of the parent or informal caregiver requires acute assistance</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Informal care-givers, prevention, depression, burnout, stress</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Psychological problems</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The Informal care-givers in Balance course consists of eight two-hour sessions and is designed for adult children who provide structural care for a parent in need of care and are under high perceived stress as a result. At the first three sessions, the participants learn to interview their own parent according to the life review method. Starting at the fourth session of the course, the perspective shifts to the informal care-givers&#146; own life. The informal care-givers focus on the meaning and effects, especially undesirable ones, of the informal care on their lives and on the balance they would like to establish in their lives in accordance with the life review method. The possibilities are addressed for introducing a better balance.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16554-0</funderId>
      <contactId>Contact54512_16554</contactId>
      <sponsorId>Sponsor53067</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54512_16554">
    <title>Dr</title>
    <forename>Ernst</forename>
    <surname>Bohlmeijer</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Trimbos-Instituut
P.O. Box 725</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3500 AS</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 2971100</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ebohlmeijer@trimbos.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53067">
    <organisation>Trimbos-Institute - Netherlands Institute of Mental Health and Addiction (The Netherlands)</organisation>
    <website>http://www.trimbos.nl/default37.html</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>P.O. Box 725</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3500 AS</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 2971100</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@trimbos.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.416017.5</gridId>
    <rorId>https://ror.org/02amggm23</rorId>
  </sponsor>
  <funder id="Funder16554-0">
    <name>The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-07-04T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2007-05-30T00:00:00.000Z">81465865</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effect of electrical neurostimulation on collateral perfusion during acute coronary occlusion</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Neurostimulation can improve collateral perfusion measured as a coronary wedge pressure (Pw)/aortic pressure (Pa) ratio, during acute coronary occlusion.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary endpoint was collateral perfusion, the Pw/Pa ratio. This was measured during a one-minute balloon inflation during PCI. The Pw/Pa ratio was measured in each patient during two ischaemic episodes. To compare the Pw/Pa ratio with and without electrical neurostimulation, the Pw/Pa ratio is measured intracoronary, using a pressure wire.</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN81465865</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, active controlled, crossover trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-01-10T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-05-10T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="37603721-b3d4-43a5-8a65-17a38c12c6b8">
	  <name>Thorax Centre</name>
	  <address/>
	  <city>Groningen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>9713 GZ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with stable angina
2. Evidence of myocardial ischaemia
3. Planned for elective Percutaneous Coronary Intervention (PCI)</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60</totalTarget>
      <exclusion>1. Recent myocardial infarction
2. Prior coronary artery bypass grafting
3. Undtable angina
4. Conduction disturbances
5. Pacemaker
6. Internal cardio-defibrillator</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-01-10T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-05-10T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Angina pectoris, electrical neurostimulation, coronary collaterals, angioplasty</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Ischaemic heart diseases</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The intervention was electrical neurostimulation, during five minutes before and during the one-minute ischaemic episode. Within a patient we measured during the one-minute ischaemic episode the collateral perfusion, with and without electrical neurostimulation. The ischaemic episode was established by balloon inflation during elective PCI.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17597524 Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="4909579f-7266-424f-9850-f719318cfec2" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-06-27T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17597524"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16565-0</funderId>
      <contactId>Contact54523_16565</contactId>
      <sponsorId>Sponsor53078</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54523_16565">
    <title>Dr</title>
    <forename>J.</forename>
    <surname>de Vries</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Thorax Centre 
University Medical Centre Groningen
Hanzeplein 1</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>9713 GZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">j.de.vries@thorax.umcg.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53078">
    <organisation>University Medical Centre Groningen (UMCG) (The Netherlands)</organisation>
    <website>http://www.umcg.nl/azg/nl/english/azg/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Thorax Centre
Department of Cardiology</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>9700 RB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.4494.d</gridId>
    <rorId>https://ror.org/03cv38k47</rorId>
  </sponsor>
  <funder id="Funder16565-0">
    <name>University Medical Centre Groningen (UMCG) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-21T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2007-05-30T00:00:00.000Z">77521636</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Transjugular Intrahepatic Porto-systemic Shunt (TIPS) with Gore-tex® covered stent-graft versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Transjugular Intrahepatic Porto-systemic Shunt (TIPS) using covered stents will be equally or more effective, cost-effective and safe as/safer than endoscopic treatment in the secondary prevention of gastro-oesophageal variceal bleeding.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Recurrence of variceal bleeding</primaryOutcome>
      <secondaryOutcome>1. Occurrence of treatment failure (either switch to other therapy -&#147;cross-over&#148;- or death)
2. Incidence of encephalopathy, defined as occurrence of grade II, III or IV encephalopathy
3. Liver function (according to Child-Pugh class)
4. Mortality
5. Quality of life
6. Costs</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN77521636</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, multicentre, active controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4a48d23c-9302-4d1b-be7d-d576d91977d9">
	  <name>Erasmus Medical Centre</name>
	  <address/>
	  <city>Rotterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3015 CE</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients presenting with a first or second episode of oesophageal or gastric variceal bleeding, as documented by endoscopy and meeting accepted diagnostic criteria
2. Initial stabilisation (absence of evidence of continued bleeding)
3. Informed consent
4. Aged more than 18 and less than 76 years</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>124</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>124</totalTarget>
      <exclusion>1. History of serious or refractory encephalopathy, unrelated to gastrointestinal bleeding
2. History of significant heart failure (New York Heart Association [NYHA] class III &amp; IV)
3. Portal hypertension due to other causes than liver disease (e.g. portal vein or splenic vein thrombosis)
4. Previous TIPS placement
5. Advanced hepatocellular carcinoma
6. Severely compromised liver function (Child-Pugh score greater than 13)
7. Sepsis and/or multiorgan failure</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Gastro-oesophageal variceal bleeding</description>
	<diseaseClass1>Digestive System</diseaseClass1>
	<diseaseClass2>Gastro-oesophageal variceal bleeding</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Transjugular Intrahepatic Porto-systemic Shunt (TIPS)(intervention group): 
A shunt is made between the portal vein and the systemic veins, which decreases blood pressure in the portal vein to normal. This decreases the risk of re-bleeding. The procedure takes approximately two hours.

Endoscopic treatment (control group): 
The bleeding varices are ligated or sclerosed. The pressure in the portal vein remains too high. This procedure has to be repeated several times until the varices are completely obliterated.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16555-0</funderId>
      <contactId>Contact54513_16555</contactId>
      <sponsorId>Sponsor53068</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54513_16555">
    <title>Dr</title>
    <forename>F.H.D. </forename>
    <surname>Sebus </surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Erasmus Medical Centre
Department of Radiology
&#146;s-Gravendijkwal 230</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3015 CE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)10 4632277</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">f.sebus@erasmusmc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53068">
    <organisation>Erasmus Medical Centre (The Netherlands)</organisation>
    <website>http://www.erasmusmc.nl/content/englishindex.htm#http://www.erasmusmc.nl/content/englishindex.htm</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Radiology
Dr. Molewaterplein 50</address>
      <city>Rotterdam</city>
      <country>Netherlands</country>
      <zip>3015 GE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5645.2</gridId>
    <rorId>https://ror.org/018906e22</rorId>
  </sponsor>
  <funder id="Funder16555-0">
    <name>The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-21T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-05-30T00:00:00.000Z">53810679</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Bortezomib (Velcade®) therapy combined with Donor Lymphocyte Infusion in patients with relapsed multiple myeloma following allogeneic stem cell transplantation</title>
      <scientificTitle/>
      <acronym>DLI-Velcade® study</acronym>
      <studyHypothesis>The combination of DLI with bortezomib given before and after the DLI improves the Graft versus Myeloma effect without effect on the Graft versus host disease</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome is response rate. The included patients will be analysed with analysis of the m-protein at entry, after bortezomib cycle 2, 4, 6, 8 and before administration of DLI or before cycle 4,6,8 if no more DLI is given. After each DLI before administration of bortezomib
cycle 3, 5, 7 and in follow up every 2 months. Bone marrow examination
will be done on indication, for example confirmation of CR.</primaryOutcome>
      <secondaryOutcome>Secondary outcomes are evaluated at the same time points as the primary outcome. Blood samples for experimental immunology are taken before:
1. First administration of bortezomib in cycle one
2. First DLI
3. First administration of bortezomib in cycle three
4. Second DLI
5. First administration of bortezomib in cycle five
6. Third DLI
7. First administration of bortezomib in cycle seven 
8. Stopped treatment and/or occurring GvHD</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN53810679</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>interventional, non-randomised, non-controlled, multicentre trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2009-05-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="5812c995-666e-4a06-b303-b695fccf0a82">
	  <name>University Medical Centre Utrecht</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3508 GA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Male or female and at least 18 years-of-age; 
2. MM patients with any type of relapse or progressive disease following (non) myeloablative allo-SCT for which DLI is considered a treatment option (including patients previously participating in Hovon 54 or Hovon 65 studies);
3. Informed consent; 
4. Haematological parameters; Hb &gt; 4.0 mmol/L, leucocytes &gt; 1.0¡Á109/L , thrombocytes &gt; 25 ¡Á109/L, with or without transfusion</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>1. Use of the immunosuppressive drugs cyclosporin, MMF, or corticosteroids;
2. Existing GvHD &gt; grade A;
3. Any non-hematological toxicity CTC grade ¡Ý 3;
4. Neuropathy and/or neuropathic pain CTC grade ¡Ý 2; 
5. Pregnancy;
6. History of allergic reaction to compounds containing boron or mannitol;
7. Uncontrolled or severe cardiovascular disease, including myocardial infarctiin within 6 months, NYHA class III of IV heart failure (appendix E), uncontrolled angina, clinically significant pericardial disease or cardiac amyloidosis;
8. Previous use of bortezomib is not an exclusion criterion, however patients refractory to bortezomib during previous treatments are excluded from this study.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2009-05-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Multiple myeloma</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Multiple myeloma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The intervention consists of a sequential approach over bortezomib cycli (2) with DLI. The bortezemib cycli are given before and 2 weeks after the DLI infusion. If the patient reaches a CR the treatment is
stopped. If a PR is reached the patient continues with bortezomib, maximum 8 cycli. In case of a minimal reaction the patient can receive a second and third DLI, combined with bortezemib. During the study blood and bone marrow sampling will determine the response rate. This is no
control group, comparison with historical data will be performed.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Bortezomib (Velcade®), Donor Lymphocyte Infusion</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16558-0</funderId>
      <contactId>Contact54516_16558</contactId>
      <sponsorId>Sponsor53071</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54516_16558">
    <title>Dr</title>
    <forename>M.C.</forename>
    <surname>Minnema</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Centre Utrecht
Department of Haematology, B02.226
P.O. Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 2507230</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">m.c.minnema@umcutrecht.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor53071">
    <organisation>University Medical Centre Utrecht (UMCU) (The Netherlands)</organisation>
    <website>http://www.umcutrecht.nl/zorg/ </website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Haematology
P.O. Box 85500</address>
      <city>Alkmaar</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5477.1</gridId>
    <rorId>https://ror.org/04pp8hn57</rorId>
  </sponsor>
  <funder id="Funder16558-0">
    <name>University Medical Centre Utrecht (UMCU) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-10T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2007-05-25T00:00:00.000Z">09602471</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Role of rapid diagnostic testing in the context of home management of childhood fever with Coartem®: an open randomised controlled trial in a rural and seasonal malaria transmission area of Burkina Faso</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Community level treatment of malaria and/or acute respiratory infections guided by malaria Rapid Diagnostic Testing (RDT) and respiratory rate counting improves clinical recovery rate of children with febrile disease.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Clinical recovery rate at 72 hours after treatment (defined as apyrexia and axillary temperature less than 37.5°C).</primaryOutcome>
      <secondaryOutcome>1. Evaluate influence of the seasonal variation of malaria transmission on the impact, measured at eight days post onset of the treatment
2. Assess the cost-effectiveness of RDT in the context of the HMM strategy with Coartem®, measured at the end of the study  
3. Describe the operational feasibility and acceptability of RDT in the context of the HMM strategy with Coartem®, measured at the end of the study</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from the Comité d&#146;ethique pour la Recherche en Santé du Burkina (CERS-B) on the 15th February 2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN09602471</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>A60486</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open randomised, controlled, clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Diagnostic</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-05-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Burkina Faso</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1d5ee311-cc87-4d3b-9663-6c320f611fba">
	  <name>World Health Organization</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH-1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Written informed consent from parent/guardian
2. Aged 6 to 59 months
3. Weight equals 5 kg
4. Willing to comply with the study procedures
5. History of fever within the last 24 hours or documented fever (axillary temperature equals 37.5°C)</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="6.0"/>
      <upperAgeLimit unit="Months" value="59.0"/>
      <gender>Both</gender>
      <targetEnrolment>1200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1200</totalTarget>
      <exclusion>1. Severe malaria 
2. Danger signs (unable to drink or eat, incoercible vomiting, convulsions, prostration)
3. History of allergic reaction to the study drugs
4. History of treatment with artemisinin derivatives in the past seven days
5. Previous participation in this study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-05-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Malaria, acute respiratory infection</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Malaria</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients were randomised between:
1. Treatment with Coartem® and/or cotrimoxazole based on rapid diagnosis test results and respiratory rate count
2. Presumptive treatment with Coartem®, on day three after the onset of the treatment

Principal Investigator:
Tiono Alfred
Centre National de Recherche et de Formation sur le Paludisme
01 BP 2208 
Ouagadougou 01
Burkina Faso
Tel: +226 70 28 57 26
Email: t.alfred@fasonet.bf</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Coartem®, cotrimoxazole</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      
    </outputs>
    <parties>
      <funderId>Funder16430-0</funderId>
      <funderId>Funder16430-1</funderId>
      <contactId>Contact54388_16430</contactId>
      <sponsorId>Sponsor52942</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54388_16430">
    <title>Dr</title>
    <forename>Franco</forename>
    <surname>Pagnoni</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>World Health Organization 
20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52942">
    <organisation>UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) </organisation>
    <website>http://www.who.int/tdr/topics/mim/default.htm</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>World Health Organization
20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder16430-0">
    <name>Multilateral Initiative on Malaria (MIM)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16430-1">
    <name>United Nations Children's Fund (UNICEF)/United Nations Development Programme (UNDP)/World Bank/World Health Organization (WHO) - Special Programme for Research and Training in Tropical Diseases (TDR)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-05T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-05-01T00:00:00.000Z">59798735</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of selective COX-2 inhibition on neuroinflammation in Parkinson's disease</title>
      <scientificTitle/>
      <acronym>COXPKPD (COX-2 inhibition monitored by PK11195 in Parkinson's Disease)</acronym>
      <studyHypothesis>Celecoxib inhibits cerebral activated microglia in Parkinson's disease</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>One baseline and one follow-up Positron Emission Tomography (PET) scan (PK11195) and one Magnetic Resonance Imaging (MRI) scan will be performed to assess the reduction of specific cerebral radiotracer uptake (volume of distribution according to Logan graphical method) after celecoxib.</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Medical Ethics Review Committee of the University Medical Center Groningen. Approval pending as of 28 February 2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN59798735</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>16901</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open, non-randomised, non-placebo controlled, pilot phase trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="cee260f2-c435-4e29-84b5-ee4a168c5a35">
	  <name>University Medical Center Groningen (UMCG)</name>
	  <address/>
	  <city>Groningen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>9700 RB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Early Parkinson's disease patients
2. Hoehn and Yahr Parkinson's Disease Rating Scale (HY) 1 - 2</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>Gastrointestinal diseases</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Parkinson's disease</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Parkinson's disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Interventions amended as of 05/09/2007: 
All participants will receive celecoxib oral medication of 100 mg daily for 1 month. 

Interventions provided at time of registration: 
Celecoxib oral medication of 100 mg daily for 1 month.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Celecoxib</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16254-0</funderId>
      <funderId>Funder16254-1</funderId>
      <contactId>Contact54209_16254</contactId>
      <sponsorId>Sponsor52763</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54209_16254">
    <title>Prof</title>
    <forename>Klaus</forename>
    <surname>Leenders</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Center Groningen (UMCG) 
Hanzeplein 1</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>9700 RB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52763">
    <organisation>University Medical Center Groningen (UMCG) (The Netherlands)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Hanzeplein 1</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>9700 RB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">k.l.leenders@neuro.umcg.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.4494.d</gridId>
    <rorId>https://ror.org/03cv38k47</rorId>
  </sponsor>
  <funder id="Funder16254-0">
    <name>University Medical Center Groningen (UMCG) Neurology department deparmental funding (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16254-1">
    <name>Stichting International Parkinson Fonds (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-21T00:00:00.000Z" version="16">
    <isrctn dateAssigned="2007-04-30T00:00:00.000Z">41474531</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Randomised, controlled, double-blind clinical study on the effect of a functional milk-product on metabolism of men with diagnosed metabolic syndrome</title>
      <scientificTitle/>
      <acronym>EFOMS (Effect of Functional milk product On the Metabolic Syndrome)</acronym>
      <studyHypothesis>The goal of the investigation is the question, to what extent the risk of the metabolic syndrome may be reduced by substances naturally occurring in milk. The pathophysiology of the metabolic syndrome is characterized by an insulin resistance, a dyslipidaemia, an essential hypertension and adiposity of the central type and frequently leads to early manifestation of type 2 diabetes mellitus and atherosclerosis. Such metabolic disturbances increase in the industrialized countries and in the developing countries, too, and represent an important economical and public-health cost factor. It is necessary to identify the relevant factors of human nutrition and to develop potential avoidance strategies, e.g. by development of functional food. The cow-milk derived substances, which will be used in this study have had influenced individual components of the metabolic syndrome and lowered  the risk of components of the metabolic syndrome in an animal trial.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Change of blood fructosamine concentration during the intervention period</primaryOutcome>
      <secondaryOutcome>1. Insulin sensitivity
2. Endothelial function
3. Blood pressure
4. Waist-to-hip ratio
5. Postprandial concentration of several hormones and blood parameters linked to fat and carbohydrate metabolism</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethic committee of the medical faculty of the Christian-Albrechts-University of Kiel, (Germany), approved on 09.01.2007, Ref: A171/06</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN41474531</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>The study is a randomised double-blind placebo-controlled intervention study over 8 weeks</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-02-05T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-05-23T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c5998fd7-083f-4264-8051-4ba5dfc054b3">
	  <name>Hermann-Weigmann-Str. 1</name>
	  <address/>
	  <city>Kiel</city>
	  <state/>
	  <country>Germany</country>
	  <zip>24103</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Men, 45-70 years old, with a metabolic syndrome as defined by the International Diabetes Federation, 2006 (A new IDF worldwide definition of the metabolic syndrome: the rationale and the results - Diabetes Voice, Vol. 50 Issue 3, 2005)</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60 volunteers (30 for each the verum and control group)</totalTarget>
      <exclusion>1. Participation in a clinical study with a medicament or a medicinal product within the last 30 days or simultaneous participation in another clinical examination
2. Intake of nitrate and/or calcium antagonists and/or alpha-blockers, which affect the blood pressure
3. Known metabolic or gastro-intestinal diseases, which affects the absorption, metabolism or excretion of food or food component
4. Condition after operation of the gastro-intestinal tract, which affect gastro-intestinal motility
5. Hemoglobin &lt; 12 g/dL
6. Malfunction of blood coagulation or drugs, leading to malfunction of blood coagulating diabetes
7. Operation within the last 3 months, which still affects the current state of health
8. Illness of thyroid gland, which has metabolic and/or cardiovascular effect
9. Known hepatitis B, hepatitis C, HIV infection or chronic liver damage
10. Kidney insufficiency
11. Hypercalcaemia
12. Drug or alcohol abuse
13. Intake of drugs affecting the absorption, metabolism or excretion of food components or the gastro-intestinal
14. Intake of hormone preparations
15. Vegetarianism, anorexia, bulimia
16. Known milk protein allergy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-02-05T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-05-23T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Metabolic syndrome</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Metabolic syndrome</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The volunteers of the verum group will take one portion of the functional milk-product (product code 966125, a non-registered product) once a day after lunch with a dessert for 56 days. The product of the control group is based on meat protein and is isoenergetic and isonitrogenous.

Primary and secondary outcome measures will be analysed before and at the end of the intervention.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>milk product</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16261-0</funderId>
      <contactId>Contact54216_16261</contactId>
      <sponsorId>Sponsor52770</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54216_16261">
    <title>Prof</title>
    <forename>Juergen</forename>
    <surname>Schrezenmeir</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Hermann-Weigmann-Str. 1</address>
      <city>Kiel</city>
      <country>Germany</country>
      <zip>24103</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+49 (0)431 609  2220</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">juergen.schrezenmeir@bfel.de</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52770">
    <organisation>Humana GmbH (Germany)</organisation>
    <website>http://www.humana.de</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Bielefelder Strasse 66</address>
      <city>Herford</city>
      <country>Germany</country>
      <zip>32051</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </sponsor>
  <funder id="Funder16261-0">
    <name>Humana GmbH (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-25T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2007-03-01T00:00:00.000Z">72748991</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A televised, web-based randomised trial of an herbal remedy (valerian) for insomnia</title>
      <scientificTitle/>
      <acronym>SøvnStudien</acronym>
      <studyHypothesis>The primary objective is to evaluate whether valerian root (valerian) improves the self-assessed quality of sleep compared with placebo for people with primary insomnia</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Proportion of participants in each group with an improvement in self-assessed quality of sleep of &gt; or = 0.5 units between the average score for the 2 weeks before and 2 weeks during treatment</primaryOutcome>
      <secondaryOutcome>1. Proportion of participants in each group with an improvement of &gt; or = 0.5 units between the average score for the 2 weeks before and 2 weeks during treatment for each of the four variables: 
1.1 Sleep latency
1.2 Number of awakenings
1.3 Total sleep time
1.4 Energy level during the day

2. Mean changes in the five outcomes listed above

3. Global self-assessment

If a difference is not found between the treatment groups for the primary and secondary variables, the following explorative variables will be analysed:
1. Proportion of participants in each group with any improvement in mean difference (i.e. all score changes &gt; 0) between the average score for the 2 weeks before and 2 weeks during treatment for each of the five variables: 
1.1 Quality of sleep
1.2 Sleep latency
1.3 Number of awakenings
1.4 Total sleep time
1.5 Energy level during the day

2. Difference in the profile of the five endpoints during the intervention period taking into account the baseline period, including a potential time effect</secondaryOutcome>
      <trialWebsite>http://sovnstudien.forskningspuls.no/</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Regional Committee for Medical Research Ethics for Southern Norway (Regional komité for medisinsk forskningsetikk, Sør- Norge) 5 January 2006, Ref: S-05280</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN72748991</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2005001TVT</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double-blind, parallel group, placebo controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2007-01-29T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-03-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Norway</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4cd12084-91df-42fd-a3c6-13a0e1b4e932">
	  <name>Norwegian Knowledge Centre for the Health Services</name>
	  <address/>
	  <city>Oslo</city>
	  <state/>
	  <country>Norway</country>
	  <zip>N-0130</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged 18 &#150;75 years, both inclusive
2. Insomnia lasting more than one month
3. Pittsburgh Sleep Quality Index (PSQI) score of &gt; 5
4. Provide name of primary physician
5. Access to internet and own email address
6. At least 10 days of the sleep diary completed prior to randomisation</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Not Specified</gender>
      <targetEnrolment>550</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>500 to 550</totalTarget>
      <exclusion>1. Secondary insomnia
2. Use of hypnotics by prescription
3. Depression
4. Alcohol or drug abuse 
5. Psychotherapy within the past six months
6. Sleep apnoea, periodic limb movements disorder or restless legs syndrome
7. Pregnant or lactating women or women of childbearing potential who do not use an approved method of contraception (oral contraceptives orIntrauterine device [IUD])
8. Shift workers
9. History of hypersensitivity to valerian or its constituents
10. Participant rating of &#145;usually&#146; or &#145;always&#146; to the following questions in the Global Sleep Assessment Questionnaire:
During the past four weeks, how often:
a. Did you hold your breath, have breathing pauses, or stop breathing in your sleep?
b. Did you have restless or "crawling" feelings in your legs at night that went away if you moved your legs?
c. Did you have repeated rhythmic leg jerks or leg twitches during your sleep?
d. Did you have nightmares, or did you scream, walk, punch, or kick in your sleep?
e. Did any of the following disturb you in your sleep: 
f. Pain? 
g. Other physical symptoms?
h. Medications? 
i. Did you snore loudly?
11. Current participation in another trial using an investigational compound</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2007-01-29T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-03-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Primary insomnia</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Insomnia</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Coated Valerian Forte tablets 200 mg extract per tablet, corresponding to 1200 mg Valeriana officinalis. 3 tablets to be taken every night for 14 days

Information about the study will be televised nationally on a weekly health program. Viewers interested in participation will be invited to visit the web pages of the study to enrol. Participant registration and data collection will be by use of Internet.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17940604 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="8cc482e2-f5b6-4155-9ed5-54daca75364f" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-10-17T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17940604"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16073-0</funderId>
      <contactId>Contact54019_16073</contactId>
      <sponsorId>Sponsor52571</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54019_16073">
    <title>Dr</title>
    <forename>Andrew David</forename>
    <surname>Oxman</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Norwegian Knowledge Centre for the Health Services 
P.O. Box 7004
St. Olavs plass</address>
      <city>Oslo</city>
      <country>Norway</country>
      <zip>N-0130</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">oxman@online.no</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52571">
    <organisation>Norwegian Knowledge Centre for the Health Services (Norway)</organisation>
    <website>http://www.kunnskapssenteret.no</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>P.O. Box 7004
St. Olavs plass</address>
      <city>Oslo</city>
      <country>Norway</country>
      <zip>N-0130</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">post@kunnskapssenteret.no</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.425407.0</gridId>
    <rorId>https://ror.org/01thff661</rorId>
  </sponsor>
  <funder id="Funder16073-0">
    <name>Norwegian Knowledge Centre for the Health Services (Norway)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-03T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2007-02-28T00:00:00.000Z">14949974</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Methods for evaluating the extent to which different ways of presenting evidence of the effects of health care help people make decisions that are consistent with their own values: a randomised trial</title>
      <scientificTitle/>
      <acronym>HIPPO pilot</acronym>
      <studyHypothesis>Pilot study - development of methodology to: 
1. Analyse which of several presentations of evidence of treatment effects best help people to make treatment decisions congruent with their own values
2. Compare visual analogue scales and category rating scales as value elicitation instruments</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Acceptance or rejection of statin treatment
2. Estimated probability to accept or reject statin treatment in relation to value score</primaryOutcome>
      <secondaryOutcome>1. To investigate the feasibility of conducting Internet-based randomised trials comparing different risk reduction presentations
2. To compare two methods of eliciting values
3. Four ways of weighting the elicited values to calculate a total value
4. To generate hypotheses and calculate sample size for a confirmatory study comparing six summary statistics for communicating evidence of reduced risk of Coronary Heart Disease (CHD) with statin therapy for treatment of high cholesterol</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>This study was approved by the ethics review board at the University at Buffalo on the 15 May 2002 with several renewals.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN14949974</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>HIPPO 1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-10-31T00:00:00.000Z</overallStartDate>
      <overallEndDate>2002-12-04T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Norway</country>
	<country>United States of America</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0891a4c2-6486-4c45-a201-171abb237fc7">
	  <name>Norwegian Knowledge Centre for the Health Services</name>
	  <address/>
	  <city>Oslo</city>
	  <state/>
	  <country>Norway</country>
	  <zip>0130</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. 18 years old
2. Fluent in English or Norwegian
3. Must give informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>770</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>770</totalTarget>
      <exclusion>Not meeting inclusion requirements</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-10-31T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2002-12-04T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>N/A</description>
	<diseaseClass1 xmlns:isrctn="http://www.67bricks.com/isrctn">Other</diseaseClass1>
	<diseaseClass2>N/A</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Six different summary statistics presenting ten year risk reduction effect of statins on coronary heart disease in the treatment of hypercholesteremia.

The methodological aspects reported in this study include comparison of two value elicitation instruments (visual analogue scales and category rating scales), four theory-grounded approaches to weighting elicited values, and six summary statistics to evaluate the extent to which they promote decisions consistent with elicited values. In addition, we report hypothesis generation and sample size calculation for a randomised controlled trial comparing the same six summary statistics for communicating evidence of reduced risk of coronary heart disease, as well as on the feasibility of conducting this type of Internet-based randomised trial.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16017-0</funderId>
      <contactId>Contact53963_16017</contactId>
      <sponsorId>Sponsor52512</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53963_16017">
    <title>Dr</title>
    <forename>Andrew</forename>
    <surname>Oxman</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Norwegian Knowledge Centre for the Health Services
P.O. Box 7004 
St Olavs Plass</address>
      <city>Oslo</city>
      <country>Norway</country>
      <zip>0130 </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52512">
    <organisation>Norwegian Research Council (Norway)</organisation>
    <website>http://www.forskningsradet.no</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>P.O. Box 2700 
St. Hanshaugen</address>
      <city>Oslo</city>
      <country>Norway</country>
      <zip>0131</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.13985.36</gridId>
    <rorId>https://ror.org/00epmv149</rorId>
  </sponsor>
  <funder id="Funder16017-0">
    <name>Norwegian Research Council (Norway) (project 135210 - A series of randomised trials comparing different ways of presenting health evidence on the Internet)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-14T00:00:00.000Z" version="19">
    <isrctn dateAssigned="2007-02-26T00:00:00.000Z">91751187</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Bowel Preparation for elective Left-Sided Colonic Surgery</title>
      <scientificTitle/>
      <acronym>BP LSCS</acronym>
      <studyHypothesis>The objective of this study is to ascertain the best method of bowel preparation, prior to elective left-sided colonic surgery in terms of patient comfort and surgical efficacy. Sodium phosphate enemas (Colex) and bisacodyl (tablet and suppository) are to be compared. The occurrence of infections (wound, peritonitis) and anastomotic leaks will be monitored.

Null hypotheses are:
1. Patients in both groups experience pain and discomfort equally
2. The surgeon finds no difference in the condition of the left hemicolon intraoperatively
3. No difference in incidence of infection is found
4. No difference in incidence of anastomotic leaks is found</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Questionnaires will be used to assess the opinions of patients and surgeons. The parameters are recorded in a five point scale.</primaryOutcome>
      <secondaryOutcome>The occurrence of infection (wound or peritonitis) and anastomotic leaks is determined by standard postoperative care and is established when the clinical diagnosis is made.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from the local ethics committee (Medisch Ethische Toetsingscommissie Atrium MC - Maaslandziekenhuis) on the 30th October 2006.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN91751187</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>NL14234.096.06</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, active controlled, parallel group, single blinded trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-11-06T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-06-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e5e425f8-a382-41d5-8089-433c45252b58">
	  <name>Atrium Medisch Centrum Heerlen</name>
	  <address/>
	  <city>Heerlen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>6401 CX</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>The study population will consist of adult patients undergoing elective left-sided colonic surgery. Left-sided colonic surgery includes the following procedures: 
1. Left hemicolectomy
2. Sigmoid resection
3. Low anterior resection
4. Hartmann procedure
5. Reconstruction of colostomy
6. Abdominoperineal resection by Miles

Procedures on the transverse colon will also be included as this can result intraoperatively in a left hemicolectomy. Reasons for surgery vary, examples are malignancy, diverticulitis, Crohns disease and ulcerative colitis.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>Exclusion criteria are:
1. Use of Klean-Prep
2. Contra-indications for use of bisacodyl and Colex
3. Emergency procedures</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-11-06T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-06-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Bowel preparation, sodium phosphate enema, solonic surgery, bisacodyl</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2>Colonic surgery</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Interventions in the bisacodyl group:
1. Evening before surgery (8 p.m.) - bisacodyl tablet 5 mg, four tablets, oral administration 
2. Morning of surgery (6 a.m.) - bisacodyl suppository 10 mg, one suppository, rectal administration

Intervention in the Colex group:
1. Evening before surgery (8 p.m.) - Colex 133 ml, enema, rectal administration
2. Morning of surgery (6 a.m.) - Colex 133 ml, enema, rectal administration</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Bisacodyl, sodium phosphate (Colex)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder16225-0</funderId>
      <contactId>Contact54180_16225</contactId>
      <sponsorId>Sponsor52734</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54180_16225">
    <title>Dr</title>
    <forename>C</forename>
    <surname>van der Leeuw</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Atrium Medisch Centrum Heerlen
Chirurgie</address>
      <city>Heerlen</city>
      <country>Netherlands</country>
      <zip>6401 CX </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)64 847 7103</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">C.vanderLeeuw@student.unimaas.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52734">
    <organisation>Atrium Medisch Centrum (The Netherlands)</organisation>
    <website>http://www.atriummc.nl/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>P.O. Box 4446</address>
      <city>Heerlen</city>
      <country>Netherlands</country>
      <zip>6401 CX</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.414040.5</gridId>
    <rorId>https://ror.org/0367sye10</rorId>
  </sponsor>
  <funder id="Funder16225-0">
    <name>Atrium Medisch Centrum (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-05T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2007-02-26T00:00:00.000Z">31186536</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The efficacy of physiotherapy upon shoulder function following axillary dissection in breast cancer: a pilot study</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Physiotherapy is effective in patients with mastectomy and Axillary Lymph Node Dissection (ALND), for shoulder/arm mobility and pain primarily and quality of life secondarily.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Shoulder mobility (flexion [0 - 180°], abduction [0 - 180°]), measured by use of a digital inclinometer under standardised conditions
2. Pain in the shoulder/arm, measured using the VAS score (zero to ten, zero = no pain, ten = unbearable pain)</primaryOutcome>
      <secondaryOutcome>1. Disabilities in daily life, measured by the DASH (Disabilities of the Arm, Shoulder and Hand) questionnaire (zero to 100, zero = no functional problems, 100 = maximal problems)
2. Oedema (ml), measured in both arms by means of water displacement, grip strength (Kg) of both hands, measured using the hand-held dynamometer and quality of life, as measured by the SIP (Sickness Impact Profile-short version) questionnaire (zero to 68, zero = good health status, 68 = sever physically disabled)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Added as of 05/09/2007: The regional medical ethics board approved the study.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN31186536</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, active controlled, parallel group, single blinded  multicentre trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-08-11T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-11-04T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4b3f34e6-648f-4059-8e70-d4460a5805e4">
	  <name>University Medical Centre Nijmegen (UMCN)</name>
	  <address/>
	  <city>Nijmegen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>6500 HB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. 18 years of age and older
2. Breast cancer with an ALND
3. A Visual Analogue Scale (VAS)-pain score (zero to ten) of one minimally
4. Moderate shoulder disabilities in daily life (minimal three points on a five points disability score list)</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Female</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>1. Patients with a previous contra-lateral mastectomy
2. Patients with insufficient knowledge of the Dutch language to fill in the questionnaires</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-08-11T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-11-04T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Breast cancer</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Breast cancer</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients assigned to the treatment group started physiotherapy two weeks following surgery in a private practice of their own choice. The research assistant contacted the physiotherapist who had to comply with the treatment regime and supplied him or her with information regarding the project and treatment guidelines. This information consisted of:
1. A guideline containing advice and exercises for arm/shoulder, posture correction, coordination exercises, exercises for muscular strength and improvement of the general physical condition
2. Exercises to prevent lymph oedema
3. Instruction for scar massage if necessary
4. A registration form to report the content of the treatment sessions and a three-point scale to indicate whether the amount of treatment sessions was sufficient

The total number of treatments was nine (nine being usually covered by the healthcare insurance), once or twice weekly for the first three weeks, thereafter once a fortnight or less. Patients were asked to perform home exercises on a daily basis for approximately ten minutes a day.

Patients assigned to the control group received a leaflet flyer with advice and exercises for the arm/shoulder for the first weeks following surgery and had no further personal contact with a physiotherapist.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17760981 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="e870b2e2-73b4-4fee-bcb6-40a79ef1a591" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-08-30T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17760981"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16219-0</funderId>
      <contactId>Contact54174_16219</contactId>
      <sponsorId>Sponsor52728</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54174_16219">
    <title>Dr</title>
    <forename>C H G</forename>
    <surname>Beurskens</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Centre Nijmegen (UMCN)
Afd. Fysiotherapie 645 
P.O. Box 9101</address>
      <city>Nijmegen</city>
      <country>Netherlands</country>
      <zip>6500 HB </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+ 31 (0)24 361 3812</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">c.beurskens@fysiocss.umcn.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52728">
    <organisation>University Medical Centre Nijmegen (UMCN) (The Netherlands)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Department of Physiotherapy</address>
      <city>Nijmegen</city>
      <country>Netherlands</country>
      <zip>6500 HB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.10417.33</gridId>
    <rorId>https://ror.org/05wg1m734</rorId>
  </sponsor>
  <funder id="Funder16219-0">
    <name>Not provided at time of registration</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-17T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2007-02-26T00:00:00.000Z">08189331</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Metabolic control with Glucose-Insulin-Potassium infusion in acute myocardial infarction</title>
      <scientificTitle/>
      <acronym>GIPS II</acronym>
      <studyHypothesis>Treatment with Glucose-Insulin-Potassium (GIK) infusion during the acute phase of myocardial infarction has been proposed as therapeutic intervention for protection of the ischaemic myocardium.

Current evidence suggests an effect in patients with acute myocardial infarction without signs of heart failure at admission treated with reperfusion therapy (i.e. primary coronary angioplasty). There is also evidence for the treatment with insulin-glucose infusion in combination with strict metabolic control for at least three months thereafter for patients with type two diabetes mellitus (i.e. a history of diabetes mellitus, previously treated with oral hypoglycaemic agents or blood glucose level at admission greater than or equal to 11.1 mmol/l) and acute myocardial infarction.

Recently, it has been shown that obtaining and maintaining normoglycaemia (i.e. plasma-glucose concentrations of 4.4 and 6.1 mmol/l) in patients admitted to a Surgical Intensive Care Unit will lead to a marked reduction in morbidity and mortality.

This study will address what the effects will be of metabolic intervention with or without the infusion of GIK on 30-day and one-year mortality in patients eligible for reperfusion therapy (i.e. primary coronary angioplasty or thrombolysis).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>30-day mortality (death from any cause and cardiovascular death).</primaryOutcome>
      <secondaryOutcome>1. One-year mortality
2. Analysis of pre-specified subgroups</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approval received from the local ethics committee (Medisch Ethische Toetsings Commissie) on the 2nd May 2003 (ref: 02.1280).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN08189331</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, active controlled, parallel group, multicentre trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-03-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="347a2e6e-a288-4fc2-bdb1-44adeeb4b079">
	  <name>Diagram B.V. Zwolle</name>
	  <address/>
	  <city>Zwolle</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>8011 NB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Acute myocardial infarction diagnosed by:
1.1. Chest pain suggestive for acute myocardial infarction
1.2. Symptom-onset less than six hours after hospital admission
1.3. Electrocardiogram (ECG) with ST-T segment elevation more than 1 mV in two or more leads
2. Patients are eligible for either primary coronary angioplasty or thrombolysis
3. Patient who has given his or her informed consent to take part in the study</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>900</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>900</totalTarget>
      <exclusion>1. Unwillingness to participate
2. Presence of heart failure (either one of these symptoms):
2.1. Heart rate more than 90 beats/minute
2.2. Systolic blood pressure less than 100 mmHg with anterior myocardial infarction
2.3. Killip class greater than or equal to II (third heart sound, greater than or equal to hand-wide rales)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-03-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute myocardial infarction</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Myocardial infarction</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>An infusion of 80 mmol potassium chloride in 500 ml 20% glucose with a rate of 2 ml/kilogram body weight/hour over an 12 hour period in a peripheral venous line. The infusion is started as soon as possible after admission to the hospital after determination of blood-glucose level in combination with reperfusion therapy. A continuous infusion of short-acting insulin (50 units Actrapid HM [Novo Nordisk, Copenhagen, Denmark] in 49.5 ml of 0.9 percent sodium chloride) with the use of a perfusor-pump will also be started.
Blood-glucose levels will be measured hourly. Baseline insulin infusion dose and adjustments of insulin dose will be based on a nomogram to obtain and maintain blood-glucose levels of 6.0 to 10.0 mmol/l.

The insulin infusion will be stopped one hour prior to the discontinuation of the glucose-potassium infusion. After the Glucose-Potassium (GK) infusion is stopped insulin may be continued based on glucose measurements according to conventional care or until the infusion rate is less than 1 IU/hour.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Glucose-Insulin-Potassium (GIK) infusion</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in https://pubmed.ncbi.nlm.nih.gov/16631017 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="5bb19281-2972-4a52-9a1b-eab75f430b02" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-04-18T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/16631017"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16229-0</funderId>
      <funderId>Funder16229-1</funderId>
      <contactId>Contact54184_16229</contactId>
      <sponsorId>Sponsor52738</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54184_16229">
    <title>Dr</title>
    <forename>J</forename>
    <surname>Klijn</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Diagram B.V. Zwolle 
Van Nahuysplein 6 </address>
      <city>Zwolle</city>
      <country>Netherlands</country>
      <zip>8011 NB </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)38 426 2997</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">j.klijn@diagram-zwolle.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52738">
    <organisation>Isala Klinieken (The Netherlands)</organisation>
    <website>http://www.isala.nl/Pages/default.aspx</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Locatie Weezenlanden
Department of Cardiology
Groot Wezenland 20</address>
      <city>Zwolle</city>
      <country>Netherlands</country>
      <zip>8011 JW</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.452600.5</gridId>
    <rorId>https://ror.org/046a2wj10</rorId>
  </sponsor>
  <funder id="Funder16229-0">
    <name>Netherlands Heart Foundation (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder16229-1">
    <name>Guidant (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-20T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2007-02-23T00:00:00.000Z">13256080</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A phase II study to investigate the effect of Glivec® (imatinib mesylate, formerly known as STI571) in patients with inoperable medullary thyroid carcinoma</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>In the pathogenesis of medullary thyroid carcinoma a mutation of the rearranged during transfection (RET) tyrosine kinase system plays an essential role. In animal models the tyrosine kinase inhibitor imatinib showed tumor regression. So a phase II study in patients with progressive medullary thyroid carcinoma with imatinib may open new treatment possibilities.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary objective is to determine the objective response rate (partial and complete responses) in subjects with advanced medullary thyroid carcinoma.</primaryOutcome>
      <secondaryOutcome>1. To determine the time to tumour progression
2. To evaluate overall survival
3. To evaluate the safety profile of Glivec® in advanced medullary thyroid carcinoma</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN13256080</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>CSTI571BNL07; METC 03-044</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Observational phase II study</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Single-centre</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-07-11T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-07-11T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="6c01d901-b34b-4ed8-bc1c-28ab1f3c4bf2">
	  <name>University Medical Centre Utrecht (UMCU)</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3584 CX</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients over 18 years of age
2. The subject has advanced histologically proven medullary thyroid cancer. Advanced disease is defined as locally recurrent disease or metastatic disease that is not amenable to curative resection. The subject must have measurable disease.
3. The subject has not received anti-tumor radiotherapy or chemotherapy therapy within four weeks (six weeks for nitrosourea, mitomycin-C or any antibody therapy) of the start of imatinib administration
4. The subject has an Eastern Cooperative Oncology Group (ECOG) performance score of zero to two  
5. Adequate end organ function, defined as the following: 
5.1. Total bilirubin less than or equal to 1.5 x upper limit of normal (ULN)
5.2. Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) less than 2.5 x ULN
5.3. Creatinine less than 1.5 x ULN
5.4. Absolute neutrophil count (ANC) more than 1.5 x 10^9/L
5.5. Platelets more than 100 x 10^9/L
6. Female patients of childbearing potential must have negative pregnancy test within seven days before initiation of study drug dosing. Postmenopausal women must be amenorrhoeic for at least 12 months to be considered of non-childbearing potential. Male and female patients of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to three months following discontinuation of study drug.
7. Life expectancy of more than three months (in the absence of any intervention)
8. The subject has voluntarily signed an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved informed consent prior to any study specific procedures</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>15</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>15</totalTarget>
      <exclusion>1. The subject is less than five years free of another primary malignancy except: 
1.1. If the other primary malignancy is not currently clinically significant nor requiring active intervention, or 
1.2. If the other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ
2. The subject is with known brain metastases
3. The subject has received any other investigational agents within 28 days of first day of study drug dosing
4. The subject has a current history of a class three to four cardiovascular disability status in accordance with the New York Heart Association Functional Classification:
4.1. Class three is defined as marked limitation of physical activity, comfortable at rest, but less than ordinary activity causes fatigue or dyspnea
4.2. Class four is defined as being unable to carry on any physical activity without symptoms and symptoms are present even at rest. Also, if any physical activity is undertaken, symptoms are increased
5. Female patients who are pregnant or breast-feeding
6. Patient has another severe and/or life-threatening medical disease
7. The subject has an acute or known chronic liver disease (e.g., chronic active hepatitis, cirrhosis)
8. The subject has a known diagnosis of human immunodeficiency virus (HIV) infection
9. The subject has received chemotherapy within four weeks (six weeks for nitrosourea, mitomycin-C or any antibody therapy) prior to study entry
10. The subject had a major surgery within two weeks prior to study entry
11. The subject uses therapeutic anticoagulation with warfarins. Low-molecular weight heparin (e.g. Fragmin®) or heparin is permitted.
12. The subject with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-07-11T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-07-11T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Medullary thyroid carcinoma</description>
	<diseaseClass1>Cancer</diseaseClass1>
	<diseaseClass2>Thyroid carcinoma</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Oral treatment with 600 - 800 mg imatinib daily.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames>Imatinib mesylate (Glivec®)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17579194 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="2a509938-e8a4-44aa-a743-ad3ef43c3380" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17579194"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder16197-0</funderId>
      <contactId>Contact54152_16197</contactId>
      <sponsorId>Sponsor52706</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact54152_16197">
    <title>Dr</title>
    <forename>B A</forename>
    <surname>Zonnenberg</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University Medical Centre Utrecht (UMCU)
Department of Medical Oncology
Heidelberglaan 100</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3584 CX </zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 250 6308</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">B.Zonnenberg@umcutrecht.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52706">
    <organisation>University Medical Centre Utrecht (UMCU) (The Netherlands)</organisation>
    <website>http://www.umcutrecht.nl/zorg/ </website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>P.O. Box 85500</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3508 GA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5477.1</gridId>
    <rorId>https://ror.org/04pp8hn57</rorId>
  </sponsor>
  <funder id="Funder16197-0">
    <name>Novartis Pharma B.V. (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-19T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2007-01-16T00:00:00.000Z">41920953</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Naturopathic Care for Low Back Pain: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym>NCLBP</acronym>
      <studyHypothesis>Will naturopathic care including acupuncture, diet counselling, and deep breathing be equally or more effective than a physiotherapy equivalent?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Oswestry, Roland and Morris Disability Questionnaire</primaryOutcome>
      <secondaryOutcome>1. Short Form health survey (SF-36)
2. Spinal Forward Flexion
3. Medication and adjunctive treatment usage</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Internal Review Board of The Canandian College of Naturopathic Medicine. Obtained in January 2005.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN41920953</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>LBPT01</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-09-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="eeca79f8-7369-4c63-ae9a-a8aca0b1e5fa">
	  <name>Department of Clinical Epidemiology</name>
	  <address/>
	  <city>Toronto</city>
	  <state/>
	  <country>Canada</country>
	  <zip>M2K 1E2</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Mentally competent volunteers 18 to 65, male or female
2. Low back pain of more than six weeks duration
3. Normal on physical examination at the pre-study physical</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>75</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>75</totalTarget>
      <exclusion>1. History of spinal operations
2. Current history of herniated disk
3. Current history of systemic rheumatological disease, ankylosing spondylitis, tumors, infection
4. Pregnancy</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-09-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic low back pain</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Low back pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Active: acupuncture, dietary counseling, relaxation exercises
Control: education on physiotherapy exercises</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://doi.org/10.1371/journal.pone.0000919 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="708e9871-fb4f-41a8-aad3-f78aacb39c4c" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-09-19T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://doi.org/10.1371/journal.pone.0000919"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15936-0</funderId>
      <funderId>Funder15936-1</funderId>
      <funderId>Funder15936-2</funderId>
      <contactId>Contact53882_15936</contactId>
      <sponsorId>Sponsor52431</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53882_15936">
    <title>Dr</title>
    <forename>Edward</forename>
    <surname>Mills</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Clinical Epidemiology
The Canadian College of Naturopathic Medicine
1255 Sheppard Ave. E.</address>
      <city>Toronto</city>
      <country>Canada</country>
      <zip>M2K 1E2</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52431">
    <organisation>The Canadian College of Naturopathic Medicine (Canada)</organisation>
    <website>http://www.ccnm.edu/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>1255 Sheppard Ave E.</address>
      <city>Toronto</city>
      <country>Canada</country>
      <zip>M2K 1E2</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.418588.8</gridId>
    <rorId>https://ror.org/03pjwtr87</rorId>
  </sponsor>
  <funder id="Funder15936-0">
    <name>Canada Post Corporation</name>
    <fundRef/>
  </funder>
  <funder id="Funder15936-1">
    <name>Canadian Union of Postal Workers</name>
    <fundRef/>
  </funder>
  <funder id="Funder15936-2">
    <name>The Canadian College of Naturopathic Medicine</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-08T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2007-01-05T00:00:00.000Z">27796329</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled trial to evaluate the effectiveness of community Paramedic Practitioners managing Older People calling 999 with minor conditions</title>
      <scientificTitle/>
      <acronym>PPOPS</acronym>
      <studyHypothesis>Aims:
1. Comparing differences in patient experience and satisfaction of community paramedic practitioners with the existing standard service.
2. Comparing the clinical and cost effectiveness of community paramedic practitioners with the existing standard service.
3. Assessing the effects of community paramedic practitioners on ambulance service and Emergency Department (ED) performance.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Emergency Department attendance or hospital admission between zero and 28 days
2. Interval from time of call to time of discharge
3. Patient satisfaction with the service received</primaryOutcome>
      <secondaryOutcome>1. Investigations and treatments prescribed
2. Subsequent use of health services within 28 days
3. Health status and mortality at 28 days
4. Costs</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study was approved by North Sheffield LREC on the 31st March 2003, (ref: NS2002 9 1452).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN27796329</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>577/1962</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Cluster randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Other</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-09-26T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1611d966-66ad-4b25-b275-e9f995803909">
	  <name>Health Services Research</name>
	  <address/>
	  <city>Sheffield</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>S1 4DA</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients aged 60 years and above were eligible for study inclusion following a call to the ambulance service if the call:
1. Originated from a Sheffield postcode
2. Was received between 08:00 am and 20:00 pm
3. Presenting with a complaint that fell within the scope of practice of the paramedic practitioners</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>2200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>2200</totalTarget>
      <exclusion>No exclusion criteria</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-09-26T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Minor injuries such as falls, lacerations, epistaxis, minor burns, foreign body - ENT (Ears, Nose and Throat) only</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Minor injuries</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention:
A community based paramedic scheme intended to deliver patient centred care to older people calling the emergency services with conditions triaged as not immediately life threatening.

Control group:
Care as usual. In practice, this was an ambulance, followed by conveyance to an ED (unless the patient refused to travel to hospital).</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17916813 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="ae64ec4f-12a5-4aac-82b3-5370f6a31010" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-11-03T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17916813"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15822-0</funderId>
      <contactId>Contact53762_15822</contactId>
      <sponsorId>Sponsor52315</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53762_15822">
    <title>Dr</title>
    <forename>Suzanne</forename>
    <surname>Mason</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Health Services Research 
School of Health and Related Research
University of Sheffield
Regent Street</address>
      <city>Sheffield</city>
      <country>United Kingdom</country>
      <zip>S1 4DA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52315">
    <organisation>The Health Foundation (UK)</organisation>
    <website>http://www.health.org.uk/</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>90 Long Acre</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>WC2E 9RA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.453604.0</gridId>
    <rorId>https://ror.org/02bzj4420</rorId>
  </sponsor>
  <funder id="Funder15822-0">
    <name>The Health Foundation (UK) (ref: 577/1962)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-29T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2007-01-04T00:00:00.000Z">10862635</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Pilot study of efficacy of anakinra in acute gouty arthritis</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Treatment with anakinra will decrease the signs and symptoms of acute gout.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Pain of arthritis
2. Signs of arthritis</primaryOutcome>
      <secondaryOutcome>Biological markers of inflammation</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics committee approval is pending, approval expected in January 2007.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN10862635</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2006-1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Open label pilot study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-01-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8209f180-fa32-4d47-a7be-2b06811eabd2">
	  <name>Rheumatology Service</name>
	  <address/>
	  <city>Lausanne</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>1011</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Acute gout as defined by American College of Rheumatology (ACR) criteria
2. Acute arthritis due to gout which is unresponsive to conventional therapy with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), colchicine or steroids
3. Patients with acute gout who have had side effects or intolerance to either NSAIDs, colchicine or steroids</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>10</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>10</totalTarget>
      <exclusion>1. Patients with on-going or untreated infectious diseases 
2. Patients with rheumatoid arthritis, lupus or vasculitis
3. Patients concurrently treated with anti-Tumour Necrotising Factor (TNF) therapies 
4. Patients with active cancer</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-01-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Acute gout</description>
	<diseaseClass1>Musculoskeletal Diseases</diseaseClass1>
	<diseaseClass2>Acute gout</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Treatment with 100 mg anakinra daily subcutaneously for three days</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Anakinra</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17352828 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="94ae020d-57fe-44c5-86c7-dedff977db67" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17352828"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15830-0</funderId>
      <contactId>Contact53770_15830</contactId>
      <sponsorId>Sponsor52323</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53770_15830">
    <title>Prof</title>
    <forename>Alexander</forename>
    <surname>So</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Rheumatology Service
Centre Hospitalier Universitaire Vaudois (CHUV)
Av Pierre Decker</address>
      <city>Lausanne</city>
      <country>Switzerland</country>
      <zip>1011</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52323">
    <organisation>University Hospital Complex of Vaud (Centre Hospitalier Universitaire Vaudois [CHUV]) (Switzerland)</organisation>
    <website>http://www.chuv.ch/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Rheumatology
Department of Medicine
University of Lausanne</address>
      <city>Lausanne</city>
      <country>Switzerland</country>
      <zip>1011</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)21 314 14 50</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">secretariat.so@chuv.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.8515.9</gridId>
    <rorId>https://ror.org/05a353079</rorId>
  </sponsor>
  <funder id="Funder15830-0">
    <name>Service of Rheumatology of the Centre Hospitalier Universitaire, Vaudois (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-19T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2007-01-03T00:00:00.000Z">23191708</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Assessment of Geriatric Team as a new medical technology</title>
      <scientificTitle/>
      <acronym>Geriatric Team</acronym>
      <studyHypothesis>Do home visits have advantages when compared to outpatient or in-hospital assessment of patients referred to a geriatric department?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Hospital admissions
2. Patient satisfaction</primaryOutcome>
      <secondaryOutcome>Cost-effectiveness</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Study is approved by the Local Ethical Committee (the Ethical Committee of Fyen and Vejle Counties), on the 3rd April 2000 (ref. no.: 20000057).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN23191708</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>262-67-1999</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Denmark</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c1f6ed6e-6b32-4667-a720-d270c72bb7d3">
	  <name>Department of Geriatric Medicine, G</name>
	  <address/>
	  <city>Odense C</city>
	  <state/>
	  <country>Denmark</country>
	  <zip>DK-5250</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All patients referred to the geriatric department and able to give informed consent</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>600</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>600</totalTarget>
      <exclusion>Patients unable to give informed consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Multimorbidity, functional decline</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Multimorbidity</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Home visit performed by a multidisciplinary team:
1: Acute patients are randomised to next day home visits by the geriatric team or to next admission to the geriatric wards
2: Elective patients are randomised to home visits by the geriatric team or to the outpatient clinic</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15860-0</funderId>
      <contactId>Contact53800_15860</contactId>
      <sponsorId>Sponsor52354</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53800_15860">
    <title>Dr</title>
    <forename>Lars Erik</forename>
    <surname>Matzen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Geriatric Medicine, G
Odense University Hospital</address>
      <city>Odense C</city>
      <country>Denmark</country>
      <zip>DK-5250</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">lars.matzen@ouh.fyns-amt.dk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52354">
    <organisation>National Board of Health (Denmark)</organisation>
    <website>http://www.sst.dk/Planlaegning_og_behandling/Medicinsk_teknologivurdering.aspx?lang=en</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>Centre for Education and Health Technology Assessment
Sundhedsstyrelsen 
Islands Brygge 67</address>
      <city>Copenhagen</city>
      <country>Denmark</country>
      <zip>DK-2300</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">cemtv@sst.dk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.416535.0</gridId>
    <rorId>https://ror.org/04r17y386</rorId>
  </sponsor>
  <funder id="Funder15860-0">
    <name>National Board of Health (Denmark) - Center for Evaluation of Medical Technology (ref: 262-67-1999)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-19T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2006-12-29T00:00:00.000Z">32222677</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised controlled trial of smoking cessation advice and nicotene replacement therapy delivered by dental hygienists in a dental setting</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To determine the feasibility and efficacy of a smoking cessation intervention, delivered by dental hygienists in a cohort of periodontal patients attending an outpatient hospital department.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Self -reported quit rates validated by Carbon Monoxide (CO) and salivary cotinine</primaryOutcome>
      <secondaryOutcome>1. Changes in smoking behaviour including reduction in number of cigarettes (and change in cotinine levels), and increase in numbers of quit attempts</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Glasgow Dental Hospital and School Area Dental Ethics Committee in January 2001.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN32222677</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Other</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Scotland</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f2712255-65bc-462e-99b4-b293624b9715">
	  <name>Level 8</name>
	  <address/>
	  <city>Glasgow</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>G2 3JZ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Adult (more than 16 years) smokers of at least ten cigarettes
2. Informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>120</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>120</totalTarget>
      <exclusion>1. Adult (more than 16 years) smokers of less than ten cigarettes
2. Currently receiving smoking cessation therapy elsewhere</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Smoking addiction</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Smoking addiction</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Intervention arm: smoking cessation advice based on the 5As (Ask, Advise, Assess, Assist, Arrange) and Nicotene Replacement Therapy (NRT)
Control arm: usual care (very brief advice)</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17475005 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="2263e2ce-0483-48cc-81f9-416b6ec5e93d" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-05-02T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17475005"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15894-0</funderId>
      <funderId>Funder15894-1</funderId>
      <funderId>Funder15894-2</funderId>
      <contactId>Contact53836_15894</contactId>
      <sponsorId>Sponsor52389</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53836_15894">
    <title>Dr</title>
    <forename>Viv </forename>
    <surname>Binnie</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Level 8
Glasgow Dental School
378 Sauchiehall Street</address>
      <city>Glasgow</city>
      <country>United Kingdom</country>
      <zip>G2 3JZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)141 211 9802</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">v.binnie@dental.gla.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52389">
    <organisation>University of Glasgow (UK)</organisation>
    <website>http://www.gla.ac.uk/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>University Avenue</address>
      <city>Glasgow</city>
      <state xmlns:isrctn="http://www.67bricks.com/isrctn">Scotland</state>
      <country>United Kingdom</country>
      <zip>G12 8QQ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">v.binnie@dental.gla.ac.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.8756.c</gridId>
    <rorId>https://ror.org/00vtgdb53</rorId>
  </sponsor>
  <funder id="Funder15894-0">
    <name>The University of Glasgow (UK) - covering the cost of cotinine analysis</name>
    <fundRef/>
  </funder>
  <funder id="Funder15894-1">
    <name>Smoking Concerns (UK) - local NHS Stop smoking body, donating NRT</name>
    <fundRef/>
  </funder>
  <funder id="Funder15894-2">
    <name>All other costs were covered internally by NHS departments taking part in the trial</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-20T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-11-29T00:00:00.000Z">05215453</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of rosiglitazone, compared to sulphonylurea, on endothelial function in Chinese patients with type two diabetes</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>1. Rosiglitazone improves endothelial function independent of its effect on glycemic control
2. Rosiglitazone affects soluble receptor of advanced glycation end products independent of its effect on glycemic control</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Changes in endothelial function in patients with type two diabetes</primaryOutcome>
      <secondaryOutcome>1. Changes in blood pressure and metabolic parameters such as C-reactive protein. 
2. Changes in serum soluble Receptor for Advanced Glycation End products (sRAGE) and advanced glycation end products.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster on the 19th March 2004 (ref: UW 04-045 T/367).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN05215453</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>HKCTR-1</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-03-23T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-04-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Hong Kong</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="4c924cb5-d2de-4e32-b345-b444606abd22">
	  <name>The University of Hong Kong</name>
	  <address/>
	  <city>Pokfulam</city>
	  <state/>
	  <country>Hong Kong</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Chinese men and women aged 30 to 70 years
2. Type two diabetes (defined by the World Health Organization [WHO] criteria) diagnosed after 30 years of age
3. On diet with/without sulphonylurea (less than or equal to half-maximum dose) with/without metformin for at least six months
4. No change in anti-diabetic, lipid lowering and anti-hypertensive in preceding 12 weeks
5. Body Mass Index (BMI) more than or equal to 23 and less than or equal to 35 kg/m^2
6. Systolic blood pressure less than or equal to 160 mmHg and diastolic blood pressure less than or equal to 90 mmHg
7. HbA1c levels between 7.5 and 10.5% inclusively (normal less than or equal to 6.1%) on at least two occasions in the past three months
8. Female patients must be post-menopausal (i.e. more than six months without menstrual period), surgically sterilised, or using hormonal contraceptives or intrauterine devices</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>68</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>68</totalTarget>
      <exclusion>1. Pregnancy or lactation
2. Any clinically significant abnormality identified on the screening physical examination, laboratory tests, or electrocardiogram which, in the judgement of the investigator, would preclude the safe completion of the study
3. Use of anti-diabetic drugs other than metformin or sulphonylurea within 12 weeks
4. Use of any investigational drug within 30 days or five half-lives (whichever is longer) preceding the first dose of study medication
5. Patients with a documented history of significant hypersensitivity to any drugs including thiazolidinedione and sulphonylurea (e.g., difficulty in swallowing or breathing, or tachycardia)
6. Active alcohol or drug abuse within the last six months
7. Presence of clinically significant renal or hepatic disease:
7.1. Serum creatinine above Upper Normal Range (UNR) (creatinine more than 128 umol/L for males and more than 107 umol/L for females)
7.2. Proteinuria more than 1 gm/day
7.3. Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), total bilirubin, or alkaline phosphatase more than two times above UNR
8. Significant anaemia (haemoglobin less than 11 g/dl for males or less than 10 g/dl for females)
9. Patients with haemoglobinopathies
10. Leukocyte count less than 3.0 x 10^9/L or platelet count less than 120 x 10^9/L
11. Patients with severe angina, coronary insufficiency, heart failure (New York Heart Association [NYHA] class III or IV), or history of cardiovascular event in the past six months
12. Patients with electrocardiographic evidence of left ventricular hypertrophy based upon the maximal voltage of Sv1 plus the maximal voltage of Rv5 or Rv6 more than 3.5 mV and ST-T segment changes
13. Symptomatic diabetic neuropathy of sufficient severity to require treatment for control of symptoms (e.g. painful peripheral neuropathy, symptomatic orthostatic hypotension, urinary retention, pedal ulcers, gastric stasis, etc.)
14. Patients with history of psychiatric illness</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-03-23T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-04-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Type two diabetes</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Diabetes mellitus</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients were randomised to receive add-on therapy with either rosiglitazone 4 mg or glibenclamide 5 mg (or gliclazide 80 mg) daily while keeping the doses of their usual anti-diabetic agents constant. After four weeks, the doses of the add-on therapy were doubled in subjects with fasting blood glucose level greater than 8.0 mmol/l and without symptomatic or asymptomatic hypoglycemia defined as blood glucose level less than 3.0 mmol/l. The dosages of all anti-diabetic agents were then kept constant for another 20 weeks.

There was no washout period and all study medications were administered orally.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Rosiglitazone and sulphonylurea</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17639302 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="6123f1f0-fd23-4e64-9de6-95404d331462" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17639302"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15807-0</funderId>
      <funderId>Funder15807-1</funderId>
      <contactId>Contact53747_15807</contactId>
      <sponsorId>Sponsor52299</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53747_15807">
    <title>Prof</title>
    <forename>Karen</forename>
    <surname>Lam</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>The University of Hong Kong
Queen Mary Hospital</address>
      <city>Pokfulam</city>
      <country>Hong Kong</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52299">
    <organisation>Hong Kong University Research Committee (Hong Kong)</organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>7/F., Shui On Centre
6-8 Harbour Road</address>
      <city>Wanchai</city>
      <country>Hong Kong</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.194645.b</gridId>
    <rorId>https://ror.org/02zhqgq86</rorId>
  </sponsor>
  <funder id="Funder15807-0">
    <name>Hong Kong University Research Committee (Hong Kong) (project no. HKU 7637/05M)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15807-1">
    <name>HK Innovation and Technology Support Programme (Hong Kong) (project no. ITS/048/03)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-02T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-11-20T00:00:00.000Z">87589121</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Improving patient reassurance through an early intervention prior to exercise stress testing</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Providing information about normal findings prior to a exercise stress test will improve reassurance and reduce anxiety about symptoms following the investigation in patients with a negative test result.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Patients&#146; reported reassurance.
2. Levels of worry about their health and belief that something is seriously wrong with their heart, measured immediately following the test and at one month following testing.</primaryOutcome>
      <secondaryOutcome>Complaints of chest pain and whether continuing to take cardiac medication.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by New Zealand Ministry of Health Ethics Committee (ref AKY/04/05/121) on 21 May, 2004.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN87589121</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-10-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>New Zealand</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="45f157c1-a7e3-4ba6-9321-948f83971b77">
	  <name>Department of Psychological Medicine</name>
	  <address/>
	  <city>Auckland</city>
	  <state/>
	  <country>New Zealand</country>
	  <zip>1001</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients referred for exercise stress test with negative findings</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>90</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>90</totalTarget>
      <exclusion>1. Aged less than 18 years
2. Previously diagnosed cardiac pathology
3. No symptoms of chest pain
4. Undertaking the stress exercise test as part of a pre-surgical medical examination
5. Positive exercise stress test</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Symptoms of chest pain</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Chest pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Group one: standard information. 
Group two: a pamphlet explaining the function and meaning of negative results from the test.
Group three: the pamphlet and a brief discussion about what normal results of the test mean.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=17259186 Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="6dcdd103-4dee-4480-a562-3ca5fdf0bb2f" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-02-17T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&amp;db=pubmed&amp;list_uids=17259186"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15754-0</funderId>
      <contactId>Contact53692_15754</contactId>
      <sponsorId>Sponsor52246</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53692_15754">
    <title>Prof</title>
    <forename>Keith</forename>
    <surname>Petrie</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Psychological Medicine
Faculty of Medical and Health Sciences
University of Auckland
Private Bag 92019</address>
      <city>Auckland</city>
      <country>New Zealand</country>
      <zip>1001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">kj.petrie@auckland.ac.nz</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor52246">
    <organisation>University of Auckland (New Zealand)</organisation>
    <website>http://www.auckland.ac.nz/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Private Bag 92019</address>
      <city>Auckland</city>
      <country>New Zealand</country>
      <zip>1001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">kj.petrie@auckland.ac.nz</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.9654.e</gridId>
    <rorId>https://ror.org/03b94tp07</rorId>
  </sponsor>
  <funder id="Funder15754-0">
    <name>University of Auckland (New Zealand)</name>
    <fundRef>http://dx.doi.org/10.13039/501100001537</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-15T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-11-03T00:00:00.000Z">75663024</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>BAsel Stent KostenEffektivitaets Trial (Basel Stent cost-effectiveness trial)</title>
      <scientificTitle/>
      <acronym>BASKET (BAsel Stent KostenEffektivitaets Trial)</acronym>
      <studyHypothesis>Drug Eluting Stents (DES) are not cost-effective in a real world setting when compared to bare metal stents.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Six month cost-effectiveness with effectiveness defined as reduction of major adverse cardiac events - i.e., cardiac death, non-fatal myocardial infarction and target vessel revascularisation.</primaryOutcome>
      <secondaryOutcome>1. Mortality from other cause, target vessel ischemia by myocardial perfusion Single Photon Emission Computed Tomography (SPECT).
2. Effectiveness of DES in patients with myocardial infarction and saphenous vein graft disease. 
3. Cost-effectiveness as defined above after 18 and 36 months.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the local ethics committee of the University of Basel, March 27, 2003.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN75663024</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Prospective randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-05-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="a0aeba82-f29d-4e72-8396-2a0c41b87555">
	  <name>Cardiology Department</name>
	  <address/>
	  <city>Basel</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH-4031</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Coronary artery disease suitable for interventional therapy.

All patients referred for cardiac catheterisation and subsequent Percutaneous Coronary Intervention (PCI) irrespective of clinical indication, who are able to provide written informed consent.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>826</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>826</totalTarget>
      <exclusion>1. In-stent-restenosis
2. Target vessel diameter equal to or greater than 4 mm
3. No informed consent</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-05-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Coronary artery disease</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Coronary artery disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>PCI in a real world setting (chronic and acute disease). Patients randomised 2:1 to drug eluting versus bare metal stents.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2005 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=16154019 Results
2007 Other publications in https://pubmed.ncbi.nlm.nih.gov/17980734 -month cost-effectiveness analysis:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="caafc7de-7862-4d1f-82d5-708af2be21aa" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2005-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=AbstractPlus&amp;list_uids=16154019"/>
	<description>Results</description>
	<productionNotes/>
      </output>
      <output id="7d0a1e1f-460a-453d-9b2d-132a7eaa8735" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2007-11-03T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17980734"/>
	<description>-month cost-effectiveness analysis:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15761-0</funderId>
      <funderId>Funder15761-1</funderId>
      <contactId>Contact53699_15761</contactId>
      <sponsorId>Sponsor52253</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53699_15761">
    <title>Prof</title>
    <forename>Matthias</forename>
    <surname>Pfisterer</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Cardiology Department
University Hospital
Petersgraben 4</address>
      <city>Basel</city>
      <country>Switzerland</country>
      <zip>CH-4031</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52253">
    <organisation>University Hospital Basel (Switzerland)</organisation>
    <website>http://www.universitaetsspital-basel.ch/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Petersgraben 4</address>
      <city>Basel</city>
      <country>Switzerland</country>
      <zip>CH-4031</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.410567.1</gridId>
    <rorId>https://ror.org/04k51q396</rorId>
  </sponsor>
  <funder id="Funder15761-0">
    <name>University Hospital, Basel (Switzerland)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15761-1">
    <name>Cardiac Research Foundation, Basel (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-19T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-10-30T00:00:00.000Z">34049135</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Prospective pilot study: evaluation of a new dressing for patients treated in peritoneal dialysis</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Evaluation of a new Peritoneal Dialysis (PD) dressing.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Dressing advantages are evaluated via questionnaires, which have to be filled in at specific time schedule. Comfort and safety evaluation will be performed by the patient at the end of each period of product use (end of PD Immo use and end of usual dressing use).</primaryOutcome>
      <secondaryOutcome>Handling is also evaluated via the patient questionnaire.
The incidence of Adverse Events (AE) will be followed during the study period.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Submitted to CPP Grenoble (reference number: 06-GAMB-1), will receive verdict on 20th September 2006.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN34049135</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>1445</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Monocentric, open, comparative study</studyDesign>
      <primaryStudyDesign>Observational</primaryStudyDesign>
      <secondaryStudyDesign>Single-centre</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-09-25T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-11-25T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>France</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="6ebe2e13-0265-4b93-b0a0-c06abd13656c">
	  <name>AGDUC</name>
	  <address/>
	  <city>Grenoble</city>
	  <state/>
	  <country>France</country>
	  <zip>38 700</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with well healed exit site
2. Patients treated for at least three months in peritoneal dialysis irrespective of the treatment mode
3. Patients with healthy skin judged by investigator
4. Patients aged 18 years and older
5. Patients having signed a written consent (informed consent) to participate in the study</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>1. Patients treated in hemodialysis
2. Patients with diagnosed abdominal pain not related with PD-solution
3. Peritonitis within one month prior to the study
4. Presence of exit-site, tunnel infection
5. Patients with ongoing peritonitis
6. Patients participating in other studies during the period of this study
7. Patients practising swimming
8. Patients under guardianship
9. Pregnancy, lactation</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-09-25T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-11-25T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic renal failure</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Chronic renal failure</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Evaluation of dressing advantages via questionnaires</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15339-0</funderId>
      <contactId>Contact53264_15339</contactId>
      <sponsorId>Sponsor51813</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53264_15339">
    <title>Dr</title>
    <forename>Robert</forename>
    <surname>Milongo</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>AGDUC
Hôpital La Tronche</address>
      <city>Grenoble</city>
      <country>France</country>
      <zip>38 700</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor51813">
    <organisation>Gambro Industries (France)</organisation>
    <website>http://www.gambro.com/start.aspx?id=752</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Clinical Affairs Department
61 Avenue Tony Garnier</address>
      <city>Lyon</city>
      <country>France</country>
      <zip>69 007</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.487322.8</gridId>
    <rorId>https://ror.org/01mgtdr23</rorId>
  </sponsor>
  <funder id="Funder15339-0">
    <name>Gambro Industries (France)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-28T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-10-18T00:00:00.000Z">98820688</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effect of Hydrocortisone Treatment modality on Glycemic Control in patients with Septic Shock</title>
      <scientificTitle/>
      <acronym>HTGCSS</acronym>
      <studyHypothesis>Continuous hydrocortisone infusion will reduce the fluctuations in blood glucose levels in septic shock patients when compared to bolus treatment.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Mean blood glucose levels in study groups and the number of hyperglycemic (more than 7 mmol/l) and hypoglycemic (less than 3 mmol/l) episodes.</primaryOutcome>
      <secondaryOutcome>Shock reversal during the five day study period and the amount of nursing workload needed to maintain normoglycemia.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics commitee of Päijät-Häme Central Hospital, approval gained on 25th February 2005 (Code Q 71).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN98820688</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised prospective trial. Patients are randomised to receive hydrocortisone either by bolus or by continuous infusion in blocks of four patients. Study is not blinded nor placebo controlled.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-07-05T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Finland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d3af8922-4a06-4341-9f28-dc949462f82b">
	  <name>Kuopio University Hospital</name>
	  <address/>
	  <city>Kuopio</city>
	  <state/>
	  <country>Finland</country>
	  <zip>70211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Septic shock patients meeting the criteria for septic shock according to the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>48</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>48</totalTarget>
      <exclusion>1. Patients under 18 years of age
2. Patients with diabetes 
3. Patients receiving glucocorticoids</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-07-05T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Vasopressor-dependent septic shock</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Septic shock</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Septic shock patients who are considered to benefit from the corticosteroid treatment are randomly assigned to receive hydrocortisone either by bolus treament or by continuous infusion with equivalent dose (200 mg/day). During the study period a strict normoglycemic goal is maintained with continuous insulin infusion.  Duration of hydrocortisone treatment was five days.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Hydrocortisone</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17306016 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="e5afb3c6-a5f9-452c-8211-0c7896675f98" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-01-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17306016"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15387-0</funderId>
      <funderId>Funder15387-1</funderId>
      <contactId>Contact53319_15387</contactId>
      <sponsorId>Sponsor51866</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53319_15387">
    <title>Dr</title>
    <forename>Esko</forename>
    <surname>Ruokonen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Kuopio University Hospital
PO Box 1777</address>
      <city>Kuopio</city>
      <country>Finland</country>
      <zip>70211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor51866">
    <organisation>Päijät-Häme Central Hospital (Finland)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Keskussairaalankatu 7</address>
      <city>Lahti</city>
      <country>Finland</country>
      <zip>15850</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+358 3 81911</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">pekka.loisa@phks.fi</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.440346.1</gridId>
    <rorId>https://ror.org/02v92t976</rorId>
  </sponsor>
  <funder id="Funder15387-0">
    <name>Medical Research Fund of Tampere University Hospital (Finland)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15387-1">
    <name>Medical Research Fund of Päijät-Häme Central Hospital (Finland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-13T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2006-10-16T00:00:00.000Z">87889245</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Circuit Weight Training to lower Blood Pressure in Obese individuals with Resistant Hypertension</title>
      <scientificTitle/>
      <acronym>CT, ORH &amp; BP</acronym>
      <studyHypothesis>In comparison with the Usual Care group (UC), obese hypertensive individuals undergoing 12 weeks of Circuit Weight Training (CWT), will exhibit greater reductions in blood pressure.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Efficacy of prescribing circuit weight training in reducing blood pressure of obese resistant hypertensives</primaryOutcome>
      <secondaryOutcome>1. Effiacy of circuit weight training in reducing weight
2. Increasing cardio-respiratory endurance
3. Improving glycemic control and lipid profiles 
4. Enhancing Health Related Quality of Life (HRQL)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>University of Alberta Health Research Ethics Board (HREB) (ref no: 6276).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN87889245</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>RF-06-0419</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride>Stopped</overallStatusOverride>
      <reasonAbandoned>This study has been cancelled due to the private fitness centre pulling out of the trial.</reasonAbandoned>
      <overallStartDate>2006-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-02-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Canada</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="af1cc191-7497-485f-8b7a-5662bc1d5ca9">
	  <name>Clinical Pharmacology and Internal Medicine</name>
	  <address/>
	  <city>Alberta</city>
	  <state/>
	  <country>Canada</country>
	  <zip>T6G 2B7</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged 25 to 70 years
2. Obese (Body Mass Index [BMI] more than 30 kg/m^2)
3. Mean 24 hour ambulatory blood pressure of 150/99 mmHg or less (on drug therapy)</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40 (20 randomised into either group)</totalTarget>
      <exclusion>1. White-coat hypertension
2. Secondary hypertension
3. Unstable cardiovascular disease
4. Not residing in Edmonton or the surrounding area</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-02-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride>Stopped</recruitmentStatusOverride>
    </participants>
    <conditions>
      <condition>
	<description>Obesity and /or resistant hypertension</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Hypertension</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Circuit Weight Training (CWT) group: Individuals will be prescribed an exercise regimen based on baseline fitness and strength assessments and their exercise blood pressure response. Loads prescribed will be low resistance but high volume (two to three sets of 15 repetitions). Subjects will be asked to train on at least three non-consecutive days of the week and given free membership to local health club facilities for the duration of the intervention (12 weeks). Adherence to CWT intervention will be monitored via electronic attendance records at the health club facilities

Usual Care (UC) Group: Individuals randomly assigned to the usual care group will be asked to continue their current level of activity for the duration of the intervention (12 weeks).

Both groups will recieve the same nutritional counselling at the start of the intervention.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15075-0</funderId>
      <contactId>Contact52912_15075</contactId>
      <sponsorId>Sponsor51462</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52912_15075">
    <title>Dr</title>
    <forename>Raj</forename>
    <surname>Padwal</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Clinical Pharmacology and Internal Medicine
University of Alberta 
2E3.22 Walter C. Mackenzie Health Sciences Center
8440 - 112 Street
Edmonton</address>
      <city>Alberta</city>
      <country>Canada</country>
      <zip>T6G 2B7</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+1 780 407 8153</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">rpadwal@ualberta.ca</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51462">
    <organisation>University of Alberta (Canada)</organisation>
    <website>http://www.ualberta.ca</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>114 St - 89 Avenue
Edmonton</address>
      <city>Alberta</city>
      <country>Canada</country>
      <zip>T6G 2E1</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.17089.37</gridId>
    <rorId>https://ror.org/0160cpw27</rorId>
  </sponsor>
  <funder id="Funder15075-0">
    <name>University of Alberta Hospital Foundation (Canada) (ref: RF-06-0419)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-06T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-09-29T00:00:00.000Z">14811769</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A clinical comparison of self-etching primer with conventional etch during fixed appliance treatment</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Does self etching primer provide satisfactory clinical performance with similar failure rates compared to conventional etch?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Percentage bond failure rate.</primaryOutcome>
      <secondaryOutcome>Not provided at time of registration.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN14811769</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N0155160660</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-12-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-12-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>England</country>
	<country>United Kingdom</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8fe58a4c-788f-4b7b-b6f6-f7ac7f82a4e5">
	  <name>Dept of Oral and Maxollofacial Surgery</name>
	  <address/>
	  <city>Bury</city>
	  <state/>
	  <country>United Kingdom</country>
	  <zip>BL9 7TD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients requiring fixed appliance treatment.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>40</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>40</totalTarget>
      <exclusion>Patients who require bands or have heavily restored teeth.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-12-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-12-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Oral Health</description>
	<diseaseClass1>Oral Health</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Randomised controlled trial: self-etching primer compared to conventional etch.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/18042825 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="e4978f90-3539-449c-b9bb-e97148a52403" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/18042825"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15527-0</funderId>
      <funderId>Funder15527-1</funderId>
      <contactId>Contact53460_15527</contactId>
      <sponsorId>Sponsor52007</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53460_15527">
    <title>Mr</title>
    <forename>PA</forename>
    <surname>BANKS</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Dept of Oral and Maxollofacial Surgery
Fairfield General Hospital
Rochdale Old Road</address>
      <city>Bury</city>
      <country>United Kingdom</country>
      <zip>BL9 7TD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor52007">
    <organisation>Record Provided by the NHSTCT Register - 2006 Update - Department of Health</organisation>
    <website>http://www.dh.gov.uk/Home/fs/en</website>
    <sponsorType>Government</sponsorType>
    <contactDetails>
      <address>The Department of Health, Richmond House, 79 Whitehall</address>
      <city>London</city>
      <country>United Kingdom</country>
      <zip>SW1A 2NL</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+44 (0)20 7307 2622</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">dhmail@doh.gsi.org.uk</email>
    </contactDetails>
    <privacy>Public</privacy>
  </sponsor>
  <funder id="Funder15527-0">
    <name>Pennine Acute Hospitals NHS Trust (UK)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15527-1">
    <name>NHS R&amp;D Support Funding (UK)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-22T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2006-09-28T00:00:00.000Z">37259753</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The GRONORUN study: is a gradual training program for novice runners effective in preventing running related injuries? A randomised controlled trial</title>
      <scientificTitle/>
      <acronym>GRONORUN</acronym>
      <studyHypothesis>A more gradual training program for novice runners will result in a reduction of running related injuries in novice runners.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The incidence of running related injuries.</primaryOutcome>
      <secondaryOutcome>1. The severity of running related injuries
2. The compliance with the training programme and drop out</secondaryOutcome>
      <trialWebsite>http://www.gronorun.nl</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN37259753</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-07-11T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-07-10T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="c346205c-2b20-4402-a42c-363c6517be25">
	  <name>P.O. Box 30001</name>
	  <address/>
	  <city>Groningen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>9700 RB</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Novice runners (maximum of 30 minutes a month) between 18 and 65 years of age.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>532</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>532</totalTarget>
      <exclusion>No injury of lower limb in the past three months before the start of the study.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-07-11T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-07-10T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Running related injuries</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Running related injuries</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>A gradual training programme lasting 13 weeks is performed by the intervention group according to prepare for a four mile run. The increase of running load is 10% per week (time). 

The control group will train for the four mile run using a classic training program lasting eight weeks.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Protocol article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17331264 Study protocol
2008 Results article in https://pubmed.ncbi.nlm.nih.gov/17940147 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="d1987121-8850-448a-8b07-9eae378d5e6c" outputType="protocolarticle" artefactType="ExternalLink" dateCreated="2007-03-02T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17331264"/>
	<description>Study protocol</description>
	<productionNotes/>
      </output>
      <output id="230c004d-7728-47c5-8795-b9b35bee3400" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2008-01-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17940147"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15422-0</funderId>
      <contactId>Contact53355_15422</contactId>
      <sponsorId>Sponsor51902</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53355_15422">
    <title>Dr</title>
    <forename>S W</forename>
    <surname>Bredeweg</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>P.O. Box 30001</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>9700 RB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)50 3611023</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">s.bredeweg@sport.umcg.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51902">
    <organisation>University Medical Center Groningen (UMCG), University Center for Sport, Exercise and Health (The Netherlands)</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>P.O. Box 30001</address>
      <city>Groningen</city>
      <country>Netherlands</country>
      <zip>9700 RB</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)50 3613366</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">g.j.pepping@sport.umcg.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.4494.d</gridId>
    <rorId>https://ror.org/03cv38k47</rorId>
  </sponsor>
  <funder id="Funder15422-0">
    <name>The Netherlands Organisation for Health Research and Development (Zon-MW) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-19T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-09-25T00:00:00.000Z">85753869</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Prophylactic fluconazole is effective in preventing fungal colonisation and infection in preterm neonates: a multicentre, randomised trial in Italy</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To evaluate the efficacy of fluconazole prophylaxis in prevention of fungal colonisation and infection (colonisation by Candida spp., or invasive infection caused by Candida spp.) in preterm very low birth weight (i.e., less than 1500 g at birth) infants in Neonatal Intensive Care Units (NICUs).</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary objective of the study was to evaluate the effectiveness of  3 and 6 mg/kg fluconazole compared with placebo in the prevention of Candida colonisation and infection in the preterm very low birth weight neonates admitted to the participant NICUs.</primaryOutcome>
      <secondaryOutcome>1. Assessment of the incidence of Gram-positive and Gram-negative sepsis
2. Mortality (overall and Candida-attributable)
3. Rate of progression from colonisation to infection
4. Necrotising enterocolitis
5. Ligation of patent ductus arteriosus
6. Threshold retinopathy of prematurity requiring surgery
7. Severe (grade 3-4) intraventricular haemorrhage
8. Bronchopulmonary dysplasia
9. Alteration of liver function as measured by serum AST, ALT, direct bilirubin and gamma-Glutamyl Transferase (gGT) values at baseline and at the end of all administrations</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics Board of the Fondazione Crescere Insieme al Sant'Anna-ONLUS approved of the study on the 15/04/2004. The Fondazione is a Charity and Scientific Foundation of the Sant' Anna Hospital Institution.

Each participating Institution reviewed the protocol and was notified of the Fondazione's approval:
1. Policlinico Umberto I^ of Rome
2. Carlo Poma Hospital of Mantua
3. Mangiagalli Hospital of Milan
4. S. Matteo Hospital of Pavia
5. Arcispedale of Reggio Emilia
6. Fatebenefratelli Hospital of Benevento
7. Department of Pediatrics, University of Messina
8. Department of Pediatrics, University of Bologna</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN85753869</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, prospective, randomised, double-blind, placebo-controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-07-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Italy</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="92bc6f11-696a-4d9c-ab14-03aa71f8a16f">
	  <name>Neonatology and Hospital NICU</name>
	  <address/>
	  <city>Torino</city>
	  <state/>
	  <country>Italy</country>
	  <zip>10126</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All neonates with birth weight less than 1500 g (i.e. Very Low Birth Weight [VLBW]) born within the study period, whether at one of the eight Institutions or elsewhere, were eligible for the study.</inclusion>
      <ageRange>Neonate</ageRange>
      <gender>Both</gender>
      <targetEnrolment>267</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>267</totalTarget>
      <exclusion>1. Parental refusal
2. Admission after 72 hours of life
3. Death prior to 72 hours of life
4. Liver failure (defined as three-fold elevation of Aspartate Aminotransferase [AST] and/or Alanine Aminotransferase [ALT] above the reference values)</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-07-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Neonatal fungal infection</description>
	<diseaseClass1>Neonatal Diseases</diseaseClass1>
	<diseaseClass2>Neonatal fungal infection</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>The regimens in the two intervention groups was 6 and 3 mg/kg of fluconazole (DIFLUCAN®; Pfizer Italia S.p.A.; Latina/Roma; Italy) every third day for the first two weeks, then every other day. 

Six weeks (in infants with birth weight less than 1000 g, i.e. Extremely Low Birth Weight [ELBW]) and four weeks (in the infants with birth weight 1001 to 1500 g) were chosen as the duration of therapy on the basis of the currently published data, unless earlier discharge or need for systemic antifungal therapy due to the onset of proven or presumed invasive fungal infection.

Prophylaxis started from day of life three via a single dose intravenously or orally (via orogastric tube), depending on the availability of a venous line and/or the tolerance of oral feeding. Infants in the control group received placebo (1 ml saline) in the same way.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Fluconazole prophylaxis</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Other publications in https://pubmed.ncbi.nlm.nih.gov/16326690
2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17568029/</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="067a369d-7d1e-431d-a2a3-ac52967fe8b0" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2006-01-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/16326690"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="4cbb001c-79b6-44a2-9879-b6d1e80f288e" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-06-14T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17568029/"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15399-0</funderId>
      <contactId>Contact53331_15399</contactId>
      <sponsorId>Sponsor51878</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53331_15399">
    <title>Dr</title>
    <forename>Paolo</forename>
    <surname>Manzoni</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Neonatology and Hospital NICU
C. Spezia 60</address>
      <city>Torino</city>
      <country>Italy</country>
      <zip>10126</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+39 (0) 113 134 304</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">manzonipaolo@hotmail.it</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51878">
    <organisation>Saint Anna Foundation (Fondazione Crescere Insieme al Santa Anna [ONLUS]) (Italy)</organisation>
    <website/>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Corso Spezia 60</address>
      <city>Torino</city>
      <country>Italy</country>
      <zip>10126</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+39 (0)113 134 300</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ggomirato@hotmail.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487373.c</gridId>
    <rorId>https://ror.org/00k065b17</rorId>
  </sponsor>
  <funder id="Funder15399-0">
    <name>Pfizer Italia S.p.A. (Italy) - supplied study drugs, provided financial support with a grant, but was not involved in the concept, design, enrolment, data collection, analysis and interpretation of its results.</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-21T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2006-09-11T00:00:00.000Z">06650826</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Brief alcohol intervention in emergency</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Brief alcohol intervention for hazardous drinkers admitted to the Emergency Department.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. A 20% decrease in number of drinks per week
2. A 20% decrease in monthly binge drinking frequency
3. Number of medical consultations
4. Days hospitalised and days out of work</primaryOutcome>
      <secondaryOutcome>1. Drinking quantity
2. Frequency
3. Hazardous drinking consequences
4. Health related quality of life</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Clinical Research Ethics Committe, Faculty of Medicine, University of Lausannedate on the 8th January 2003 (ref: 193/01).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN06650826</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>3200-067949</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Quality of life</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d594436a-87e9-455c-9af9-642b2339aab1">
	  <name>Mont-Paisible 16</name>
	  <address/>
	  <city>Lausanne</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>1011</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Consecutive patients aged 18 and over admitted to the Emergency Department from 11 am to 11 pm daily from January 2003 to June 2004.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>1000</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1000</totalTarget>
      <exclusion>1. Patients under 18
2. A history of alcohol-related treatment over the last 12 months
3. Did not qualify for hazardous drinking over the last 30 days
4. Were clinically intoxicated
5. Medical condition that precluded a face-to-face interview</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Hazardous drinkers</description>
	<diseaseClass1>Mental and Behavioural Disorders</diseaseClass1>
	<diseaseClass2>Alcohol dependence</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>A single session 15 minutes brief alcohol intervention including six steps: 
1. Thank the patient for participation and provide reassurance about confidentiality 
2. Provide feedback about patient's alcohol use compared to similar measures for men and women in the Swiss community and ask the patient's opinion of the feedback 
3. Ask the patient to explore the pros and cons of his/her alcohol use 
4. Use a one to ten scale to explore patient's importance and readiness to change his/her drinking pattern 
5. Ask if the patient feels ready to set an objective and provide positive reinforcement about their ability to achieve this objective 
6. Give each patient written material including their Alcohol Screen (AUDIT) score, drinking pattern percentiles compared to the Swiss community, and their drinking pattern objectives.

There were two control groups: 
1. Control group one completed the  two minute lifestyle screener and a 30-minute face-to-face interview including assessment of alcohol use and alcohol-related consequences and a medical history. They were then contacted 12-month later for follow-up
2. Control group two completed the two minute lifestyle screener, signed a consent form and were contacted 12 month later for follow-up

Usual care does not include any intervention regarding alcohol. Alcohol use is generally adressed with a single yes-no question about patients' alcohol use. Neither systematic nor case finding stategies of counseling or referral are conducted routinely.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17565563 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="73bc3b4d-6278-41ff-a2d9-a9c68b10403f" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-08-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17565563"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder15085-0</funderId>
      <contactId>Contact52924_15085</contactId>
      <sponsorId>Sponsor51474</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52924_15085">
    <title>Dr</title>
    <forename>Jean-Bernard</forename>
    <surname>Daeppen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Mont-Paisible 16</address>
      <city>Lausanne</city>
      <country>Switzerland</country>
      <zip>1011</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">jean-bernard.daeppen@chuv.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51474">
    <organisation>Swiss National Science Foundation (Switzerland)</organisation>
    <website/>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Wildhainweg 2</address>
      <city>Bern</city>
      <country>Switzerland</country>
      <zip>3001</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">div3@snf.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.425888.b</gridId>
    <rorId>https://ror.org/00yjd3n13</rorId>
  </sponsor>
  <funder id="Funder15085-0">
    <name>Swiss National Science Foundation (Switzerland) (ref: 3200-067949)</name>
    <fundRef>http://dx.doi.org/10.13039/501100001711</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-19T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2006-07-21T00:00:00.000Z">16583435</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A prospective, randomised, double-blinded study to compare bipolar transurethral resection of the prostate (bipolar TURP) versus monopolar transurethral resection of the prostate (monopolar TURP) in terms of safety and efficacy</title>
      <scientificTitle/>
      <acronym>TURP</acronym>
      <studyHypothesis>Bipolar devices will minimise the disadvantages of the monopolar device such as the risk of electrolyte disturbances by using saline irrigation, bleeding and the risk of nervous stimulation.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. Safety bipolar TURP compared with monoploar TURP by means of  transurethral resection (TUR) syndrome
2. Blood loss
3. Number and severity of adverse events</primaryOutcome>
      <secondaryOutcome>1. Efficacy of bipolar TURP compared with monopolar TURP by means of IPSS or quality of life (QoL) scores
2. International index of erectile function (IIEF) score
3. Qmax
4. Cutting rate
5. Length of catherisation
6. Length of hospital stay
7. Length of operation
8. Impact on prostate specific antigen (PSA) level
9. Number of strictures</secondaryOutcome>
      <trialWebsite>http://www.turp.nl</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN16583435</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A prospective, randomised, double-blinded study</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-07-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2010-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="e44d9cb7-c4ea-4ff8-a2f8-cd94d52d2482">
	  <name>Academic Medical Center (AMC)</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1100 DD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Candidates for transurethral resection of the prostate (TURP)
2. Qmax less than 16 ml/sec
3. International Prostate Symptom Score (IPSS) score greater than 14
4. Voided volume greater than 125
5. Patients in retention with an indwelling catheter or intermittent catheterisation
6. Informed consent</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>94</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>94</totalTarget>
      <exclusion>1. If patient is suspected to be suffering from prostate cancer
2. Prior prostate surgery, including minimal invasive therapies
3. Active urinary tract infection
4. Known or suspected neurogenic decompensated bladder (postvoid residual urine volume [PVR] greater than 400ml/sec) or compensated detrusor function
5. Immunosuppression; using prednisone
6. Known or suspected malignant disease affecting the bladder or lower urinary tract
7. 5-alpha-reductase inhibitor within the last three months before baseline
8. Alpha-blockers within the last six weeks before baseline
9. Specific severe heart disease in whom anti-coagulant therapy might jeopardize treatment outcome</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-07-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2010-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Benign Prostatic Hyperplasia (BPH)</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Hyperplasia of prostate</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients will be randomised into either:
Group A: who will undergo a bipolar TURP
Group B: who will undergo a monopolar TURP</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15273-0</funderId>
      <funderId>Funder15273-1</funderId>
      <contactId>Contact53176_15273</contactId>
      <sponsorId>Sponsor51721</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact53176_15273">
    <title>Dr</title>
    <forename>S.A.</forename>
    <surname>Lagerveld-Zaaijer</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Academic Medical Center (AMC)
Department of Urology
P.O. Box 22660</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 5666030</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">S.A.Zaaijer@amc.uva.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51721">
    <organisation>Academic Medical Center (AMC), Department of Urology (The Netherlands)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>P.O. Box 22660</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5650.6</gridId>
    <rorId>https://ror.org/03t4gr691</rorId>
  </sponsor>
  <funder id="Funder15273-0">
    <name>Karl Storz (UK)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15273-1">
    <name>Academic Medical Center (AMC) (The Netherlands) - Department of Urology</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-07-26T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2006-07-03T00:00:00.000Z">27844532</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Correction of acidosis in hemodialysis patients. Effects on protein metabolism, investigated by tracer technique and messenger-ribonucleic acid determination for ubuquitin and proteasome subunits.</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Metabolic acidosis stimulates muscle protein breakdown, correction of acidosis results in decreased protein breakdown.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Muscle protein turnover</primaryOutcome>
      <secondaryOutcome>1. messenger-Ribonucleic Acid (mRNA) for ubuquitin and proteasome subunits
2. Plasma and muscle intracellular amino acid concentrations
3. Serum albumin</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the Ethics Committee of Karolinska Institute at Huddinge University Hospital on 11/01/1993, reference number: 196/96</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN27844532</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, controlled, crossover design</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1997-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>1998-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Sweden</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0e0d4dda-cd65-46c3-be58-d66235aa6a8d">
	  <name>Karolinska University Hospital</name>
	  <address/>
	  <city>Stockholm</city>
	  <state/>
	  <country>Sweden</country>
	  <zip>SE-171 76</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Clinically stable hemodialysis patients
2. &gt;18 Years of age</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>16</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>16</totalTarget>
      <exclusion>1. Clinically obvious malnutrition
2. Ongoing infection
3. Diabetes mellitus
4. Untreated congestive heart failure
5. Treatment with corticosteroids or other immunosuppressive agents</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1997-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>1998-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>End-stage renal failure</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Renal failure</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Adjustments of acid-base balance - in each patient, protein turnover will be measured twice, at a standard bicarbonate concentration of &lt;19 mmol/l and &gt;25 mmol/l respectively, with an interval between the two measurements (random order) of 3-4 weeks. The acid-base status will be altered by adjusting the dose of bicarbonate (oral and/or via dialysis) and protein turnover will be measured when the predialysis bicarbonate level have been low or normal for at least one week.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16931215 Results:</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="e1ffa7b4-9243-4ab4-b743-5231026d1d16" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-09-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16931215"/>
	<description>Results:</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14950-0</funderId>
      <funderId>Funder14950-1</funderId>
      <funderId>Funder14950-2</funderId>
      <funderId>Funder14950-3</funderId>
      <contactId>Contact52751_14950</contactId>
      <sponsorId>Sponsor51290</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52751_14950">
    <title>Dr</title>
    <forename>Erland</forename>
    <surname>Löfberg</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Karolinska University Hospital
Department of Renal Medicine
Solna</address>
      <city>Stockholm</city>
      <country>Sweden</country>
      <zip>SE-171 76</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 (0)85 1773768</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">erland.lofberg@karolinska.se</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51290">
    <organisation>Karolinska University Hospital (Sweden)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Department of Clinical Science
Karolinska Institute
Huddinge</address>
      <city>Stockholm</city>
      <country>Sweden</country>
      <zip>SE-14186</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+46 (0)85 8582656</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">anders.alvestrand@ki.se</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.24381.3c</gridId>
    <rorId>https://ror.org/00m8d6786</rorId>
  </sponsor>
  <funder id="Funder14950-0">
    <name>Swedish Medical Research Council (ref: 11243 and 04210)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14950-1">
    <name>Gambro AB</name>
    <fundRef/>
  </funder>
  <funder id="Funder14950-2">
    <name>Baxter Inc.</name>
    <fundRef/>
  </funder>
  <funder id="Funder14950-3">
    <name>U.S. National Institutes of Health (R01 DK37175)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-17T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-06-07T00:00:00.000Z">21267689</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Preventive health survey in elderly people</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Participation in a health survey for elderly people (60-75 years) on risk factors for cardiovascular diseases, depression, osteoporosis and falls, followed by a subsequent personalized health advice from a community nurse on lifestyle modification and/or reference to local preventive activities, will lead to a decreased risk profile within the surveyed group and to a decrease in an abbreviated risk profile in comparison to a control group.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Percentage of persons with improvement of one step or more in risk profile. Risk profile = combination of risk factors for cardiovascular diseases (4 levels), depression (4 levels), osteoporosis (2 levels) and falls (4 levels), where level 1 = low risk; 4 = high risk.

For the comparison with the control group, an abbreviated risk profile will be constructed from the risk factors that can be assessed by questionnaire.

Outcome will be assessed at start and 12 months later.</primaryOutcome>
      <secondaryOutcome>Health related quality of life (short-form questionnaire-36 [SF-36] and EQ-5D)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN21267689</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>PGO2006</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-01-13T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-07-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="ea300ff1-d17d-4b43-a511-994e069c9257">
	  <name>GGD Zeeland</name>
	  <address/>
	  <city>Goes</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>4460 AS</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Random selection of all community-dwelling elderly persons, aged 60-75 living in the Netherlands in the regions: Zuid-Beveland, Schouwen-Duiveland, Soest and Soesterkwartier (Amersfoort).</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>2000</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>2000</totalTarget>
      <exclusion>Elderly people living  in residential homes or hospital</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-01-13T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-07-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Falls, osteoporosis, cardiovascular disease, depression</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2/>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Health survey for risk factors followed by personalized advice on lifestyle and/or advice of to follow course to improve lifestyle. Health survey consists of anamnestic interview consisting of both validated questionnaires and physical examination. Control group will only receive questionnaires by mail.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15128-0</funderId>
      <funderId>Funder15128-1</funderId>
      <funderId>Funder15128-2</funderId>
      <funderId>Funder15128-3</funderId>
      <funderId>Funder15128-4</funderId>
      <funderId>Funder15128-5</funderId>
      <funderId>Funder15128-6</funderId>
      <funderId>Funder15128-7</funderId>
      <funderId>Funder15128-8</funderId>
      <funderId>Funder15128-9</funderId>
      <funderId>Funder15128-10</funderId>
      <contactId>Contact52982_15128</contactId>
      <sponsorId>Sponsor51530</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52982_15128">
    <title>Mr</title>
    <forename>C.</forename>
    <surname>Dingemanse</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>GGD Zeeland
P.O. Box 345</address>
      <city>Goes</city>
      <country>Netherlands</country>
      <zip>4460 AS</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)11 3249484</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">christine.dingemanse@ggdzeeland.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51530">
    <organisation>GGD Zeeland (The Netherlands)</organisation>
    <website/>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>P.O. Box 345</address>
      <city>Goes</city>
      <country>Netherlands</country>
      <zip>4460 AS</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.491205.b</gridId>
    <rorId>https://ror.org/042s2nd27</rorId>
  </sponsor>
  <funder id="Funder15128-0">
    <name>Community of Soest</name>
    <fundRef/>
  </funder>
  <funder id="Funder15128-1">
    <name>Community of Amersfoort</name>
    <fundRef/>
  </funder>
  <funder id="Funder15128-2">
    <name>Community of Schouwen-Duiveland</name>
    <fundRef/>
  </funder>
  <funder id="Funder15128-3">
    <name>Community of Reimerswaal</name>
    <fundRef/>
  </funder>
  <funder id="Funder15128-4">
    <name>Community of Kapelle</name>
    <fundRef/>
  </funder>
  <funder id="Funder15128-5">
    <name>Community of Goes</name>
    <fundRef/>
  </funder>
  <funder id="Funder15128-6">
    <name>Zorgkantoor</name>
    <fundRef/>
  </funder>
  <funder id="Funder15128-7">
    <name>Province of Zeeland</name>
    <fundRef/>
  </funder>
  <funder id="Funder15128-8">
    <name>GGD Zeeland</name>
    <fundRef/>
  </funder>
  <funder id="Funder15128-9">
    <name>Stichting</name>
    <fundRef/>
  </funder>
  <funder id="Funder15128-10">
    <name>Central Fund Reserves of the Former Voluntary National Health Service Administration Insurances (Centraal Fonds van Voormalig Vrijwillige Ziekenfondsverzekeringen [RvvZ])</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-20T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-06-02T00:00:00.000Z">19413357</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A multicentre, randomised, double-blind, placebo-controlled clinical trial to evaluate the use of Chinese herbal medicine in the management of endometriosis: a prospective study</title>
      <scientificTitle/>
      <acronym>Endoherb</acronym>
      <studyHypothesis>The hypothesis is that the formulated Chinese herbal treatment shows no significant difference than a placebo in the management of the symptoms of endometriosis.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Pain intensity due to endometriosis, measured quantitatively on the VAS and qualitatively as descriptive values.</primaryOutcome>
      <secondaryOutcome>1. Quality of life using the 36-item Short-Form health survey (SF-36) and a study design health survey tool
2. Serum CA 125 levels</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the University of Western Sydney's Ethics Committee on the 8th August 2002 (ref: HEC 02/098).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN19413357</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>HEC 02/098</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A multicentre, randomised, double-blind, placebo-controlled clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-11-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-11-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Australia</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="dfee35d5-ced3-40b5-970f-305f5c7f08bc">
	  <name>497 South Road</name>
	  <address/>
	  <city>South Australia</city>
	  <state/>
	  <country>Australia</country>
	  <zip>5035</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Women, aged 18 - 43 years 
2. Diagnosed with endometriosis by laparoscopy and the severity staged (grade I - IV) 
3. At least three months of pain measuring more than 30 mm on visual analogue scale (VAS) scale</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Female</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>100 participants (50 in each arm)</totalTarget>
      <exclusion>1. Menopause
2. Pregnancy
3. Liver diseases
4. Suffering from diabetes mellitus
5. Suffering from malignancies
6. Hormonal treatments
7. Anti-depressant treatments
8. Immunosuppressive conditions and treatments</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-11-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-11-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Endometriosis</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Endometriosis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>A specific Chinese herbal formula (Endoherb) versus placebo.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Endoherb</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15046-0</funderId>
      <contactId>Contact52869_15046</contactId>
      <sponsorId>Sponsor51419</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52869_15046">
    <title>Dr</title>
    <forename>Alex</forename>
    <surname>Liew</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>497 South Road
Ashford </address>
      <city>South Australia</city>
      <country>Australia</country>
      <zip>5035</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+61 (0)8 83713711</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">endoherb@tpg.com.au</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51419">
    <organisation>University of Western Sydney (Australia)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Centre for Complementary Medicine
Locked Bag 1797
Penrith South DC
New South Wales</address>
      <city>Sydney</city>
      <country>Australia</country>
      <zip>1797</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.1029.a</gridId>
    <rorId>https://ror.org/03t52dk35</rorId>
  </sponsor>
  <funder id="Funder15046-0">
    <name>University of Western Sydney (Australia)</name>
    <fundRef>http://dx.doi.org/10.13039/501100001776</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-20T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2006-05-26T00:00:00.000Z">61976169</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Therapy of frequent relapsing, steroid-sensitive nephrotic syndrome in childhood: efficacy of mycophenolate mofetil versus cyclosporin A</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Immunosuppressive therapy with mycophenolate mofetil (MMF) is as effective as cyclosporin A in preventing relapses of the nephrotic syndrome.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Number of relapses during the observation period</primaryOutcome>
      <secondaryOutcome>Decrease in GFR, hypertension and hyperlipidemia during the observation period</secondaryOutcome>
      <trialWebsite>http://www.apn-online.de/</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Ethics Committee of Charité - University Medicine Berlin (Germany) on the 2nd December 2002 (ref: 1656/Si 238).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN61976169</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>ML 16622</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, randomised, open-labelled, cross-over trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-01-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Germany</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="d182562d-8754-4caa-aa6a-9fa2e271f914">
	  <name>Augustenburger Platz 1</name>
	  <address/>
	  <city>Berlin</city>
	  <state/>
	  <country>Germany</country>
	  <zip>13353</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Children aged 3 - 17 years 
2. Frequent relapses of steroid-sensitive nephrotic syndrome, associated with minimal changes on renal biopsy
3. Glomerular Filtration Rate (GFR) greater than 70 ml/min</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="3.0"/>
      <upperAgeLimit unit="Years" value="17.0"/>
      <gender>Both</gender>
      <targetEnrolment>55</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>55</totalTarget>
      <exclusion>1. Other histological findings on renal biopsy
2. Other severe concomittant diseases
3. Decreased GFR</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-01-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Idiopathic nephrotic syndrome</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Nephrotic syndrome</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Immunosuppressive therapy with MMF versus cyclosporin A.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Mycophenolate mofetil, cyclosporin A</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14753204 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="b8f56bdc-6919-479a-a245-199e53920f87" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-01-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14753204"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14931-0</funderId>
      <funderId>Funder14931-1</funderId>
      <contactId>Contact52728_14931</contactId>
      <sponsorId>Sponsor51266</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52728_14931">
    <title>Mrs</title>
    <forename>Jutta</forename>
    <surname>Gellermann</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Augustenburger Platz 1</address>
      <city>Berlin</city>
      <country>Germany</country>
      <zip>13353</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor51266">
    <organisation>Hoffmann-La Roche AG (Germany)</organisation>
    <website>http://www.roche.de</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Emil-Barell-Strasse 1</address>
      <city>Grenzach-Wyhlen</city>
      <country>Germany</country>
      <zip>79639</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.424277.0</gridId>
    <rorId>https://ror.org/00sh68184</rorId>
  </sponsor>
  <funder id="Funder14931-0">
    <name>Hoffmann La Roche AG (Germany)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14931-1">
    <name>Charité - University Medicine Berlin (Germany)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-20T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2006-05-24T00:00:00.000Z">67656669</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A phase I, single-dose, double-blind, randomised, dose escalation study to assess the safety, tolerability and pharmacokinetics of NNZ-2566 when administered as a 10-minute infusion</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Based on pre-clinical studies, NNZ-2566 is shown to have the potential to prevent the neurological damage that can occur as a result of the traumatic brain injury. Objectives of this study are:
1. To determine the safety and tolerability of a single intravenous dose of NNZ 2566 in healthy volunteers when administered as a 10-minute infusion
2. To determine the single dose pharmacokinetics of NNZ-2566 after a 10-minute infusion</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To determine the safety and tolerability of a single intravenous dose of NNZ 2566 when administered as a 10-minute infusion.</primaryOutcome>
      <secondaryOutcome>To determine the single dose pharmacokinetics of NNZ 2566 after a 10-minute infusion.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the Alfred Ethics Committee on the 13th February 2006 (ref: 7/06).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN67656669</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Neu-2566-HV-001</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Placebo-controlled, double-blind, randomised, single-dose, dose escalation, phase I study in healthy volunteers</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-05-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-10-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Australia</country>
	<country>New Zealand</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="488bbe4f-8510-4c31-9239-8b3ee97f4e65">
	  <name>Center for Clinical Studies</name>
	  <address/>
	  <city>Melbourne</city>
	  <state/>
	  <country>Australia</country>
	  <zip>3004</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged between 18 years and 50 years (inclusive)
2. Male only: males must also agree to use adequate contraceptive precautions (unless the subject is surgically sterilised) for the duration of the study and for at least 30 days thereafter
3. Body mass index (BMI) of 18 to 30 kg/m^2
4. Healthy - this will be determined by a medical history with particular attention to:
4.1. A drug history identifying any known drug allergies and the presence of drug abuse
4.2. Any chronic use of medication
4.3. A thorough review of body systems. This will also be determined by having no clinically significant abnormal findings on physical examination, which includes an electrocardiogram (ECG), which in the opinion of the investigator would jeopardise the safety of the subject or impact on the validity of the study results
5. Volunteers with adequate venous access in their left and right arm to allow collection of blood samples and drug administration
6. Fluency in the English language
7. Have voluntarily given written informed consent to participate in this study</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Male</gender>
      <targetEnrolment>35</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>35 males</totalTarget>
      <exclusion>1. History of allergy and/or hypersensitivity to any of the stated ingredients of the formulations (including lactose intolerance). A known hypersensitivity to lidocaine or any surgical dressing which may be used in the study procedures.
2. Medical conditions:
2.1. History of clinically significant gastrointestinal, hepatic, renal, cardiovascular, dermatological, immunological, respiratory, endocrine, oncological, neurological, metabolic, psychiatric disease or haematological disorders
2.2. Any history of asthma during the last 10 years
2.3. A creatinine clearance of less than 75 ml/min calculated using Cockroft and Gault Formula
2.4. Any predisposing condition that might interfere with the absorption, distribution, metabolism, and/or excretion of drugs
2.5. History of abnormal bleeding tendencies or thrombophlebitis unrelated to venepuncture or intravenous cannulation
2.6. History of hepatitis B, a positive test for hepatitis B surface antigen, a history of hepatitis C, a positive test for hepatitis C antibody, a history of human immunodeficiency virus (HIV) infection or demonstration of HIV antibodies
3. Any evidence of organ dysfunction, or any clinically significant clinical laboratory value which, in the opinion of the investigator would jeopardise the safety of the subject or impact on the validity of the study results, including a liver function test (LFT) greater than 1.5 x upper limit of normal (ULN)
4. Those who may have difficulty abstaining from alcohol during the 48 hours prior to dose administration and until completion of blood sampling on day 7
5. History of, or current evidence of, abuse of alcohol or any drug substance, licit or illicit, or positive urine drug screen for drugs of abuse
6. Medication:
6.1. Difficulty in abstaining from any prescription medications for 14 days prior to dose administration and for the duration of the study
6.2. Difficulty in abstaining from over-the-counter (OTC) medications or herbal supplements for 14 days prior to dose administration and for the duration of the study, (with the exception of occasional analgesia, vitamin and other nutrient supplement use, at the discretion of the investigator)
7. Difficulty in abstaining from food and/or beverages that contain caffeine or other xanthines (e.g., coffee, tea, cola and chocolate) during the 24 hours prior to dose administration and whilst confined at the clinical facility
8. History of any psychiatric illness which may impair the ability to provide written informed consent
9. Poor compliers or those unlikely to attend
10. Receipt of any drug as part of a research study within 30 days of initial dose administration in this study
11. Standard blood donation (usually 550 ml) within the 12-week period before dose administration
12. Unusual dietary habits, including vegetarian diets and excessive or unusual vitamin intakes
13. Vaccination or immunisation within 30 days of initial dose administration</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-05-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-10-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Traumatic brain injury</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Traumatic brain injury</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Subjects will undergo screening to confirm eligibility. Subsequently, subjects will be admitted to the clinical facility for administration of either placebo or the active drug in a 2:5 fashion in each of the five cohorts. This in-house stay will involve collection of blood samples for pharmacokinetic (PK) analysis.  Subjects will stay for a minimum of 24 hours after initial dosing. A dose-escalation schema has been chosen to maximise safety for participants based on preclinical toxicology studies. The pre-defined dose levels are: 0.1 mg/kg, 1.0 mg/kg, 10.0 mg/kg, 20.0 mg/kg, 30.0 mg/kg. The dosing scheme will consist of a single fixed-dose intravenous infusion of NNZ-2566 over 10 minutes. Dose escalation is subject to the Data Safety Monitoring Committee's (DSMC's) recommendation.  A review time period of two to three weeks from end of dosing of each cohort is estimated to enable PK analysis prior to starting the next cohort. The study design precludes intra-subject dose-escalation. 

Subjects will then return to the unit on day 7 for an exit evaluation, which will include collection of additional blood samples for safety laboratory testing and safety monitoring.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase I</phase>
	<drugNames>NNZ-2566</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15059-0</funderId>
      <funderId>Funder15059-1</funderId>
      <funderId>Funder15059-2</funderId>
      <contactId>Contact52884_15059</contactId>
      <sponsorId>Sponsor51434</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52884_15059">
    <title>Dr</title>
    <forename>Minh</forename>
    <surname>Pham</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Center for Clinical Studies
Level 5 Burnet Tower
Amrep Precinct
89 Commercial Road</address>
      <city>Melbourne</city>
      <country>Australia</country>
      <zip>3004</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+61 (0)3 9207 1930</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">m.pham@nucleusnetwork.com.au</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51434">
    <organisation>Neuren Pharmaceuticals (New Zealand)</organisation>
    <website>http://www.neurenpharma.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Level 3
2-6 Park Avenue
Grafton</address>
      <city>Auckland</city>
      <country>New Zealand</country>
      <zip>1031</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+64 (0)9 367 7167</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mscott@neurenpharma.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487323.9</gridId>
    <rorId>https://ror.org/0503fq502</rorId>
  </sponsor>
  <funder id="Funder15059-0">
    <name>Technology New Zealand (TechNZ) (New Zealand) - grant</name>
    <fundRef/>
  </funder>
  <funder id="Funder15059-1">
    <name>Foundation for Research Science and Technology (FoRST) (New Zealand) - grant (grant ref: NRNZ0301, NRNZ0402, NRNZ0502)</name>
    <fundRef/>
  </funder>
  <funder id="Funder15059-2">
    <name>Neuren Pharmaceuticals Limited (New Zealand) - internally funded</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-10T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-05-12T00:00:00.000Z">03256458</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Safety of an aerosol attenuated measles vaccine in healthy subjects with Omron's nebuliser, Aerogen's clinical nebuliser and Trudell's nebuliser</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Respiratory administration of live measles vaccine closely mimics the natural route of measles infection. It is already established that current measles vaccines are more effective or equivalent in inducing antibody production when delivered by nebulisation compared to when delivered parenterally. Maternal antibody interference might be avoided or mucosal immunity might be enhanced. No increase in adverse side effects of respiratory administration has been noted compared to current injection practice. Aerosol delivery devices are available or being developed and could be used by lay people with limited training. Administration of the current measles vaccine via the respiratory route should now be comprehensively studied to achieve licensure for international use.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Evaluation of the safety of aerosol administration of live Edmonston Zagreb attenuated measles vaccine given to healthy volunteers.</primaryOutcome>
      <secondaryOutcome>Evaluation of the serum plaque reduction neutralisation titres before and after aerosol administration of live attenuated measles vaccine given to healthy volunteers.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by the:
1. Research Ethics Review Committee (ERC) of the World Health Organization on the 4th April 2006
2. Health Ministry Screening Committee (HMSC) of the Ministry of Health (India) on the 17th January 2006</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN03256458</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>WHO/MAP/IN/001</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, open, non-controlled, sequential by age group, parallel trial.</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Non randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Prevention</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-05-10T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>India</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="fbc92db9-2f29-4eef-b9e9-e6db12fb8d94">
	  <name>Initiative for Vaccine Research</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH-1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Male subject, 18 to 35 years old for first group
2. Male or female at the age of 1 to 17 years for second and third group
3. Residence in the study area
4. Measles immune, as determined by Plaque Reduction Neutralisation (PRN) titre greater than 120 mIU/ml
5. Healthy on the day of the visit as supported by physical examination and laboratory evaluation on preset parameters
6. Signed informed consent (subject and/or parent/guardian/legal representative)
7. Expressed interest and availability to fulfil the study requirements
8. Non pregnant as certified by pregnancy test and agreement to avoid pregnancy for at least 30 days after vaccination (women of childbearing age)
9. Willing not to receive any experimental drug or vaccine within 90 days after study vaccination</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Both</gender>
      <targetEnrolment>60</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>60 subjects for 3 sequential age groups; 20 participants in each</totalTarget>
      <exclusion>1. Human Immunodeficiency Virus (HIV) positive (serology test)
2. Pregnant (based on positive pregnancy test)
3. Immunodeficiency or suppression (disease or iatrogenic induced), seizure disorder and progressive neurological disorder
4. Enrolled in any experimental drug or vaccine study within 30 days prior to vaccination
5. Known hypersensitivity to any component of the study vaccine
6. History of thrombocytopenia or immune thrombocytopenia purpura
7. Significant psychiatric or medical illness, including pulmonary disease (such as asthma requiring medication)
8. Severe malnutrition, as indicated by current guidelines by Indian Academic of Paediatrics
9. Axillary temperature greater than 38.3°C or other acute illness on the day of scheduled vaccination
10. Household contact who has a medical history suggestive of disease or drug induced immunodeficiency or suppression (e.g. ongoing treatment with an immunosuppressive agent, chronic diarrhoea for greater than one month, fever for greater than one month, chronic cough for greater than one month, generalised dermatitis or lymphadenopathy, gastrointestinal candidiasis)
11. Receipt of any licensed vaccine within 30 days prior to vaccination</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-05-10T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Measles infection</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Measles infection</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Attenuated measles aerosol vaccine administrated via the following devices: 
1. Omron's nebuliser
2. Aerogen's clinical nebuliser
3. Trudell's nebuliser</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Measles vaccine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder15057-0</funderId>
      <contactId>Contact52881_15057</contactId>
      <sponsorId>Sponsor51431</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52881_15057">
    <title>Dr</title>
    <forename>Ana-Maria Henao</forename>
    <surname>Restrepo</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Initiative for Vaccine Research
World Health Organization
20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor51431">
    <organisation>World Health Organization (WHO) (Switzerland) </organisation>
    <website>http://www.who.int/vaccine_research/en/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Initiative for Vaccine Research
20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder15057-0">
    <name>World Health Organization (WHO) (Switzerland)</name>
    <fundRef>http://dx.doi.org/10.13039/100004423</fundRef>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-06T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-04-24T00:00:00.000Z">27914471</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A comparison of the efficacy and effectiveness of dihydroartemisinin-piperaquine and artesunate-mefloquine in the treatment of falciparum malaria</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Non-inferiority of efficacy and effectiveness of dihydroartemisinin-piperaquine compared to mefloquine-artesunate for the treatment of uncomplicated falciparum malaria in adults and children in western Myanmar.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Polymerase chain reaction (PCR) adjusted parasitological failure rates by day 42</primaryOutcome>
      <secondaryOutcome>1. Vivax appearances
2. Gametocytaemia (person gametocyte weeks between day 0 and 42)
3. Whole blood piperaquine levels at day 7
4. Adverse effects</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Approved by Doctors Without Borders (Medecins sans Frontieres [MSF]) Ethical Review Board on 05/12/2003</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN27914471</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>An open randomised comparison</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-12-08T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-03-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Myanmar</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1363b470-5dde-430b-bdc0-0e1ce5679d5c">
	  <name>Thanlwin Road 62 A</name>
	  <address/>
	  <city>Yangon</city>
	  <state/>
	  <country>Myanmar</country>
	  <zip>-</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Patients with fever (axillary temperature &gt;37.5°C), or a history of fever within 48 hours
2. Confirmed falciparum malaria (mixed infection P. falciparum with P. vivax and/or P. malariae were included), with more than 500 but less than 100,000 asexual parasites per ml</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>640</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>640</totalTarget>
      <exclusion>1. Signs of severe and complicated malaria
2. Children below one-year-old
3. Pregnant women
4. Patients with a history of taking mefloquine during the previous two months
5. Patients taken any other antimalarial drugs in the previous 48 hours
6. Patients with a history of psychiatric diseases</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-12-08T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-03-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Falciparum malaria</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Falciparum malaria</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Comparison of two different treatment regimes: dihydroartemisinin-piperaquine and mefloquine-artesunate. Both treatment regimes were given observed or not observed; total of four study groups.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Dihydroartemisinin-piperaquine and artesunate-mefloquine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=16798391 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="50837bb6-41aa-45f4-8f02-fa9d7daa68de" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-06-24T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&amp;cmd=Retrieve&amp;dopt=Abstract&amp;list_uids=16798391"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14551-0</funderId>
      <contactId>Contact52284_14551</contactId>
      <sponsorId>Sponsor50768</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52284_14551">
    <title>Dr</title>
    <forename>Frank</forename>
    <surname>Smithuis</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Thanlwin Road 62 A</address>
      <city>Yangon</city>
      <country>Myanmar</country>
      <zip>-</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+95 1 534679</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">msfh_yangon@mptmail.net.mm</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50768">
    <organisation>Doctors Without Borders (Medecins sans Frontieres [MSF]) (The Netherlands)</organisation>
    <website>http://www.artsenzondergrenzen.nl</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Plantage Middenlaan 14</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1018DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 5208700</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@amsterdam.msf.org</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.452780.c</gridId>
    <rorId>https://ror.org/04237en35</rorId>
  </sponsor>
  <funder id="Funder14551-0">
    <name>Internally funded by Doctors Without Borders (Artsen zonder Grenzen MSF) (Holland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-10T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2006-03-31T00:00:00.000Z">08525528</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Effectiveness and pharmacovigilance of Lapdap™ and Coartem® for the treatment of uncomplicated falciparum malaria in northeastern Tanzania</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Lapdap™ is likely to be as effective as Coartem® in malaria management when used in an unsupervised situation.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To assess the effectiveness of Lapdap™ and Coartem® through clinical and parasitological responses.</primaryOutcome>
      <secondaryOutcome>1. To document the frequency and type of potential drug related adverse events
2. To assess community compliance and acceptability of Lapdap™ and Coartem® use
3. To determine the prevalence and to monitor the development of dhfr/dhps gene mutations which are markers of resistance</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received on the 10th July 2005.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN08525528</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>A40744</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-10-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Switzerland</country>
	<country>Tanzania</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="f746c5b1-9957-428d-b8b8-74f355bc2bb4">
	  <name>World Health Organization</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH-1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Age between 6 and 59 months (although the lower age limit for Lapdap™ use is three months according to the label, malaria is rare among those below six months of age)
2. Weight of 5 - 16 kg
3. Presence of fever (axillary temperature greater than or equal to 37.5°C) and/or history of fever within two days
4. Uncomplicated malaria, slide-confirmed mono-infection of P. falciparum with 1000 - 100,000 rings/µl
5. The ability to attend follow-up visits
6. Informed consent provided by parent or guardian</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Months" value="6.0"/>
      <upperAgeLimit unit="Months" value="59.0"/>
      <gender>Both</gender>
      <targetEnrolment>2600</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>2600</totalTarget>
      <exclusion>1. Malnutrition, defined as a child whose weight-for-height is below -3 SDs or less than 70% of the median of the National Center for Health Statistics (NCHS)/World Health Organization (WHO) normalised reference values
2. Known history of G6PD defficiency, methaaemogloin reductase deficiency, Haemoglobin M or E, or porphyria
3. Evidence of severe malaria as defined in WHO 2000
4. Hb equal to or less than 7 g/dl
5. Hypersensitivity to biguanides (e.g. proguanil, chlorproguanil) or sulphonamides such as fancidar and septrin
6. Evidence of concomitant fibrile infection
7. Treatment with antimalarial drugs within the past 14 days or 7 days with quinine (full course), proguanil, artemisinins, tetracycline doxycycline or clindamycin. Patient shall not be excluded on the basis of reported prior treatment with other anti-malarial drugs within the past 24 hours if they have a temperature and parasitemia.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-10-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Malaria</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Malaria</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Lapdap™ versus Coartem®.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Lapdap™, Coartem®</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14960-0</funderId>
      <funderId>Funder14960-1</funderId>
      <contactId>Contact52763_14960</contactId>
      <sponsorId>Sponsor51306</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52763_14960">
    <title>Dr</title>
    <forename>Ahmed</forename>
    <surname>Bellah</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>World Health Organization
20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor51306">
    <organisation>UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) </organisation>
    <website>http://www.who.int</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>World Health Organization
20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder14960-0">
    <name>Gates Foundation (USA)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14960-1">
    <name>Glaxo SmithKline (GSK) (USA) - donating the Lapdap™ free of charge</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-17T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-03-29T00:00:00.000Z">83323477</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Bioavailability of the fixed dose formulation Rifafour containing isoniazid, rifampicin pyrazinamide, ethambutol and the World Health Organization (WHO) recommended first line antiretroviral drugs zidovudine, lamivudine, efavirenz administered to new Tuberculosis (TB) patients at different levels of immunosuppression</title>
      <scientificTitle/>
      <acronym>PK-TB-HAART</acronym>
      <studyHypothesis>The optimal time to initiate concomitant therapies is currently not known but is based on balancing the risk of HIV disease progression against the discontinuation of therapies due to toxicities, side effects and/or unforeseen drug-drug interactions. 

The study will investigate the bioavailability of anti-tuberculosis drugs and anti-retroviral drugs administered in fixed dose combinations to HIV/TB co-infected immuno-compromised individuals commencing concomitant HIV and TB therapy compared with anti-retroviral drugs administered to HIV-infected patients without clinical TB and anti-tuberculosis drugs to TB patients with HIV commencing TB therapy only, thereby determining the effects of the level of immunosuppression on the bioavailability of the drugs and any drug interactions.

Please note that ethics approval and secondary outcome measures were added to this record on 17th September 2007. Any changes are noted under this date.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To investigate the bioavailability of anti-tuberculosis drugs and anti-retroviral drugs administered in fixed dose combinations to HIV/TB co-infected immuno-compromised individuals commencing concomitant HIV and TB therapy compared with anti-retroviral drugs administered to HIV-infected patients without clinical TB and anti-tuberculosis drugs to TB patients with HIV commencing TB therapy only thereby determining the effects of the level of immunosuppression on the bioavailability of the drugs and any drug interactions.</primaryOutcome>
      <secondaryOutcome>1. Bioavailability of both Antiretroviral drugs and anti-TB drugs (rifampicin and isoniazid) as affected by CD4 count levels in co-infected TB-HIV patients (Comparison of drug levels of HAART by CD4 count stratum, stratified by presence/absence of ARVs) 
2. Bioavailability of anti TB- drugs as affected by drug-drug interactions with anti-retroviral drugs in co-infected TB-HIV patients (comparison of TB drug levels between subjects given both ARVs and anti-TB drugs and those given anti-TB drugs alone, stratified by CD4 count stratum)
3. Homogeneity between drug-drug interactions over the two CD4 strata, or extent of modification by CD4 count of the effect of drug-drug interaction
4. Bioavailability of anti-retroviral drugs as affected by drug-drug interactions with anti-TB medications (comparison of ARV drug levels between HIV infected non TB infected individuals with CD4 count less than 200 cells/ µl given only ARVs and TB/HIV co-infected subjects at the same CD4 count given both anti-TB and HAART)
5. Safety parameters - including biochemical and haematological Adverse Events (AE) and Serious Adverse Events (SAE)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Amended as of 17/09/2007:
Ethics approval received from the MRC South Africa on the 17th May 2006.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN83323477</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>A40607</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2006-05-30T00:00:00.000Z</overallStartDate>
      <overallEndDate>2008-05-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>South Africa</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="b3ddc1d7-4df9-4396-87ef-a653029efb45">
	  <name>World Health Organization</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH-1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Aged 18 to 65 years
2. Human Immunodeficiency Virus (HIV) treatment-naive patients (established by history)
3. No history of previous anti-TB chemotherapy within the previous 24 months
4. A traceable home address and contact details to facilitate home visits with a firm commitment to remain traceable and to be able to access a defined treatment/service point for 24 months
5. Not currently enrolled in any other drug or treatment trials
6. Informed consent for HIV testing and PK testing
7. Informed consent to participate in the trial
8. For female subjects, the following conditions are to be met:
8.1. Has been post-menopausal for at least one year, or
8.2. Is surgically incapable of bearing children, or
8.3. Is of childbearing potential and all of the following conditions are met:
8.3.1. Has a negative pregnancy test (urine) immediately before study entry (and later confirmed by a another pregnancy test)
8.3.2. Must agree to use an accepted method of contraception (i.e. barrier methods or intrauterine device [IUD]). The subject must agree to continue with the same method throughout the study
Note: If a patient is using a long-acting hormonal contraceptive (such as Depot-Provera), the patient can be enrolled in the study, however she should be advised to use it in conjunction with a barrier method or IUD due to the known pharmacokinetic interaction between the various study medications and hormonal contraceptives. If an oral hormonal agent is in use, the patient will be advised to change the method of contraception in favour of barrier methods. No patient will be enrolled who does not accept to use barrier methods or IUD for contraception.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>120</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>120</totalTarget>
      <exclusion>1. Evidence (laboratory and clinical history) of pre-existing non-tuberculosis disease likely to affect the response to, or assessment of treatment effects or represent contraindications to the study medication:
1.1. Diabetes mellitus
1.2. Liver impairment (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] greater than 2.5 x the upper limit of normal value)
1.3. Renal failure (serum creatinine greater than 1.5 x the upper limit of normal value)
1.4. Epilepsy
1.5. Optical neuritis
1.6. Pancreatitis (lipase greater than 1.5 x the upper limit of normal value)
1.7. Neutropenia (total neutrophil count less than 1200 cells/l)
1.8. Anaemia (haemoglobin less than 8 g/dl)
1.9. Any other condition that in the view of the country Principal Investigator represents a contraindication to the study medication
2. Mental illness (clinical suspicion of schizophrenia, manic-depressive illness, dementia)
3. Stage IV disease requiring concomitant medications that may potentially interact with study drugs (according to WHO staging system)
4. Weight below 30 kg
5. Moribund or clinical evidence of severe illness
6. Patients exposed to other medication that may (on the basis a known interaction, or a strong theoretical basis) affect study drug levels. Exclusion of a volunteer on the basis of a potential interaction will be at the discretion of the principal investigator
7. Of childbearing age and refusing to use either barrier or IUD method of contraceptive for the duration of the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2006-05-30T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2008-05-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Tuberculosis (TB) and Human immunodeficiency virus (HIV)</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Human immunodeficiency virus (HIV)</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Patients are assigned to the following groups:
1. TB/HIV co-infected (220 - 349 CD4 T cells/µl) treated with anti-TB chemotherapy and Highly Active Anti-Retroviral Therapy (HAART)
2. TB/HIV co-infected (220 - 349 CD4 T cells/µl) treated with anti-TB chemotherapy
3. TB/HIV co-infected (350 - 500 CD4 T cells/µl) treated with anti-TB chemotherapy and HAART
4. TB/HIV co-infected (350 - 500 CD4 T cells/µl) treated with anti-TB chemotherapy
5. TB/HIV co-infected (less than 200 CD4 T cells/µl) receiving anti-TB chemotherapy and HAART
6. HIV infected without active TB (less than 200 CD4 T cells/µl) receiving HAART

There are 20 patients in each arm. Patients are randomised to groups 1 - 4. In groups 5 and 6 the first 20 patients in each arm meeting the inclusion/exclusion criteria and consenting to be in the study will be included.

The trial aims:
1. To investigate whether the bioavailability of both anti-retroviral drugs and anti-TB drugs (rifampicin and isoniazid) are affected by CD4 count levels in co-infected TB-HIV patients (comparison of drug levels of highly active anti-retroviral therapy [HAART] by CD4 count stratum, stratified by presence/absence of Anti-Retrovirals [ARVs])
2. To investigate whether the bioavailability of anti-TB drugs are affected by drug-drug interactions with anti-retroviral drugs in co-infected TB-HIV patients (comparison of TB drug levels between subjects given both ARVs and anti-TB drugs and those given anti-TB drugs alone, stratified by CD4 count stratum)
3. To investigate whether the bioavailability of anti-retroviral drugs is affected by drug-drug interactions with anti-TB medications (comparison of ARV drug levels between HIV infected non-TB infected individuals with CD4 count less than 200 cells/µl given only ARVs and TB/HIV co-infected subjects at the same CD4 count given both anti-TB and HAART)

For further information please contact Dr Onyebujoh at the address listed below or Dr Melba Gomes at gomesm@who.int</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Rifafour containing isoniazid, rifampicin pyrazinamide, ethambutol and zidovudine, lamivudine, efavirenz</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14949-0</funderId>
      <funderId>Funder14949-1</funderId>
      <funderId>Funder14949-2</funderId>
      <contactId>Contact52749_14949</contactId>
      <sponsorId>Sponsor51288</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52749_14949">
    <title>Dr</title>
    <forename>Philip</forename>
    <surname>Onyebujoh</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>World Health Organization
20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 4478</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">onyebujohp@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51288">
    <organisation>World Health Organization (WHO) (Switzerland)</organisation>
    <website>http://www.who.int</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>20 Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH-1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 4478</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">onyebuhjohp@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder14949-0">
    <name>World Health Organization (WHO) (Switzerland)</name>
    <fundRef>http://dx.doi.org/10.13039/100004423</fundRef>
  </funder>
  <funder id="Funder14949-1">
    <name>GlaxoSmithKline (GSK) - drug supply</name>
    <fundRef/>
  </funder>
  <funder id="Funder14949-2">
    <name>Merck &amp; Co Inc. - drug supply</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-20T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-02-17T00:00:00.000Z">18723747</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Influence of ibuprofen-arginine on serum levels of nitric oxide metabolites in patients with chronic lower back pain: a single-blind, placebo-controlled pilot trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>The present study investigates whether ibuprofen-arginine has a cyclooxygenase-independent pain modulating property besides its known anti-inflammatory effect.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>No metabolites.</primaryOutcome>
      <secondaryOutcome>Pain intensity (VAS).</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local ethics committee (Kantonale Ethics commission Zurich) on the 8th November 2002 (ref: 427).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN18723747</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2003DR4004</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>A single-blind, placebo-controlled pilot trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-03-04T00:00:00.000Z</overallStartDate>
      <overallEndDate>2003-10-14T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="244eea26-6ebb-438e-9e9c-4ad64620ef94">
	  <name>Department of Rheumatology</name>
	  <address/>
	  <city>Zurich</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH-8091</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Non-specific chronic lower back pain (Visual Analogue Scale [VAS] greater than or equal to 60).</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>20</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>20</totalTarget>
      <exclusion>Specific lower back pain.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-03-04T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2003-10-14T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Lower back pain</description>
	<diseaseClass1>Injury, Occupational Diseases, Poisoning</diseaseClass1>
	<diseaseClass2>Lower back pain</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Ibuprofen-arginine 400 mg (verum) was administered orally once.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Ibuprofen-arginine 400 mg (verum)</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in https://pubmed.ncbi.nlm.nih.gov/17013995 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>true</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="1f3089cf-2288-41bb-8407-b8b4e77cfcae" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17013995"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14814-0</funderId>
      <contactId>Contact52586_14814</contactId>
      <sponsorId>Sponsor51111</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52586_14814">
    <title>Dr</title>
    <forename>Haiko</forename>
    <surname>Sprott</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Rheumatology
Institute of Medical Research
University Hospital of Zurich
Gloriastrasse 25</address>
      <city>Zurich</city>
      <country>Switzerland</country>
      <zip>CH-8091</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)44 255 3010</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">haiko.sprott@usz.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51111">
    <organisation>Zambon Svizzera S.A. (Switzerland)</organisation>
    <website>http://www.inpharzam.ch/</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>Via Industria 13
Casella postale 200</address>
      <city>Cadempino</city>
      <country>Switzerland</country>
      <zip>CH-6814</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)91 960 4118</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Ralf.Ruffmann@zambongroup.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487420.d</gridId>
    <rorId>https://ror.org/04zrd1t35</rorId>
  </sponsor>
  <funder id="Funder14814-0">
    <name>Zambon Svizzera S.A. (Switzerland)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-19T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-02-08T00:00:00.000Z">63217062</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effectiveness of intrauterine insemination (IUI) in subfertile couples with an isolated cervical factor: a randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>1. We hypothesised a beneficial effect of IUI in couples with an isolated cervical factor
2. Furthermore we hypothesised that the post-coital test can identify those couples who would benefit from IUI without ovarian hyperstimulation</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary endpoint was ongoing pregnancy within six months. Ongoing pregnancy was defined as the presence of foetal cardiac activity at transvaginal sonography at a gestational age of at least 12 weeks.</primaryOutcome>
      <secondaryOutcome>Secondary endpoints were total number of clinical pregnancies, miscarriages and multiple pregnancies.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN63217062</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>2</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, randomised, active controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2002-06-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="84bdb550-270a-48fb-af67-705fc644fdfa">
	  <name>Academic Medical Center</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1100 DD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Couples with a cervical factor and otherwise no factors that reduced their fertility i.e. a prognosis for a treatment independent ongoing pregnancy in the next year higher than 30%. A cervical factor was diagnosed by a well-timed, non-progressive post-coital test (PCT) with normal semen parameters.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>100</totalTarget>
      <exclusion>All other subfertile couples</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2002-06-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Subfertility</description>
	<diseaseClass1>Pregnancy and Childbirth</diseaseClass1>
	<diseaseClass2>Subfertility</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Couples were randomly allocated to IUI for six months or expectant management for six months. In the first three IUI cycles no controlled ovarian hyperstimulation (COH) was given. If these attempts failed subsequent IUI cycles were performed with COH.

Couples allocated to expectant management were followed until an ongoing pregnancy occurred within six months. If no pregnancy occurred, follow-up ended after this period. If a pregnancy miscarried, follow-up continued until the next pregnancy or the end of the six months period.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17482611 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="eea86a69-b58e-4776-861e-8e3455edcc8b" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17482611"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14749-0</funderId>
      <contactId>Contact52518_14749</contactId>
      <sponsorId>Sponsor51038</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52518_14749">
    <title>Mrs</title>
    <forename>P</forename>
    <surname>Steures</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Academic Medical Center
Center of Reproductive Medicine
OFO-project
H4-213
P.O. Box 22660</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1100 DD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)20 5663857</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">ofoproject@amc.uva.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51038">
    <organisation>Academic Medical Center Amsterdam (The Netherlands)</organisation>
    <website/>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Meibergdreef 9</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1105 AZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5650.0</gridId>
  </sponsor>
  <funder id="Funder14749-0">
    <name>The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-21T00:00:00.000Z" version="23">
    <isrctn dateAssigned="2006-02-08T00:00:00.000Z">48902136</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Surgical excision versus antibiotic treatment for non-tuberculous mycobacterial cervicofacial lymphadenitis in children (CHIMED): a multicentre randomised controlled trial</title>
      <scientificTitle/>
      <acronym>CHIMED</acronym>
      <studyHypothesis>Non-tuberculous mycobacteria (NTM) are a common cause of chronic cervicofacial lymphadenitis in children, especially between the age of 1 and 5 years.The disease is usually unilateral, occurring in the submandibular or preauricular area. The nodes suppurate and form a chronic sinus tract.

The optimal treatment of Non-Tuberculous Mycobacterial (NTM) cervical lymphadenitis in children has not been established. Until recently surgical excision was the standard treatment, but the number of reports of successful antibiotic treatment is increasing, questioning surgery as the preferred treatment. In this randomised, multicenter trial we compared surgical excision to antibiotic treatment.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Primary endpoint was cure, defined as regression of the enlarged lymph node by at least 75%, with cure of the fistula and total skin closure without local recurrence or de novo lesions at six months, as assessed by clinical and ultrasound evaluation.</primaryOutcome>
      <secondaryOutcome>Secondary outcome measures were surgical complications and side effects of the medication.</secondaryOutcome>
      <trialWebsite>http://www.mycobacterie.nl</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from Medical Ethics Committee (MEC) ont he 1st November 2001 (ref: 00/182).</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN48902136</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>945-02-019</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, multicentre clinical trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>GP practice</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2001-09-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-12-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="fd15643f-60f0-44ba-bef6-321398bbdb96">
	  <name>A1-1</name>
	  <address/>
	  <city>Amsterdam</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>1105  AZ</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Children between 0 - 15 years old with a possible NTM lymphadenitis were referred by pediatricians, otolaryngologists, oral and maxillofacial surgeons and general practitioners from all over the country.

Inclusion criteria: an enlarged cervicofacial lymphadenitis for a period longer than three weeks, with negative serology for other infectious causes of chronic lymphadenitis (Cytomegalo Virus [CMV], Epstein-Barr Virus [EBV], adenovirus, bartonella and toxoplasmosis).</inclusion>
      <ageRange>Child</ageRange>
      <lowerAgeLimit unit="Years" value="0.0"/>
      <upperAgeLimit unit="Years" value="15.0"/>
      <gender>Both</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>100 patients with NTM cervical lymphadenitis</totalTarget>
      <exclusion>Excluded were immunocompromised patients and patients using immunosuppressive drugs.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2001-09-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-12-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Chronic cervicofacial lymphadenitis</description>
	<diseaseClass1>Circulatory System</diseaseClass1>
	<diseaseClass2>Lymphadenitis</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>To compare surgical excision of involved lymph nodes with antibiotic therapy consisting of a three-month course of Clarithromycin and Rifabutin.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Clarithromycin, rifabutin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Other publications in https://pubmed.ncbi.nlm.nih.gov/15184446
2005 Other publications in https://pubmed.ncbi.nlm.nih.gov/15705324
2005 Other publications in https://pubmed.ncbi.nlm.nih.gov/16267728</publicationDetails>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="c06f78b0-23f9-4b6d-b2bd-7a01213f9410" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2004-06-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15184446"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="312d1825-d233-4e77-94d8-5c92630ccf04" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2005-01-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15705324"/>
	<description/>
	<productionNotes/>
      </output>
      <output id="bce4b393-ba21-44f7-9daf-c53baa357b87" outputType="otherpublications" artefactType="ExternalLink" dateCreated="2005-12-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/16267728"/>
	<description/>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14731-0</funderId>
      <contactId>Contact52493_14731</contactId>
      <sponsorId>Sponsor51008</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52493_14731">
    <title>Dr</title>
    <forename>Jerome</forename>
    <surname>Lindeboom</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>A1-1
Meibergdreef 9
Department of Oral and Maxillofacial Surgery
Academic Medical Center</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>1105  AZ</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
  </contact>
  <sponsor id="Sponsor51008">
    <organisation>The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands) </organisation>
    <website>http://www.zonmw.nl</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>Laan van Nieuw Oost-Indie 334</address>
      <city>Den Haag</city>
      <country>Netherlands</country>
      <zip>2509 AE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)70 3495259</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">bijlsma@zonmw.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.438427.e</gridId>
    <rorId>https://ror.org/01yaj9a77</rorId>
  </sponsor>
  <funder id="Funder14731-0">
    <name>The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands) (ref: 945-02-019)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-10-02T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-02-01T00:00:00.000Z">85737357</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Intermittent malaria treatment and iron supplementation for the control of malaria and anaemia in infants in the Forest Belt of rural Ghana: a double-blind randomised controlled trial</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>To establish whether preventive treatment or iron supplementation given at EPI prevented either severe anaemia or malaria.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1. To assess the effectiveness of intermittent malaria treatment (1.25 mg pyrimethamine plus 25 mg sulfadoxine/kg) given at  10 weeks, 14 weeks and 9 months through the EPI programme in the control of malaria and severe anaemia in infancy
2. To determine the effect of intermittent malaria treatment in infancy on the risk of malaria and anaemia in childhood after completion of trial
3. To evaluate the effect of daily iron supplementation (2 mg/kg) given from 10 weeks to 12 months through the EPI programme on the control of malaria and severe anaemia
4. To assess the socio-cultural factors influencing acceptability of treatment modalities 
5. To evaluate the cost effectiveness of interventions</primaryOutcome>
      <secondaryOutcome>No secondary outcome measures</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received on the 17th June 1999.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN85737357</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>980643</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>1999-06-17T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-06-17T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Ghana</country>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="8263f984-cc13-47d9-8801-a317d17b67e1">
	  <name>20, Avenue Appia</name>
	  <address/>
	  <city>Geneva-27</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>CH 1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>All infants aged at least 10 weeks attending a Mother and Child Health (MCH) Clinic or Child Welfare Clinic (CWC) in the Afigya-Sekyere District, Ashanti Region and are permanent residents in the district. Their mothers or main carers should have given informed consent to participate in the trial.</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>1800</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>450 infants/arm - 1800 infants in total randomised</totalTarget>
      <exclusion>Infants who are not permanent residents of Afigya-Sekyere District, Ashanti Region.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>1999-06-17T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-06-17T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Malaria</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Malaria</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Double blind placebo controlled trial. One of the following treatments given to children at the time of DPT2, DPT3 and measles vaccination:
1. Iron supplementation and placebo
2. Placebo and sulphadoxine pyrimethamine
3. Iron supplementation and sulphadoxine pyrimethamine</description>
	<interventionType>Supplement</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Iron supplementation, sulphadoxine pyrimethamine</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14724-0</funderId>
      <contactId>Contact52486_14724</contactId>
      <sponsorId>Sponsor51001</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52486_14724">
    <title>Dr</title>
    <forename>Melba</forename>
    <surname>Gomes</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 791 3813</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">gomesm@who.int</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor51001">
    <organisation>UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) </organisation>
    <website>http://www.who.int/</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>20, Avenue Appia</address>
      <city>Geneva-27</city>
      <country>Switzerland</country>
      <zip>CH 1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.3575.4</gridId>
    <rorId>https://ror.org/01f80g185</rorId>
  </sponsor>
  <funder id="Funder14724-0">
    <name>United Nations Children's Fund (UNICEF)/United Nations Development Programme (UNDP)/World Bank/World Health Organization (WHO) - Special Programme for Research and Training in Tropical Diseases (TDR)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-21T00:00:00.000Z" version="21">
    <isrctn dateAssigned="2006-01-25T00:00:00.000Z">87984926</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Atorvastatin treatment and vaccination efficacy</title>
      <scientificTitle/>
      <acronym/>
      <studyHypothesis>Statin treatment may modulate, either negatively or positively, antibody responses to vaccination antigens.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The main outcome variable was the achievement of antibody levels greater than 20 IU/l against the hepatitis A virus one month after vaccination.</primaryOutcome>
      <secondaryOutcome>1. A secondary outcome variable was the mean log-transformed antibody titre 
2. To document the effects of atorvastatin on total blood cholesterol, Low Density Lipoprotein Cholesterol (LDL-C), High Density Lipoprotein Cholesterol (HDL-C), triglycerides, and high-sensitivity C-Reactive Protein (hs-CRP)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The protocol was approved by the Ethics Committee of the Geneva University Hospital (CE-04-029) and written informed consent was obtained from all participants</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN87984926</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Interventional, double-blind, randomised, placebo-controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2004-11-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-06-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Switzerland</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="891ab170-269e-4c50-87af-e41c413a0510">
	  <name>Cardiology Division</name>
	  <address/>
	  <city>Geneva</city>
	  <state/>
	  <country>Switzerland</country>
	  <zip>1211</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Men and women who were greater than 18 years old were eligible for inclusion if they had neither morbidities nor immunity to hepatitis A</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>312</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>312</totalTarget>
      <exclusion>1. Anti-hepatitis A antibodies greater than 10 IU/l
2. Hypercholesterolemia
3. Hepatitis
4. Myositis
5. Chronic alcohol abuse
6. Pregnant or breast-feeding women
7. Volunteers on drug therapy except oral contraceptives</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2004-11-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-06-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Hepatitis A</description>
	<diseaseClass1>Infections and Infestations</diseaseClass1>
	<diseaseClass2>Hepatitis A</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Subjects were immunised against hepatitis A and subsequently received atorvastatin (40 mg per day) or placebo for a period of 28 days after immunisation.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Atorvastatin</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder14628-0</funderId>
      <funderId>Funder14628-1</funderId>
      <contactId>Contact52385_14628</contactId>
      <sponsorId>Sponsor50896</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52385_14628">
    <title>Prof</title>
    <forename>Francois</forename>
    <surname>Mach</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Cardiology Division
Geneva University Hospital
24 Rue Micheli-du-Crest</address>
      <city>Geneva</city>
      <country>Switzerland</country>
      <zip>1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 382 72 34</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">francois.mach@medecine.unige.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50896">
    <organisation>Geneva University Hospital (Switzerland)</organisation>
    <website>http://www.cardiology-geneva</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>Cardiology Division
24 rue Micheli-du-Crest</address>
      <city>Geneva</city>
      <country>Switzerland</country>
      <zip>1211</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+41 (0)22 372 72 00</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">marjorie.burkhard@hcuge.ch</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.150338.c</gridId>
    <rorId>https://ror.org/01m1pv723</rorId>
  </sponsor>
  <funder id="Funder14628-0">
    <name>Geneva University Hospital (Switzerland) - Department of Medicine</name>
    <fundRef/>
  </funder>
  <funder id="Funder14628-1">
    <name>University of Geneva Cardiology Foundation (GECOR) (Switzerland) - had no role in the study design, analysis of data or report writing</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-07-03T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2006-01-18T00:00:00.000Z">46117662</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Comparison of the equivalence of ceftriane plus azithromycin or doxycycline for the treatment of pelvic inflammatory disease</title>
      <scientificTitle/>
      <acronym>DAZ</acronym>
      <studyHypothesis>1 g of azithromycin once a week for two weeks is equivalent to 14 days of 200 mg doxycycline per day.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>The primary outcome for the trial is clinical cure, defined as improvement or absence of the initial pain at day 14 compared to baseline.</primaryOutcome>
      <secondaryOutcome>1. A clinical cure, defined as 70% or greater reduction in the total tenderness score at day 14 compared to baseline
2. Histological cure defined as absence of plasma cell per X120 field in the endometrial stroma and &lt;5 neutrophils per X400 field in the endometrial surface
3. Absence of Neisseria gonorrhea and Chlamydia trachomatis on endometrial samples on day 30 by PCR techniques</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Hospital de Clinicas de Porto Alegre (HCPA) Institutional Review Board (ref: IRB0000921)</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN46117662</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>03-006</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomized double-blinded placebo trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-08-10T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-05-10T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Brazil</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="60d73c57-815a-413d-8764-5f05f2e6165e">
	  <name>Rua Ramiro Barcelos, 2350/1125</name>
	  <address/>
	  <city>Porto Alegre</city>
	  <state/>
	  <country>Brazil</country>
	  <zip>90035-003</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. A history of pelvic discomfort for a period of 30 days or less
2. Findings of pelvic organ tenderness (uterine or adnexal) on bimanual examination
3. Leukorrhea and/or mucopurulent cervicitis and/or untreated known positive gonococcal or chlamydial cervicitis</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Female</gender>
      <targetEnrolment>112</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>112</totalTarget>
      <exclusion>1. Current pregnancy as demonstrated by beta-Human Chorionic Gonadotrophin (HCG) or ultrasonography
2. Inability to tolerate an outpatient oral regimen as demonstrated by the vomiting of eight ounces of water one hour after taking 10 mg of metoclopramide
3. Presence of tubo-ovarian abscess, appendicitis or hemorrhagic ovarian cysts confirmed by ultrasound or laparoscopy
4. Pelvic pain over 30 days duration
5. Allergy to ceftriaxone, azithromycin or doxycycline
6. Antimicrobial therapy within seven days of recruitment
7. Delivery, abortion or gynecological surgery within 30 days
8. Prior hysterectomy or bilateral salpingectomy
9. Homelessness
10. Fever
11. Abdominal rebound tenderness</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-08-10T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-05-10T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Pelvic inflammatory disease</description>
	<diseaseClass1>Urological and Genital Diseases</diseaseClass1>
	<diseaseClass2>Pelvic inflammatory disease</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Eligible patients were invited to participate in the doxycycline azithromycin protocol (DAZ). After giving written consent, a standardized interview, examination and specimen collection techniques were taken. Only three researchers will perform the physical exams. Whenever possible, the researcher that performed the first clinical examination on the first visit also did follow up on that patient.
A standardized screening examination, including a visual pain scale (0-10), and the McCormick modified pain scale was performed in the same sequence by the three researchers. A complete blood count, endometrial biopsy, urinalysis, and erythrocyte sedimentation rate will be performed on the first visit.
Endometrial samples will be divided into two equal amounts. One will be snap frozen in liquid nitrogen for Polymerase Chain Reaction (PCR) analysis and the other will be fixed in formaldehyde for histological analysis.
After the initial interview, the patient will receive a parenteral 250 mg ceftriaxone injection and will be randomly allocated to one of two treatment groups.

Randomization and treatment:
A restricted randomization sequence list was generated by computer, and was kept concealed from the researcher until the moment of assignment. We will consider subjects in blocks of four at a time to create the allocation sequence. After the patient is enrolled in the protocol, she will be blindly assigned to a coded treatment, either 14 days doxycycline or 1 g of azithromycin per week for two weeks. To avoid bias, the medication will be manipulated by the hospital pharmacy and will be put in identically coded blisters (treatment A, treatment B). To confirm compliance, a treatment of just seven days will be given to the patient, forcing her to return in seven days to receive the rest of the treatment. Because of the difference in the amount of capsules in each treatment, the azithromycin blister was filled up with placebo.
In the first visit, the patient will receive 250 mg intramuscular ceftriaxone and a blister for seven days treatment. The first dose of the medication (1 g of azythromycin, or 200 mg of doxycycline) will be taken in front of the physician. She will receive a leaflet and instructions of how she should take the rest of the medication. Special attention was taken about warning against taking the medication on an empty stomach, using analgesics, and abstaining from sexual intercourse until the treatment was completed. All women will be advised to have their partner treated with 1 g of azithromycin.

Endometrial biopsy and definition of endometritis:
The endometrial biopsy was performed at the office using a Karman plastic curette (MedGyn Products Inc., Lombard, IL, USA). Histopathological endometritis was defined by the presence of  ≥1 plasma cell per X120 field in the endometrial stroma plus ≥5 neutrophils per X400 field in the endometrial surface.
PCR techniques will be used to investigate the presence of Neisseria gonorrhea and Chlamydia trachomatis in the endometrial samples.

Follow-up and adherence:
Participants will be monitored with in-person visits at 2, 7, 14 and 30 days. In each visit, the gynecological examination and the assessment of the pain will be registered. On day 7, the patient will return the first blister and receive the second one. Again, the first dose will be taken in front of the physician. On day 14, she will return the second blister. Adherence will be checked by absence of capsules in each blister. On day 30, another endometrial biopsy will be performed to measure histological cure and blood tests will be repeated.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Ceftriane, azithromycin and doxycycline</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17601896 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="46de5042-8aab-407e-824e-7cd7f0713018" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-07-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17601896"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14275-0</funderId>
      <contactId>Contact52016_14275</contactId>
      <sponsorId>Sponsor50476</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52016_14275">
    <title>Prof</title>
    <forename>Ricardo</forename>
    <surname>Savaris</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Rua Ramiro Barcelos, 2350/1125</address>
      <city>Porto Alegre</city>
      <country>Brazil</country>
      <zip>90035-003</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">rsavaris@hcpa.ufrgs.br</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50476">
    <organisation>Foundation for the Incentive of Research (Fundacao de Incentivo a Pesquisa) (FIPE) (Brazil)</organisation>
    <website>http://www.hcpa.ufrgs.br/default.asp?sacao=Institucional&amp;sPagina=96&amp;gSysCodigoConexao=</website>
    <sponsorType>Charity</sponsorType>
    <contactDetails>
      <address>Rua Ramiro Barcelos 2350/2
Andar</address>
      <city>Porto Alegre</city>
      <country>Brazil</country>
      <zip>90035-003</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">l-cpesquisas@hcpa.ufrgs.br</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.470786.a</gridId>
    <rorId>https://ror.org/040y74d88</rorId>
  </sponsor>
  <funder id="Funder14275-0">
    <name>Foundation for the Incentive of Research (Fundacao de Incentivo a Pesquisa) (FIPE) (Brazil)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-09-21T00:00:00.000Z" version="20">
    <isrctn dateAssigned="2006-01-09T00:00:00.000Z">67437862</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>A randomised, double-blind, placebo-controlled study of Glypromate® in patients undergoing coronary artery bypass graft surgery</title>
      <scientificTitle/>
      <acronym>SNUG (Studying Neurons Using Glypromate®)</acronym>
      <studyHypothesis>Study is designed:
1. To determine the pharmacokinetics of Glypromate® in patients undergoing Coronary Artery Bypass Graft (CABG) surgery with/without valve replacement/repair
2. To show that Glypromate® use is not associated with major adverse events when compared to placebo in people undergoing CABG surgery</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>To determine the pharmacokinetics of Glypromate® in patients undergoing CABG surgery to assess dose-response relationships.</primaryOutcome>
      <secondaryOutcome>To monitor the safety profile of Glypromate® treatment compared to placebo in patients undergoing CABG. Data will be collected through to discharge or day 14 whichever comes first.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN67437862</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>Neu-GPE-CABG-001</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-09-26T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-02-28T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>New Zealand</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0a0f92a8-60ad-4e6c-965a-e0d6dad614f8">
	  <name>University of Auckland</name>
	  <address/>
	  <city>Auckland</city>
	  <state/>
	  <country>New Zealand</country>
	  <zip>1031</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Participants must meet all of the following criteria:
1. Be at least 60 years of age
2. Be scheduled for non-urgent, on-pump CABG surgery
3. Be willing to provide written informed consent
4. Be agreeable to be undergo all study tests (collection of blood for PK assessment)

The Glypromate®/placebo infusion will be commenced at the start of chest closure providing the following criteria are met:
1. The patient has been successfully weaned off the bypass pump
2. The patient does not have an Intra-Aortic Balloon Pump (IABP)
3. The anaesthetist has assessed the patient as having no contraindications to receiving Glypromate®/placebo medication</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>30</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>30</totalTarget>
      <exclusion>A participant will be ineligible if he/she meets any of the following criteria:
1. Body weight less than 55 kg or more than 120 kg
2. Scheduled to undergo a significant concomitant surgical procedure (e.g. carotid endarterectomy, aortic root repair or replacement, Deep Hypothermic Circulatory Arrest [DHCA] or pulmonary resection)
3. Has a pre or perioperative mechanical assist device or IABP inserted for shock/low output syndrome
4. Renal insufficiency (serum creatinine greater than 0.17 mmol/l) or renal failure requiring dialysis
5. Chronic hepatic failure and/or cirrhosis
6. History of significant haematologic or coagulation disorders, including thrombocytopenia (platelet count less than 50,000), known hypercoagulable state, or recurrent deep vein thrombosis
7. Current participation or participation within the seven days prior to the start of this study in another investigational drug or device study
8. History of or any current condition that in the investigator's opinion would interfere with study participation or evaluation of results</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-09-26T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-02-28T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Coronary Artery Bypass Graft (CABG) surgery</description>
	<diseaseClass1>Surgery</diseaseClass1>
	<diseaseClass2>Coronary Artery Bypass Graft (CABG) surgery</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>This phase two study will be conducted in two stages:

In stage 1 (conducted at the Principal Investigator's site only), patients will be randomised in a 1:1 fashion to receive intravenous (IV) Glypromate® 1 mg/kg/hr for four hours or 3 mg/kg/hr for four hours. Two to four patients are expected to be enrolled into this open-label stage of the study.

In stage 2, participants from five centres will be randomised in a 1:1:1 fashion to receive IV Glypromate® 1 mg/kg/hr for four hours or IV Glypromate® 3 mg/kg/hr over four hours or IV Placebo (normal saline) for four hours. The Glypromate®/Placebo infusion will commence at the start of chest closure.

Participants will be observed from randomisation through to discharge or day 14, whichever comes sooner.</description>
	<interventionType>Drug</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Phase II</phase>
	<drugNames>Glypromate®</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails/>
      <publicationStage/>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
        
      </outputs>
    <parties>
      <funderId>Funder13735-0</funderId>
      <funderId>Funder13735-1</funderId>
      <funderId>Funder13735-2</funderId>
      <funderId>Funder13735-3</funderId>
      <contactId>Contact51422_13735</contactId>
      <sponsorId>Sponsor49825</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact51422_13735">
    <title>Prof</title>
    <forename>Alan</forename>
    <surname>Merry</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>University of Auckland
Mercy Hospital
98 Mountain Road
Epsom</address>
      <city>Auckland</city>
      <country>New Zealand</country>
      <zip>1031</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+64 (0)9 623 5700</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">a.merry@auckland.ac.nz</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor49825">
    <organisation>Neuren Pharmaceuticals Limited (New Zealand)</organisation>
    <website>http://www.neurenpharma.com</website>
    <sponsorType>Industry</sponsorType>
    <contactDetails>
      <address>P.O. Box 9923
Newmarket</address>
      <city>Auckland</city>
      <country>New Zealand</country>
      <zip>1031</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+64 (0)9 367 7167 ext 89771</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">mscott@neurenpharma.com</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.487323.9</gridId>
    <rorId>https://ror.org/0503fq502</rorId>
  </sponsor>
  <funder id="Funder13735-0">
    <name>Grant from a New Zealand Government Agency, Foundation for Research Science and Technology.</name>
    <fundRef/>
  </funder>
  <funder id="Funder13735-1">
    <name>Grant type: Technology for Business Growth</name>
    <fundRef/>
  </funder>
  <funder id="Funder13735-2">
    <name>Grant title: Implementation for Phase II for Glypromate</name>
    <fundRef/>
  </funder>
  <funder id="Funder13735-3">
    <name>Study is also internally funded by Neuren Pharmaceuticals Limited (New Zealand)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-04T00:00:00.000Z" version="25">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">52543592</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Efficacy of transfusions with platelets stored in platelet additive solution II versus plasma</title>
      <scientificTitle>A multicenter randomised study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma</scientificTitle>
      <acronym/>
      <studyHypothesis>Utilisation of platelets stored in additive solutions has several advantages. A former Randomised Controlled Trial (RCT) testing platelets stored in platelet additive solution II versus plasma excluded patients with factors of increased platelet consumption. In this study also this category of patients are included and we expect to find differences in outcome, as compared to the previous study.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>1- and 24-hour corrected count increment.</primaryOutcome>
      <secondaryOutcome>1. Bleeding complications
2. Transfusion reactions
3. Transfusion interval</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>The study protocol was approved by the Leiden University Medical Center and HagaZiekenhuis ethics committees and conducted according to the Guidelines of Good Clinical Practice.</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN52543592</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>P03.113</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, randomised, double blinded, active controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-10-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2005-04-30T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="def5a331-7199-4947-8d61-0992295f2d3c">
	  <name>Leyenburg Hospital,</name>
	  <address/>
	  <city>Den Haag</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>2504 LN</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Patients greater than 18 years expected to receive platelet transfusions.</inclusion>
      <ageRange>Adult</ageRange>
      <lowerAgeLimit unit="Years" value="18.0"/>
      <gender>Both</gender>
      <targetEnrolment>195</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>195</totalTarget>
      <exclusion>HLA- and/or HPA allo-immunisation</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-10-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2005-04-30T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Platelet transfusion</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Transfusion</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Platelet transfusion, trigger based.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in https://pubmed.ncbi.nlm.nih.gov/16825492 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="be13d427-03d4-43cc-8d4e-2c8868e51f71" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-11-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/16825492"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14500-0</funderId>
      <contactId>Contact52162_14500</contactId>
      <sponsorId>Sponsor50712</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52162_14500">
    <title>Dr</title>
    <forename>J.L.H</forename>
    <surname>Kerkhoffs</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Leyenburg Hospital,
Department of Hematology,
P.O. Box 40551</address>
      <city>Den Haag</city>
      <country>Netherlands</country>
      <zip>2504 LN</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">JeanLouis.Kerkhoffs@bloodrtd.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50712">
    <organisation>Leyenburg Hospital (The Netherlands) - Department of Hematology</organisation>
    <website/>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>P.O. Box 40551</address>
      <city>Den Haag</city>
      <country>Netherlands</country>
      <zip>2504 LN</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.413591.b</gridId>
    <rorId>https://ror.org/03q4p1y48</rorId>
  </sponsor>
  <funder id="Funder14500-0">
    <name>Not provided at time of registration</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-12-04T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">48093674</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Transfusion induced complications = transfusion associated complications? study</title>
      <scientificTitle>The effects of leukocyte filtered versus buffy coat depleted erythocyte transfusions in major surgery patients</scientificTitle>
      <acronym>TACTICS</acronym>
      <studyHypothesis>Does removal of allogeneic white blood cells by filtration reduce postoperative complications?</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Postoperative:
1. In-hospital mortality
2. Duration of intensive care stay</primaryOutcome>
      <secondaryOutcome>1. Postoperative multi organ failure
2. Postoperative infections
3. Length of hospital stay
4. Costs/benefits of universal leukocyte depletion for the Dutch health care
5. Role of perioperative medication

Follow up :
1. Long term survival
2. Cancer recurrence in GI patients
3. Predictive role of cytokines and related genes</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN48093674</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>n/a</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, randomised, double blinded, active controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Hospital</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2000-03-23T00:00:00.000Z</overallStartDate>
      <overallEndDate>2001-12-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="0d866563-6d00-4802-9cfc-a065aee450f6">
	  <name>Sanquin Blood Supply Foundation</name>
	  <address/>
	  <city>Leiden</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>2310 CD</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>Acute aneurysm-, elective aneurysm-, orthopaedic- and large gastro-intestinal surgery patients.</inclusion>
      <ageRange>Adult</ageRange>
      <gender>Both</gender>
      <targetEnrolment>1548</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>1548</totalTarget>
      <exclusion>1. Under 18 years of age
2. Transfusions received within 3 months prior to inclusion
3. Pre existing medical indication for filtered red blood cell transfusions</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2000-03-23T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2001-12-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Blood transfusions complications</description>
	<diseaseClass1>Signs and Symptoms</diseaseClass1>
	<diseaseClass2>Blood transfusions</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Transfusions of filtered red blood cell concentrates versus transfusion of stored buffy coat depleted red blood cell concentrates.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2004 Results article in https://pubmed.ncbi.nlm.nih.gov/15142885 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="5c1e9b42-ce5c-478d-bd72-7f4d3ee43b53" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2004-05-29T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/15142885"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14510-0</funderId>
      <funderId>Funder14510-1</funderId>
      <contactId>Contact52156_14510</contactId>
      <sponsorId>Sponsor50754</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52156_14510">
    <title>Dr</title>
    <forename>J.A.</forename>
    <surname>Hilten, van</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Sanquin Blood Supply Foundation
P.O. Box 2184</address>
      <city>Leiden</city>
      <country>Netherlands</country>
      <zip>2310 CD</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)71 5685060</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">Joost.vanhilten@bloodrtd.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50754">
    <organisation>Leiden University Medical Centre (LUMC) (Netherlands)</organisation>
    <website>http://www.lumc.nl/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Albinusdreef 2
P.O. Box 9600</address>
      <city>Leiden</city>
      <state/>
      <country>Netherlands</country>
      <zip>2300 RC</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5132.5</gridId>
    <rorId>https://ror.org/027bh9e22</rorId>
  </sponsor>
  <funder id="Funder14510-0">
    <name>The Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14510-1">
    <name>Sanquin Bloodbank Amsterdam (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-09T00:00:00.000Z" version="24">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">17616323</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Oral vitamin B12 supplementation and cognitive performance in elderly people</title>
      <scientificTitle/>
      <acronym>Brain12 study</acronym>
      <studyHypothesis>Counteract the process of cognitive impairment in elderly people with mild vitamin B12 deficiency through oral supplementation with vitamin B12 or a combination of vitamin B12 with folic acid</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Cognitive performance.</primaryOutcome>
      <secondaryOutcome>Blood biochemistry.</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN17616323</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised, double blinded, placebo controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2003-05-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2004-10-31T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="1a4defcb-ece4-4701-bd32-b3af17793199">
	  <name>Wageningen University,</name>
	  <address/>
	  <city>Wageningen</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>6700 EV</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Men and women aged 70 years or older
2. Mild vitamin B12 deficiency defined as vitamin B12 concentration between 100 and 300 picomol/L and MMA concentration greater than 0.32 micromol/L and creatinine concentration less than 120 micromol/L</inclusion>
      <ageRange>Senior</ageRange>
      <gender>Both</gender>
      <targetEnrolment>195</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>195</totalTarget>
      <exclusion>1. Severe cognitive impairment
2. Anemia
3. Gastrointestinal surgery
4. Use of vitamin B12 injections or supplements containing &gt; 50 micrograms vitamin B12 and/or 25 micrograms folic acid
5. Less than 90% compliance during a 2 week placebo run in period
6. No written informed consent
7. Participation in other studies</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2003-05-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2004-10-31T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Vitamin B12 deficiency</description>
	<diseaseClass1>Nutritional, Metabolic, Endocrine</diseaseClass1>
	<diseaseClass2>Vitamin B12 deficiency</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>1. 1,000 microgram vitamin B12/day
2. 1,000 microgram vitamin B12 and 400 microgram folic acid/day
3. Placebo</description>
	<interventionType>Supplement</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames>Vitamin B12, folic acid</drugNames>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2006 Results article in https://pubmed.ncbi.nlm.nih.gov/16895884 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="51d2c940-f376-4a4f-9b39-cc183be83d1b" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2006-08-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/16895884"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14512-0</funderId>
      <funderId>Funder14512-1</funderId>
      <funderId>Funder14512-2</funderId>
      <contactId>Contact52235_14512</contactId>
      <sponsorId>Sponsor50733</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52235_14512">
    <title>Dr</title>
    <forename>Simone</forename>
    <surname>Eussen</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Wageningen University,
Division of Human Nutrition
P.O. Box 8129</address>
      <city>Wageningen</city>
      <country>Netherlands</country>
      <zip>6700 EV</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)317 485395</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">simone.eussen@wur.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50733">
    <organisation>The Netherlands Organisation for Health Research and Development (ZonMw) (Netherlands)</organisation>
    <website>http://www.zonmw.nl</website>
    <sponsorType>Research organisation</sponsorType>
    <contactDetails>
      <address>P.O. Box 93245</address>
      <city>Den Haag</city>
      <state/>
      <country>Netherlands</country>
      <zip>2509 AE</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)70 349 5111</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">info@zonmw.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.438427.e</gridId>
    <rorId>https://ror.org/01yaj9a77</rorId>
  </sponsor>
  <funder id="Funder14512-0">
    <name>Nutricia Research Foundation (The Netherlands)</name>
    <fundRef>http://dx.doi.org/10.13039/501100001720</fundRef>
  </funder>
  <funder id="Funder14512-1">
    <name>European Union BIOMED (Europe)</name>
    <fundRef/>
  </funder>
  <funder id="Funder14512-2">
    <name>Kelloggs' Benelux (Belgium)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-11-07T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">77274716</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>The effects of a functional fitness training in children with cerebral palsy</title>
      <scientificTitle/>
      <acronym>FITPRO-CP</acronym>
      <studyHypothesis>Children with cerebral palsy will benefit from functional fitness training.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Aerobic capacity.</primaryOutcome>
      <secondaryOutcome>1. Activities of daily life
2. Participation
3. Competence
4. Quality of life</secondaryOutcome>
      <trialWebsite>http://www.netchild.nl</trialWebsite>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Ethics approval received from the local medical ethics committee</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN77274716</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>05-092</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Multicentre, randomised, single blinded, active controlled, parallel group trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Treatment</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-10-15T00:00:00.000Z</overallStartDate>
      <overallEndDate>2006-06-15T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="9e626677-cf0b-4b84-bd7e-7c2f428e1f3e">
	  <name>Revalidatiecentrum De Hoogstraat</name>
	  <address/>
	  <city>Utrecht</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>3583 TM</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Cerebral palsy
2. Gross Motor Function Classification System (GMFCS) I or II
3. Age 7 - 20 years
4. Informed consent</inclusion>
      <ageRange>Not Specified</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>100</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>100</totalTarget>
      <exclusion>1. Cardiac or respiratory conditions that may be affected by exercise
2. Surgical or orthopaedic procedures during or up to three months prior to the study</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-10-15T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2006-06-15T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Cerebral parese (cerebral palsy)</description>
	<diseaseClass1>Nervous System Diseases</diseaseClass1>
	<diseaseClass2>Cerebral palsy</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Fitness programme that consists of functional exercises. 45 minutes fitness training twice a week for 8 months.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17984410 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="8a21e65c-59a9-4668-a23d-cc54e08428f9" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-11-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17984410"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14343-0</funderId>
      <contactId>Contact52214_14343</contactId>
      <sponsorId>Sponsor50571</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52214_14343">
    <title>Dr</title>
    <forename>Olaf</forename>
    <surname>Verschuren</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Revalidatiecentrum De Hoogstraat
Rembrandtkade 10</address>
      <city>Utrecht</city>
      <country>Netherlands</country>
      <zip>3583 TM</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 2561211</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">o.verschuren@dehoogstraat.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50571">
    <organisation>University Medical Center Utrecht (The Netherlands)</organisation>
    <website>http://www.umcutrecht.nl/zorg/</website>
    <sponsorType>Hospital/treatment centre</sponsorType>
    <contactDetails>
      <address>WKZ, Department of Pediatric Physiotherapy
Lundlaan 6</address>
      <city>Amsterdam</city>
      <country>Netherlands</country>
      <zip>3584 EA</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)30 2504030</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">p.j.m.helders@umcutrecht.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
    <gridId>grid.7692.a</gridId>
    <rorId>https://ror.org/0575yy874</rorId>
  </sponsor>
  <funder id="Funder14343-0">
    <name>Dr WM Phelps-Stichting Voor Spastici (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial><fullTrial>
  <trial lastUpdated="2007-08-03T00:00:00.000Z" version="22">
    <isrctn dateAssigned="2005-12-20T00:00:00.000Z">12757724</isrctn>
    <trialDescription thirdPartyFilesAcknowledgement="false">
      <acknowledgment>true</acknowledgment>
      <title>Creating and maintaining functional residual capacity in preterm neonates with Respiratory Distress Syndrome (RDS)</title>
      <scientificTitle/>
      <acronym>EFURCI</acronym>
      <studyHypothesis>A sustained inflation with a mechanical device and early nasal continuous positive airway pressure is a more effective management strategy for RDS in preterm infants than conventional intervention with a self-inflating mask and bag, and reduces the requirement for mechanical ventilation and surfactant treatment.</studyHypothesis>
      <plainEnglishSummary>Not provided at time of registration</plainEnglishSummary>
      <primaryOutcome>Need of endotracheal intubation within 3 days after birth.</primaryOutcome>
      <secondaryOutcome>1. Death
2. Bronchopulmonary Dysplasia (BPD)</secondaryOutcome>
      <trialWebsite/>
      <ethicsApprovalRequired>Old ethics approval format</ethicsApprovalRequired>
      <ethicsCommittees/>
      <ethicsApproval>Not provided at time of registration</ethicsApproval>
    </trialDescription>
    <externalRefs>
      <doi>10.1186/ISRCTN12757724</doi>
      <eudraCTNumber/>
      <irasNumber/>
      <clinicalTrialsGovNumber/>
      <protocolSerialNumber>N/A</protocolSerialNumber>
    </externalRefs>
    <trialDesign>
      <studyDesign>Randomised controlled trial</studyDesign>
      <primaryStudyDesign>Interventional</primaryStudyDesign>
      <secondaryStudyDesign>Randomised controlled trial</secondaryStudyDesign>
      <trialSettings>
	<trialSetting>Not specified</trialSetting>
      </trialSettings>
      <trialTypes>
	<trialType>Not Specified</trialType>
      </trialTypes>
      <overallStatusOverride/>
      <reasonAbandoned/>
      <overallStartDate>2005-04-01T00:00:00.000Z</overallStartDate>
      <overallEndDate>2007-07-01T00:00:00.000Z</overallEndDate>
    </trialDesign>
    <participants>
      <recruitmentCountries>
	<country>Netherlands</country>
      </recruitmentCountries>
      <trialCentres>
	<trialCentre id="14ef1c34-e6e3-44e6-8f6b-968666e96b35">
	  <name>Department of Pediatrics, Leiden University Medical Center, J6-S, P.O. Box 9600</name>
	  <address/>
	  <city>Leiden</city>
	  <state/>
	  <country>Netherlands</country>
	  <zip>2300 RC</zip>
	</trialCentre>
      </trialCentres>
      <participantTypes>
	<participantType>Patient</participantType>
      </participantTypes>
      <inclusion>1. Preterm neonates
2. Gestational age range 25 - 32 weeks (more than 24 weeks and 6 days and not more than 32 weeks and 6 days)</inclusion>
      <ageRange>Neonate</ageRange>
      <gender>Not Specified</gender>
      <targetEnrolment>200</targetEnrolment>
      <totalFinalEnrolment/>
      <totalTarget>200</totalTarget>
      <exclusion>Antenatal diagnosed congenital anomalies of the cardio or respiratory system or anomalies incompatible with survival.</exclusion>
      <patientInfoSheet/>
      <recruitmentStart>2005-04-01T00:00:00.000Z</recruitmentStart>
      <recruitmentEnd>2007-07-01T00:00:00.000Z</recruitmentEnd>
      <recruitmentStatusOverride/>
    </participants>
    <conditions>
      <condition>
	<description>Respiratory Distress Syndrome, Preterm neonates</description>
	<diseaseClass1>Respiratory</diseaseClass1>
	<diseaseClass2>Respiratory Distress Syndrome</diseaseClass2>
      </condition>
    </conditions>
    <interventions>
      <intervention>
	<description>Resuscitation at birth when necessary:
Group A: Prolonged inflation of 10 seconds with a mechanical device (Neopuff t-piece resuscitator) and early CPAP treatment.
Group B: Inflation with self-inflating mask and bag conform international resuscitation guidelines.</description>
	<interventionType>Other</interventionType>
	<pharmaceuticalStudyTypes/>
	<phase>Not Specified</phase>
	<drugNames/>
      </intervention>
    </interventions>
    <results>
      <publicationPlan>Not provided at time of registration</publicationPlan>
      <ipdSharingStatement/>
      <dataPolicies>
	<dataPolicy>Not provided at time of registration</dataPolicy>
      </dataPolicies>
      <publicationDetails>2007 Results article in https://pubmed.ncbi.nlm.nih.gov/17671058 Results</publicationDetails>
      <publicationStage>Results</publicationStage>
      <biomedRelated>false</biomedRelated>
      <basicReport/>
      <plainEnglishReport/>
    </results>
    <outputs>
      <output id="10d2d3c0-fcd0-4102-b651-126e23bb21fb" outputType="resultsarticle" artefactType="ExternalLink" dateCreated="2007-08-01T00:00:00.000Z" dateUploaded="" peerReviewed="true" patientFacing="false" createdBy="Data migration">
	<externalLink url="https://pubmed.ncbi.nlm.nih.gov/17671058"/>
	<description>Results</description>
	<productionNotes/>
      </output>
    </outputs>
    <parties>
      <funderId>Funder14353-0</funderId>
      <contactId>Contact52101_14353</contactId>
      <sponsorId>Sponsor50754</sponsorId>
    </parties>
    <miscellaneous xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <ipdSharingPlan>No</ipdSharingPlan>
    </miscellaneous>
    <attachedFiles/>
  </trial>
  <contact id="Contact52101_14353">
    <title>Dr</title>
    <forename>Arjan B.</forename>
    <surname>Pas, te</surname>
    <orcid/>
    <contactTypes xmlns:ssb="http://www.67bricks.com/isrctn/functions">
      <contactType>Scientific</contactType>
    </contactTypes>
    <contactDetails>
      <address>Department of Pediatrics, Leiden University Medical Center, J6-S, P.O. Box 9600</address>
      <city>Leiden</city>
      <country>Netherlands</country>
      <zip>2300 RC</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions">+31 (0)71 5262909</telephone>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions">a.b.te_pas@lumc.nl</email>
    </contactDetails>
    <privacy>Public</privacy>
  </contact>
  <sponsor id="Sponsor50754">
    <organisation>Leiden University Medical Centre (LUMC) (Netherlands)</organisation>
    <website>http://www.lumc.nl/</website>
    <sponsorType>University/education</sponsorType>
    <contactDetails>
      <address>Albinusdreef 2
P.O. Box 9600</address>
      <city>Leiden</city>
      <state/>
      <country>Netherlands</country>
      <zip>2300 RC</zip>
      <telephone xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
      <email xmlns:ssb="http://www.67bricks.com/isrctn/functions"/>
    </contactDetails>
    <privacy>Protected</privacy>
    <gridId>grid.5132.5</gridId>
    <rorId>https://ror.org/027bh9e22</rorId>
  </sponsor>
  <funder id="Funder14353-0">
    <name>Leiden University Medical Centre  (The Netherlands)</name>
    <fundRef/>
  </funder>
</fullTrial></allTrials>